Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6414752,CL,"The CL and Vd were significantly greater at steady-state (0.42 +/- 0.20 ml/min/kg and 0.231 +/- 0.067 L/kg, respectively) than after a single dose (0.32 +/- 0.13 ml/min/kg and 0.191 +/- 0.055 L/kg, respectively).",First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414752/),[ml] / [kg·min],0.42,600,DB00313,Valproic Acid
,6414752,CL,"The CL and Vd were significantly greater at steady-state (0.42 +/- 0.20 ml/min/kg and 0.231 +/- 0.067 L/kg, respectively) than after a single dose (0.32 +/- 0.13 ml/min/kg and 0.191 +/- 0.055 L/kg, respectively).",First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414752/),[ml] / [kg·min],0.32,601,DB00313,Valproic Acid
,6414752,Vd,"The CL and Vd were significantly greater at steady-state (0.42 +/- 0.20 ml/min/kg and 0.231 +/- 0.067 L/kg, respectively) than after a single dose (0.32 +/- 0.13 ml/min/kg and 0.191 +/- 0.055 L/kg, respectively).",First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414752/),[l] / [kg],0.231,602,DB00313,Valproic Acid
,6414752,Vd,"The CL and Vd were significantly greater at steady-state (0.42 +/- 0.20 ml/min/kg and 0.231 +/- 0.067 L/kg, respectively) than after a single dose (0.32 +/- 0.13 ml/min/kg and 0.191 +/- 0.055 L/kg, respectively).",First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414752/),[l] / [kg],0.191,603,DB00313,Valproic Acid
,10757417,half-life of plasma disappearance,The half-life of plasma disappearance of valproate was 25% reduced by lithium pretreatment (0.428 +/- 0.031 h with repeated lithium pretreatment vs 0.578 +/- 0.062 h for controls).,Effects of lithium on the pharmacokinetics of valproate in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10757417/),h,0.428,1578,DB00313,Valproic Acid
,10757417,half-life of plasma disappearance,The half-life of plasma disappearance of valproate was 25% reduced by lithium pretreatment (0.428 +/- 0.031 h with repeated lithium pretreatment vs 0.578 +/- 0.062 h for controls).,Effects of lithium on the pharmacokinetics of valproate in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10757417/),h,0.578,1579,DB00313,Valproic Acid
,6810203,area under the serum concentration-time curve (AUC),There was no significant difference (p greater than 0.1) in the area under the serum concentration-time curve (AUC) between the oral (201.1 mg L-1hr) and rectal 219.6mg L-1hr) routes of administration.,Bioavailability of rectally administered valproic acid syrup. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6810203/),[mg] / [l],201.1,2524,DB00313,Valproic Acid
,6810203,area under the serum concentration-time curve (AUC),There was no significant difference (p greater than 0.1) in the area under the serum concentration-time curve (AUC) between the oral (201.1 mg L-1hr) and rectal 219.6mg L-1hr) routes of administration.,Bioavailability of rectally administered valproic acid syrup. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6810203/),[mg] / [l],219.6,2525,DB00313,Valproic Acid
,6777108,free (unbound) fraction,"After valproate, the free (unbound) fraction of phenytoin in serum rose from 9.6 +/- 0.9% (SD) to 15.6 +/- 1.4% on average (p < 0.001).",Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6777108/),%,9.6,4678,DB00313,Valproic Acid
,6777108,free (unbound) fraction,"After valproate, the free (unbound) fraction of phenytoin in serum rose from 9.6 +/- 0.9% (SD) to 15.6 +/- 1.4% on average (p < 0.001).",Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6777108/),%,15.6,4679,DB00313,Valproic Acid
,34223294,total CA duration,The mean(SD) total CA duration was 14.8(1.2) minutes.,Dose optimization of early high-dose valproic acid for neuroprotection in a swine cardiac arrest model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34223294/),min,14.8,6527,DB00313,Valproic Acid
,19645218,serum concentrations,LTG serum concentrations were increased significantly from 4.67 +/- 3.66 and 9.56 +/- 5.27 microg/ml by concomitant administration of VPA.,Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19645218/),[μg] / [ml],4.67,7483,DB00313,Valproic Acid
,19645218,serum concentrations,LTG serum concentrations were increased significantly from 4.67 +/- 3.66 and 9.56 +/- 5.27 microg/ml by concomitant administration of VPA.,Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19645218/),[μg] / [ml],9.56,7484,DB00313,Valproic Acid
,30456910,recoveries,The recoveries were in the range from 91.6 to 97.4% for VPA with RSD <3.9%.,A new derivatization method for the determination of valproic acid in serum using tetramethylammonium hydroxide as a catalyst. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30456910/),%,91.6 to 97.4,7539,DB00313,Valproic Acid
,3145327,apparent volume of distribution (Vd),"The apparent volume of distribution (Vd) of total VPA was 0.150-0.197 l/kg body wt. and of free VPA 0.911-1.58 l/kg body wt., which indicates considerable distribution of unbound VPA as well as drug binding to extravascular proteins.",Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145327/),[l] / [body·kg·wt],0.150-0.197,7774,DB00313,Valproic Acid
,3145327,apparent volume of distribution (Vd),"The apparent volume of distribution (Vd) of total VPA was 0.150-0.197 l/kg body wt. and of free VPA 0.911-1.58 l/kg body wt., which indicates considerable distribution of unbound VPA as well as drug binding to extravascular proteins.",Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145327/),[l] / [body·kg·wt],0.911-1.58,7775,DB00313,Valproic Acid
,3145327,terminal half-life,The terminal half-life of free VPA (6.4-6.7 h) was significantly shorter (P less than 0.05) than the half-life of total VPA (10.4-11.9 h).,Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145327/),h,6.4-6.7,7776,DB00313,Valproic Acid
,3145327,half-life,The terminal half-life of free VPA (6.4-6.7 h) was significantly shorter (P less than 0.05) than the half-life of total VPA (10.4-11.9 h).,Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145327/),h,10.4-11.9,7777,DB00313,Valproic Acid
,10365652,Ka,"Estimated population parameters (mean +/- SD) were: Ka, 1.15+/-1.75/h; V, 0.14+/-0.042 L/Kg; and CL, 0.902+/-0.133 L/h.",Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365652/),1/[h],1.15,9149,DB00313,Valproic Acid
,10365652,V,"Estimated population parameters (mean +/- SD) were: Ka, 1.15+/-1.75/h; V, 0.14+/-0.042 L/Kg; and CL, 0.902+/-0.133 L/h.",Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365652/),[l] / [kg],0.14,9150,DB00313,Valproic Acid
,10365652,CL,"Estimated population parameters (mean +/- SD) were: Ka, 1.15+/-1.75/h; V, 0.14+/-0.042 L/Kg; and CL, 0.902+/-0.133 L/h.",Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365652/),[l] / [h],0.902,9151,DB00313,Valproic Acid
,9029053,Liver,"Liver concentrations of 4-ene VPA and alpha-fluoro-4-ene VPA were 0.96 +/- 0.11 and 0.89 +/- 0.19 micromol/g of wet liver, respectively, at 1 hr after the dose.",A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029053/),μ,0.96,9610,DB00313,Valproic Acid
,9029053,Liver,"Liver concentrations of 4-ene VPA and alpha-fluoro-4-ene VPA were 0.96 +/- 0.11 and 0.89 +/- 0.19 micromol/g of wet liver, respectively, at 1 hr after the dose.",A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029053/),μ,0.89,9611,DB00313,Valproic Acid
,2266076,Ka,"Following the administration of the three dosage forms, the absorption varied (Ka = Syrup K 2.64 +/- 0.5; tablet 1.57 +/- 0.22; and capsule 0.55 +/- 0.55 h-1).",Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266076/),1/[h],2.64,10117,DB00313,Valproic Acid
,2266076,Ka,"Following the administration of the three dosage forms, the absorption varied (Ka = Syrup K 2.64 +/- 0.5; tablet 1.57 +/- 0.22; and capsule 0.55 +/- 0.55 h-1).",Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266076/),1/[h],1.57,10118,DB00313,Valproic Acid
,2266076,Ka,"Following the administration of the three dosage forms, the absorption varied (Ka = Syrup K 2.64 +/- 0.5; tablet 1.57 +/- 0.22; and capsule 0.55 +/- 0.55 h-1).",Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266076/),1/[h],0.55,10119,DB00313,Valproic Acid
,2266076,peak level,Valproic acid concentration reached a peak level of 102.3 micrograms.,Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266076/),μg,102.3,10120,DB00313,Valproic Acid
,2266076,bioavailability,The bioavailability of tablet and syrup formulation was not significantly different from each other but it differed from capsule form in that the bioavailability was only 52%.,Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266076/),%,52,10121,DB00313,Valproic Acid
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],3.28,10753,DB00313,Valproic Acid
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],4.23,10754,DB00313,Valproic Acid
,24240511,oral clearance (CL/F),"Based on the final model, the estimated LTG oral clearance (CL/F) for a typical patient weighing ≤25 kg, >25 to <60 kg or ≥60 kg who was concomitantly treated with CBZ was estimated to be 3.28, 4.23, or 7.15 l/h, respectively.",Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24240511/),[l] / [h],7.15,10755,DB00313,Valproic Acid
,11683247,total clearance,The plamsa total clearance of VPA was significantly increased to about 1.5 times the control (6.09 mL/min/kg vs. 4.28 mL/min/kg) by MEPM (P < 0.05).,Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683247/),[ml] / [kg·min],6.09,14753,DB00313,Valproic Acid
,11683247,total clearance,The plamsa total clearance of VPA was significantly increased to about 1.5 times the control (6.09 mL/min/kg vs. 4.28 mL/min/kg) by MEPM (P < 0.05).,Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683247/),[ml] / [kg·min],4.28,14754,DB00313,Valproic Acid
,11683247,cumulative urinary excretions,"The cumulative urinary excretions of VPA in the control and MEPM-treated groups were 0.54% and 0.62% of the dose, respectively, whereas those of VPA-G were 45.6% and 62.5%, respectively.",Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683247/),%,0.54,14755,DB00313,Valproic Acid
,11683247,cumulative urinary excretions,"The cumulative urinary excretions of VPA in the control and MEPM-treated groups were 0.54% and 0.62% of the dose, respectively, whereas those of VPA-G were 45.6% and 62.5%, respectively.",Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683247/),%,0.62,14756,DB00313,Valproic Acid
,11683247,cumulative urinary excretions,"The cumulative urinary excretions of VPA in the control and MEPM-treated groups were 0.54% and 0.62% of the dose, respectively, whereas those of VPA-G were 45.6% and 62.5%, respectively.",Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683247/),%,45.6,14757,DB00313,Valproic Acid
,11683247,cumulative urinary excretions,"The cumulative urinary excretions of VPA in the control and MEPM-treated groups were 0.54% and 0.62% of the dose, respectively, whereas those of VPA-G were 45.6% and 62.5%, respectively.",Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11683247/),%,62.5,14758,DB00313,Valproic Acid
,26412032,oral bioavailability,The oral bioavailability of paliperidone was increased by an estimated 51% (Cmax ) and 51%-52% (AUCs) when coadministered with divalproex sodium ER.,Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26412032/),%,51,14808,DB00313,Valproic Acid
,26412032,oral bioavailability,The oral bioavailability of paliperidone was increased by an estimated 51% (Cmax ) and 51%-52% (AUCs) when coadministered with divalproex sodium ER.,Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26412032/),%,52,14809,DB00313,Valproic Acid
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,43.3,15735,DB00313,Valproic Acid
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,14.1,15736,DB00313,Valproic Acid
,8764817,elimination half-life (t1/2),"The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43.3 h; in patients receiving carbamazepine (CBZ) and/or phenobarbital (PB), it was 14.1 h; and in patients receiving both VPA and CBZ/ PB or other antiepileptic drugs (AEDs), it was 28.9 h.",Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8764817/),h,28.9,15737,DB00313,Valproic Acid
,7884670,peak plasma concentration,"The mean peak plasma concentration, 34.6 +/- 8.9 mg/L, was reached after 8.6 +/- 2.7 h.",A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884670/),[mg] / [l],34.6,16901,DB00313,Valproic Acid
,7884670,td,A single Weibull function adequately described the observed data for three subjects; the mean Weibull parameters were td (the time necessary to transfer 63% of the administered drug into the systemic circulation) of 7.87 +/- 3.53 h and gamma (shape) of 1.16 +/- 0.66.,A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884670/),h,7.87,16902,DB00313,Valproic Acid
,7884670,gamma (shape),A single Weibull function adequately described the observed data for three subjects; the mean Weibull parameters were td (the time necessary to transfer 63% of the administered drug into the systemic circulation) of 7.87 +/- 3.53 h and gamma (shape) of 1.16 +/- 0.66.,A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884670/),,1.16,16903,DB00313,Valproic Acid
,7884670,td1,A double Weibull input function was used for nine subjects; the mean Weibull parameters were td1 = 2.35 +/- 1.18 h and td2 = 9.36 +/- 4.47 h and gamma 1 = 1.77 +/- 2.27 and gamma 2 = 3.68 +/- 3.26.,A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884670/),h,2.35,16904,DB00313,Valproic Acid
,7884670,td2,A double Weibull input function was used for nine subjects; the mean Weibull parameters were td1 = 2.35 +/- 1.18 h and td2 = 9.36 +/- 4.47 h and gamma 1 = 1.77 +/- 2.27 and gamma 2 = 3.68 +/- 3.26.,A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884670/),h,9.36,16905,DB00313,Valproic Acid
,7884670,gamma 1,A double Weibull input function was used for nine subjects; the mean Weibull parameters were td1 = 2.35 +/- 1.18 h and td2 = 9.36 +/- 4.47 h and gamma 1 = 1.77 +/- 2.27 and gamma 2 = 3.68 +/- 3.26.,A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884670/),,1.77,16906,DB00313,Valproic Acid
,7884670,gamma 2,A double Weibull input function was used for nine subjects; the mean Weibull parameters were td1 = 2.35 +/- 1.18 h and td2 = 9.36 +/- 4.47 h and gamma 1 = 1.77 +/- 2.27 and gamma 2 = 3.68 +/- 3.26.,A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884670/),,3.68,16907,DB00313,Valproic Acid
,7884670,half-life,The mean half-life value of the elimination phase was 14.4 +/- 4.6 h.,A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884670/),h,14.4,16908,DB00313,Valproic Acid
,31067540,trough concentration,"The patients received a phenytoin TDD of 330.5 (±104.5) mg/day, resulting in a trough concentration of 11.2 (±10.3) mg/L.",Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067540/),[mg] / [l],11.2,18085,DB00313,Valproic Acid
,31067540,volume of distribution (V),"Average parameter estimates for phenytoin volume of distribution (V), maximal elimination rate (Vmax), and Michaelis-Menten constant (Km) were 0.61 L/h/kg, 6.12 mg/kg/day, and 5.33 mg/L, respectively.",Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067540/),[l] / [h·kg],0.61,18086,DB00313,Valproic Acid
,31067540,maximal elimination rate (Vmax),"Average parameter estimates for phenytoin volume of distribution (V), maximal elimination rate (Vmax), and Michaelis-Menten constant (Km) were 0.61 L/h/kg, 6.12 mg/kg/day, and 5.33 mg/L, respectively.",Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067540/),[mg] / [d·kg],6.12,18087,DB00313,Valproic Acid
,31067540,Michaelis-Menten constant (Km),"Average parameter estimates for phenytoin volume of distribution (V), maximal elimination rate (Vmax), and Michaelis-Menten constant (Km) were 0.61 L/h/kg, 6.12 mg/kg/day, and 5.33 mg/L, respectively.",Estimation of Phenytoin Pharmacokinetic Parameters in Saudi Epileptic Patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31067540/),[mg] / [l],5.33,18088,DB00313,Valproic Acid
,17433926,serum concentration,"The average (+/-SD) carbamazepine (CBZ) dose is 8.8 +/- 4.7 mg/kg/day, yielding a mean serum concentration of 6.3 +/- 2.2 mg/liter.",Pharmacokinetics of antiepileptic drugs in elderly nursing home residents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17433926/),[mg] / [l],6.3,18536,DB00313,Valproic Acid
,328019,maximum plasma levels,Absorption was rapid with maximum plasma levels of approximately 70 microng/ml within 1--3 h.,Pharmacokinetic studies with valproic acid in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328019/),[μng] / [ml],70,18827,DB00313,Valproic Acid
,328019,half-life,DPA was eliminated with a half-life of 7.9 and 10 h.,Pharmacokinetic studies with valproic acid in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328019/),h,7.9,18828,DB00313,Valproic Acid
,328019,half-life,DPA was eliminated with a half-life of 7.9 and 10 h.,Pharmacokinetic studies with valproic acid in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328019/),h,10,18829,DB00313,Valproic Acid
,328019,total plasma clearance,Assuming 100% absorption a total plasma clearance of 10--13 ml/min and an apparent distribution volume of 0.13--0.16 l/kg were calculated.,Pharmacokinetic studies with valproic acid in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328019/),[ml] / [min],10,18830,DB00313,Valproic Acid
,328019,apparent distribution volume,Assuming 100% absorption a total plasma clearance of 10--13 ml/min and an apparent distribution volume of 0.13--0.16 l/kg were calculated.,Pharmacokinetic studies with valproic acid in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328019/),[l] / [kg],0.13,18831,DB00313,Valproic Acid
,22150444,ED(50),"Thirty minutes after the induction of SE, the calculated rat ED(50) for SPD against convulsive SE in this model was 84 mg/kg.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],84,21547,DB00313,Valproic Acid
,22150444,ED(50),"SPD ED(50) values in guinea pigs were 67 and 92 mg/kg when administered at SE onset or 40 min after SE onset, respectively.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],67,21548,DB00313,Valproic Acid
,22150444,ED(50),"SPD ED(50) values in guinea pigs were 67 and 92 mg/kg when administered at SE onset or 40 min after SE onset, respectively.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],92,21549,DB00313,Valproic Acid
,22150444,plasma levels,"Assuming linear pharmacokinetics (PK), the PK-PD (pharmacodynamic) results (rats) suggests that effective SPD plasma levels ranged between 8 and 40 mg/L (20 min after the onset of soman-induced seizures) and 12-50 mg/L (40 min after the onset of soman-induced seizures).",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [l],8 and 40,21550,DB00313,Valproic Acid
,22150444,plasma levels,"Assuming linear pharmacokinetics (PK), the PK-PD (pharmacodynamic) results (rats) suggests that effective SPD plasma levels ranged between 8 and 40 mg/L (20 min after the onset of soman-induced seizures) and 12-50 mg/L (40 min after the onset of soman-induced seizures).",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [l],12-50,21551,DB00313,Valproic Acid
,17274675,elimination half-life,"Valproic acid, commonly used in neuropsychiatry, has an elimination half-life of 4-16 hours in different populations (children vs adults, enzyme-induced vs uninduced).",Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17274675/),h,4-16,22796,DB00313,Valproic Acid
,17274675,t((1/2)F),"The estimated geometric mean t((1/2)F) in uninduced adults was 40.0 hours versus the expected elimination half-life of 12-16 hours in this population (including patients on valproic acid monotherapy); for induced patients, t((1/2)F) was 26.9 hours versus the expected elimination half-life of 6-12 hours.",Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17274675/),h,40.0,22797,DB00313,Valproic Acid
,17274675,elimination half-life,"The estimated geometric mean t((1/2)F) in uninduced adults was 40.0 hours versus the expected elimination half-life of 12-16 hours in this population (including patients on valproic acid monotherapy); for induced patients, t((1/2)F) was 26.9 hours versus the expected elimination half-life of 6-12 hours.",Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17274675/),h,12-16,22798,DB00313,Valproic Acid
,17274675,t((1/2)F),"The estimated geometric mean t((1/2)F) in uninduced adults was 40.0 hours versus the expected elimination half-life of 12-16 hours in this population (including patients on valproic acid monotherapy); for induced patients, t((1/2)F) was 26.9 hours versus the expected elimination half-life of 6-12 hours.",Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17274675/),h,26.9,22799,DB00313,Valproic Acid
,17274675,elimination half-life,"The estimated geometric mean t((1/2)F) in uninduced adults was 40.0 hours versus the expected elimination half-life of 12-16 hours in this population (including patients on valproic acid monotherapy); for induced patients, t((1/2)F) was 26.9 hours versus the expected elimination half-life of 6-12 hours.",Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17274675/),h,6-12,22800,DB00313,Valproic Acid
,31404235,apparent volume of distribution (V/F),"The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively.",Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404235/),l,12.7,23268,DB00313,Valproic Acid
,31404235,apparent clearance (CL/F),"The population estimates of the apparent volume of distribution (V/F) and apparent clearance (CL/F) were 12.7 L and 1.12 L/h, respectively.",Effects of Comedication and Genetic Factors on the Population Pharmacokinetics of Lamotrigine: A Prospective Analysis in Chinese Patients With Epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31404235/),[l] / [h],1.12,23269,DB00313,Valproic Acid
,10082174,maximum serum valproate concentration,The average maximum serum valproate concentration of 12.5 microg/ml (sustained release capsule) and 24.3 microg/ml (solution) appeared at 9.3 h and 0.58 h after dosing.,Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082174/),[μg] / [ml],12.5,24060,DB00313,Valproic Acid
,10082174,maximum serum valproate concentration,The average maximum serum valproate concentration of 12.5 microg/ml (sustained release capsule) and 24.3 microg/ml (solution) appeared at 9.3 h and 0.58 h after dosing.,Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082174/),[μg] / [ml],24.3,24061,DB00313,Valproic Acid
,10082174,AUC0-infinity,The extent of valproate absorption as reflected in the AUC data for each formulation was equivalent for the new sustained release capsule and reference formulation (AUC0-infinity: 369 +/- 88.9 and 339 +/- 76.2 microg/ml x h).,Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082174/),[μg] / [h·ml],369,24062,DB00313,Valproic Acid
,10082174,AUC0-infinity,The extent of valproate absorption as reflected in the AUC data for each formulation was equivalent for the new sustained release capsule and reference formulation (AUC0-infinity: 369 +/- 88.9 and 339 +/- 76.2 microg/ml x h).,Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082174/),[μg] / [h·ml],339,24063,DB00313,Valproic Acid
,10082174,AUC(8tau9tau),The time concentration profiles following twice daily administration of 300 mg sodium valproate in the multiple dose study showed that the extent parameters for absorption of valproate (AUC(8tau9tau) = 842 +/- 166 microg/ml x h) are equivalent with the enteric-coated preparation (AUC(8tau9tau) = 823 +/- 139 microg/ml x h).,Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082174/),[μg] / [h·ml],842,24064,DB00313,Valproic Acid
,10082174,AUC(8tau9tau),The time concentration profiles following twice daily administration of 300 mg sodium valproate in the multiple dose study showed that the extent parameters for absorption of valproate (AUC(8tau9tau) = 842 +/- 166 microg/ml x h) are equivalent with the enteric-coated preparation (AUC(8tau9tau) = 823 +/- 139 microg/ml x h).,Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082174/),[μg] / [h·ml],823,24065,DB00313,Valproic Acid
,8865320,Vmax,"On a body weight basis, the Vmax and the Km values of VPA glucuronidation estimated from liver homogenate were 1.8 mumol/min/kg and 0.3 mumol/ml, respectively; and that from microsome suspension were 1.2 mumol/min/kg and 0.16 mumol/ml, respectively.",Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865320/),[μM] / [kg·min],1.8,24252,DB00313,Valproic Acid
,8865320,Vmax,"On a body weight basis, the Vmax and the Km values of VPA glucuronidation estimated from liver homogenate were 1.8 mumol/min/kg and 0.3 mumol/ml, respectively; and that from microsome suspension were 1.2 mumol/min/kg and 0.16 mumol/ml, respectively.",Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865320/),[μM] / [kg·min],1.2,24253,DB00313,Valproic Acid
,8865320,Km,"On a body weight basis, the Vmax and the Km values of VPA glucuronidation estimated from liver homogenate were 1.8 mumol/min/kg and 0.3 mumol/ml, respectively; and that from microsome suspension were 1.2 mumol/min/kg and 0.16 mumol/ml, respectively.",Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865320/),[μM] / [ml],0.3,24254,DB00313,Valproic Acid
,8865320,Km,"On a body weight basis, the Vmax and the Km values of VPA glucuronidation estimated from liver homogenate were 1.8 mumol/min/kg and 0.3 mumol/ml, respectively; and that from microsome suspension were 1.2 mumol/min/kg and 0.16 mumol/ml, respectively.",Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865320/),[μM] / [ml],0.16,24255,DB00313,Valproic Acid
,23749495,elimination half-life (t ½,"The elimination half-life (t ½ = 40.2 h) of valproic acid was longer and the clearance rate (CL = 917 ml/h) was lower in the poor metabolizers group of UGT1A6 (552A>C) polymorphism who showed toxicity than in the intermediate metabolizers group (t ½ = 35.5 h, CL = 1,022 ml/h) or the extensive metabolizers group (t ½ = 25.4 h, CL = 1,404 ml/h).",The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23749495/),h,40.2,26768,DB00313,Valproic Acid
,23749495,clearance rate (CL,"The elimination half-life (t ½ = 40.2 h) of valproic acid was longer and the clearance rate (CL = 917 ml/h) was lower in the poor metabolizers group of UGT1A6 (552A>C) polymorphism who showed toxicity than in the intermediate metabolizers group (t ½ = 35.5 h, CL = 1,022 ml/h) or the extensive metabolizers group (t ½ = 25.4 h, CL = 1,404 ml/h).",The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23749495/),[ml] / [h],917,26769,DB00313,Valproic Acid
,23749495,t ½,"The elimination half-life (t ½ = 40.2 h) of valproic acid was longer and the clearance rate (CL = 917 ml/h) was lower in the poor metabolizers group of UGT1A6 (552A>C) polymorphism who showed toxicity than in the intermediate metabolizers group (t ½ = 35.5 h, CL = 1,022 ml/h) or the extensive metabolizers group (t ½ = 25.4 h, CL = 1,404 ml/h).",The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23749495/),h,35.5,26770,DB00313,Valproic Acid
,23749495,CL,"The elimination half-life (t ½ = 40.2 h) of valproic acid was longer and the clearance rate (CL = 917 ml/h) was lower in the poor metabolizers group of UGT1A6 (552A>C) polymorphism who showed toxicity than in the intermediate metabolizers group (t ½ = 35.5 h, CL = 1,022 ml/h) or the extensive metabolizers group (t ½ = 25.4 h, CL = 1,404 ml/h).",The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23749495/),[ml] / [h],"1,022",26771,DB00313,Valproic Acid
,23749495,t ½,"The elimination half-life (t ½ = 40.2 h) of valproic acid was longer and the clearance rate (CL = 917 ml/h) was lower in the poor metabolizers group of UGT1A6 (552A>C) polymorphism who showed toxicity than in the intermediate metabolizers group (t ½ = 35.5 h, CL = 1,022 ml/h) or the extensive metabolizers group (t ½ = 25.4 h, CL = 1,404 ml/h).",The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23749495/),h,25.4,26772,DB00313,Valproic Acid
,23749495,CL,"The elimination half-life (t ½ = 40.2 h) of valproic acid was longer and the clearance rate (CL = 917 ml/h) was lower in the poor metabolizers group of UGT1A6 (552A>C) polymorphism who showed toxicity than in the intermediate metabolizers group (t ½ = 35.5 h, CL = 1,022 ml/h) or the extensive metabolizers group (t ½ = 25.4 h, CL = 1,404 ml/h).",The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23749495/),[ml] / [h],"1,404",26773,DB00313,Valproic Acid
,29169113,flow rate,"Separation was performed on a Hypersil GOLD C18 column by isocratic elution using acetonitrile: 10mM ammonium acetate solution (90:10, v/v) as mobile phase at a flow rate of 0.3mL/min.",A rapid and simple HPLC-MS/MS method for the simultaneous quantification of valproic acid and its five metabolites in human plasma and application to study pharmacokinetic interaction in Chinese epilepsy patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169113/),[ml] / [min],0.3,27229,DB00313,Valproic Acid
,8216694,half-life,"Levels peaked within 30 minutes, and elimination of CLZ from brain and CLZ or NOR from blood was very rapid (half-life = 1.5 to 1.6 hours).",Tissue concentrations of clozapine and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216694/),h,1.5 to 1.6,27568,DB00313,Valproic Acid
,10901700,Cl(u)tb,Mean Cl(u)tb increased significantly with age up to 2 months (10 d = 2.65 +/- 1.16 ml/min/kg; 1 M = 5.11 +/- 2.49 ml/min/kg; 2 M = 12.84 +/- 3.88 ml/min/kg) before decreasing to adult levels (7.73 +/- 2.64 ml/min/kg).,Ontogeny of valproic acid disposition and metabolism: a developmental study in postnatal lambs and adult sheep. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10901700/),[ml] / [kg·min],2.65,29089,DB00313,Valproic Acid
,10901700,Cl(u)tb,Mean Cl(u)tb increased significantly with age up to 2 months (10 d = 2.65 +/- 1.16 ml/min/kg; 1 M = 5.11 +/- 2.49 ml/min/kg; 2 M = 12.84 +/- 3.88 ml/min/kg) before decreasing to adult levels (7.73 +/- 2.64 ml/min/kg).,Ontogeny of valproic acid disposition and metabolism: a developmental study in postnatal lambs and adult sheep. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10901700/),[ml] / [kg·min],5.11,29090,DB00313,Valproic Acid
,10901700,Cl(u)tb,Mean Cl(u)tb increased significantly with age up to 2 months (10 d = 2.65 +/- 1.16 ml/min/kg; 1 M = 5.11 +/- 2.49 ml/min/kg; 2 M = 12.84 +/- 3.88 ml/min/kg) before decreasing to adult levels (7.73 +/- 2.64 ml/min/kg).,Ontogeny of valproic acid disposition and metabolism: a developmental study in postnatal lambs and adult sheep. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10901700/),[ml] / [kg·min],12.84,29091,DB00313,Valproic Acid
,10901700,Cl(u)tb,Mean Cl(u)tb increased significantly with age up to 2 months (10 d = 2.65 +/- 1.16 ml/min/kg; 1 M = 5.11 +/- 2.49 ml/min/kg; 2 M = 12.84 +/- 3.88 ml/min/kg) before decreasing to adult levels (7.73 +/- 2.64 ml/min/kg).,Ontogeny of valproic acid disposition and metabolism: a developmental study in postnatal lambs and adult sheep. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10901700/),[ml] / [kg·min],7.73,29092,DB00313,Valproic Acid
,2384074,"apparent terminal half-life (t1/2, beta)","Analysis of plasma and whole brain homogenates of mice indicated that AHR-11748 has an apparent terminal half-life (t1/2, beta) of 1.0 h.","Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,1.0,29349,DB00313,Valproic Acid
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),,3.4,29350,DB00313,Valproic Acid
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,0.,29351,DB00313,Valproic Acid
,2384074,brain:plasma ratio,The brain:plasma ratio of AHR-11748 was 3.4:1 from 0.5 h to 6 h.,"Pharmacodynamics and pharmacokinetics of AHR-11748, a new antiepileptic agent, in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384074/),h,6,29352,DB00313,Valproic Acid
,17883957,Ka,"The basic model was: Ka=3.09 (h(-1)), V/F=20.4 (L), CL/F=0.296 (L/h).",Population pharmacokinetics of valproate in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883957/),1/[h],3.09,29570,DB00313,Valproic Acid
,17883957,V/F,"The basic model was: Ka=3.09 (h(-1)), V/F=20.4 (L), CL/F=0.296 (L/h).",Population pharmacokinetics of valproate in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883957/),l,20.4,29571,DB00313,Valproic Acid
,17883957,CL/F,"The basic model was: Ka=3.09 (h(-1)), V/F=20.4 (L), CL/F=0.296 (L/h).",Population pharmacokinetics of valproate in Chinese children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883957/),[l] / [h],0.296,29572,DB00313,Valproic Acid
,17883957,Ka,"The final model was: Ka=0.251+2.24 x (1-HS) (h(-1)), V/F=2.88+0.157 x WT (L), CL/F=0.106(0.98 x CO)+ 0.0157 x AGE (L/h).",Population pharmacokinetics of valproate in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883957/),,0.251,29573,DB00313,Valproic Acid
,17883957,V/F,"The final model was: Ka=0.251+2.24 x (1-HS) (h(-1)), V/F=2.88+0.157 x WT (L), CL/F=0.106(0.98 x CO)+ 0.0157 x AGE (L/h).",Population pharmacokinetics of valproate in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883957/),,2.88,29574,DB00313,Valproic Acid
,17883957,CL/F,"The final model was: Ka=0.251+2.24 x (1-HS) (h(-1)), V/F=2.88+0.157 x WT (L), CL/F=0.106(0.98 x CO)+ 0.0157 x AGE (L/h).",Population pharmacokinetics of valproate in Chinese children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883957/),[l] / [h],0.106,29575,DB00313,Valproic Acid
,17883957,CL/F,"The final model was: Ka=0.251+2.24 x (1-HS) (h(-1)), V/F=2.88+0.157 x WT (L), CL/F=0.106(0.98 x CO)+ 0.0157 x AGE (L/h).",Population pharmacokinetics of valproate in Chinese children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17883957/),[l] / [h],0.0157,29576,DB00313,Valproic Acid
,3139859,ka1,"VPA was found to be rapidly absorbed across the water routes (ka1 = 2.60 h-1), which accounted for about 70% of the total, followed by a lasting absorption via the lipid routes (ka2 = 0.108 h-1).",A pharmacokinetic model for percutaneous absorption of valproic acid and prediction of drug disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3139859/),1/[h],2.60,29619,DB00313,Valproic Acid
,3139859,ka2,"VPA was found to be rapidly absorbed across the water routes (ka1 = 2.60 h-1), which accounted for about 70% of the total, followed by a lasting absorption via the lipid routes (ka2 = 0.108 h-1).",A pharmacokinetic model for percutaneous absorption of valproic acid and prediction of drug disposition. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3139859/),1/[h],0.108,29620,DB00313,Valproic Acid
,22210332,TD(50),"CA (10-60 mmol/kg p.o.) impaired motor performance in the chimney test (TD(50) value, 58.4 mmol/kg).","Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210332/),[mM] / [kg],58.4,30702,DB00313,Valproic Acid
,8218957,terminal-phase half-life,"Overall, the pharmacokinetic of valproate were similar after infusions of 5, 10, 30, and 60 min, with an average terminal-phase half-life of 15.9 h.",Effect of infusion duration on valproate pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218957/),h,15.9,32551,DB00313,Valproic Acid
,8218957,area under the plasma concentration-time curve (AUC,"There were modest differences in overall clearances among the regimens, with the 5 min infusion producing a mean area under the plasma concentration-time curve (AUC; 1877 micrograms.h ml-1) that was significantly (13 to 16 per cent) higher than the means for the longer infusions (1614-1656 micrograms.h ml-1).",Effect of infusion duration on valproate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218957/),[h·μg] / [ml],1877,32552,DB00313,Valproic Acid
,8218957,area under the plasma concentration-time curve (AUC,"There were modest differences in overall clearances among the regimens, with the 5 min infusion producing a mean area under the plasma concentration-time curve (AUC; 1877 micrograms.h ml-1) that was significantly (13 to 16 per cent) higher than the means for the longer infusions (1614-1656 micrograms.h ml-1).",Effect of infusion duration on valproate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218957/),[h·μg] / [ml],1614-1656,32553,DB00313,Valproic Acid
,8218957,terminal volume of distribution,The shortest duration produced a significantly smaller terminal volume of distribution (12.8 vs 14.2-15.1 l) and more rapid tissue equilibration.,Effect of infusion duration on valproate pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218957/),l,12.8,32554,DB00313,Valproic Acid
,8218957,terminal volume of distribution,The shortest duration produced a significantly smaller terminal volume of distribution (12.8 vs 14.2-15.1 l) and more rapid tissue equilibration.,Effect of infusion duration on valproate pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218957/),l,14.2-15.1,32555,DB00313,Valproic Acid
,8218957,alpha-phase rate constant,The alpha-phase rate constant declined from a mean of 5.1 h-1 after the 5 min infusion to a mean of 0.9 h-1 after the 60 min infusion.,Effect of infusion duration on valproate pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218957/),1/[h],5.1,32556,DB00313,Valproic Acid
,8218957,alpha-phase rate constant,The alpha-phase rate constant declined from a mean of 5.1 h-1 after the 5 min infusion to a mean of 0.9 h-1 after the 60 min infusion.,Effect of infusion duration on valproate pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218957/),1/[h],0.9,32557,DB00313,Valproic Acid
>,21325101,free fraction,Data from a full pharmacokinetic curve (multiple blood samples during a dosing interval) showed that the free fraction of valproic acid was >60%.,High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21325101/),%,60,33429,DB00313,Valproic Acid
,7955813,area under the curve,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [h·ml],802.2,34489,DB00313,Valproic Acid
,7955813,area under the curve,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [h·ml],102,34490,DB00313,Valproic Acid
,7955813,area under the curve,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [h·ml],1235.9,34491,DB00313,Valproic Acid
,7955813,peak concentrations,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [ml],86.1,34492,DB00313,Valproic Acid
,7955813,peak concentrations,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [ml],115,34493,DB00313,Valproic Acid
,7955813,peak concentrations,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [ml],133.4,34494,DB00313,Valproic Acid
,7955813,steady-state concentrations,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [ml],66.9,34495,DB00313,Valproic Acid
,7955813,steady-state concentrations,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [ml],85,34496,DB00313,Valproic Acid
,7955813,steady-state concentrations,"Coadministration of 1200 or 2400 mg felbamate increased the mean valproic acid area under the curve (from 802.2 to 1025.4 and 1235.9 mg/hr/ml, respectively), peak concentrations (from 86.1 to 115.1 and 133.4 mg/ml, respectively), and average steady-state concentrations (from 66.9 to 85.5 and 103.0 mg/ml, respectively).",The effect of felbamate on valproic acid disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [ml],103.0,34497,DB00313,Valproic Acid
,7955813,steady-state felbamate concentrations,Average steady-state felbamate concentrations were 34.7 mg/ml for 600 mg administered twice daily and 61.2 mg/ml for 1200 mg administered twice daily.,The effect of felbamate on valproic acid disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [ml],34.7,34498,DB00313,Valproic Acid
,7955813,steady-state felbamate concentrations,Average steady-state felbamate concentrations were 34.7 mg/ml for 600 mg administered twice daily and 61.2 mg/ml for 1200 mg administered twice daily.,The effect of felbamate on valproic acid disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955813/),[mg] / [ml],61.2,34499,DB00313,Valproic Acid
,3924399,areas under the serum concentration-time curves (AUC0----infinity),"The areas under the serum concentration-time curves (AUC0----infinity) did not show any statistically significant difference (2,925.0 +/- 189.1 versus 2,816.2 +/- 162.2 h X mumol/L) between SHD and sodium valproate.",Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),[h·μM] / [l],"2,925.0",34718,DB00313,Valproic Acid
,3924399,areas under the serum concentration-time curves (AUC0----infinity),"The areas under the serum concentration-time curves (AUC0----infinity) did not show any statistically significant difference (2,925.0 +/- 189.1 versus 2,816.2 +/- 162.2 h X mumol/L) between SHD and sodium valproate.",Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),[h·μM] / [l],"2,816.2",34719,DB00313,Valproic Acid
,3924399,t1/2,The elimination parameters for SHD were t1/2 = 12.6 +/- 0.7 h and CLs = 0.008 +/- 0.0005 L/kg/h.,Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),h,12.6,34720,DB00313,Valproic Acid
,3924399,CLs,The elimination parameters for SHD were t1/2 = 12.6 +/- 0.7 h and CLs = 0.008 +/- 0.0005 L/kg/h.,Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),[l] / [h·kg],0.008,34721,DB00313,Valproic Acid
,3924399,"Vd,area","Vd,area was 0.146 +/- 0.004 L/kg.",Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),[l] / [kg],0.146,34722,DB00313,Valproic Acid
,3924399,Tmax,"Thus, the extent of bioavailability and the single-dose kinetics of SHD and sodium valproate are similar with the exception of a more rapid absorption (Tmax 2.37 versus 3.23 h) and a higher concentration (Cmax 192 versus 176 mumol/L) for SHD.",Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),h,2.37,34723,DB00313,Valproic Acid
,3924399,Tmax,"Thus, the extent of bioavailability and the single-dose kinetics of SHD and sodium valproate are similar with the exception of a more rapid absorption (Tmax 2.37 versus 3.23 h) and a higher concentration (Cmax 192 versus 176 mumol/L) for SHD.",Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),h,3.23,34724,DB00313,Valproic Acid
,3924399,Cmax,"Thus, the extent of bioavailability and the single-dose kinetics of SHD and sodium valproate are similar with the exception of a more rapid absorption (Tmax 2.37 versus 3.23 h) and a higher concentration (Cmax 192 versus 176 mumol/L) for SHD.",Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),[μM] / [l],192,34725,DB00313,Valproic Acid
,3924399,Cmax,"Thus, the extent of bioavailability and the single-dose kinetics of SHD and sodium valproate are similar with the exception of a more rapid absorption (Tmax 2.37 versus 3.23 h) and a higher concentration (Cmax 192 versus 176 mumol/L) for SHD.",Single-dose kinetics and bioavailability of sodium-hydrogen divalproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924399/),[μM] / [l],176,34726,DB00313,Valproic Acid
,3602586,Extraction efficiency,Extraction efficiency is virtually 100%.,Capillary GCMS assay of 2-n-propyl-4-pentenoic acid (4-ene VPA) in rat plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602586/),%,100,35547,DB00313,Valproic Acid
,3602586,lowest detection limit,The lowest detection limit using 80 microL of plasma is 100 ng/mL.,Capillary GCMS assay of 2-n-propyl-4-pentenoic acid (4-ene VPA) in rat plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602586/),[ng] / [ml],100,35548,DB00313,Valproic Acid
,12598414,ED(50),"3. In mice (S)-PID, (R)-PID and racemic PID were effective in preventing the 6 Hz seizures with (R)-PID being significantly (P < 0.05) more potent (ED(50) values 11 mg kg(-1), 46 mg kg(-1) and 57 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively) than (S)-PID (ED(50) values 20 mg kg(-1), 73 mg kg(-1) and 81 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],11,35776,DB00313,Valproic Acid
,12598414,ED(50),"3. In mice (S)-PID, (R)-PID and racemic PID were effective in preventing the 6 Hz seizures with (R)-PID being significantly (P < 0.05) more potent (ED(50) values 11 mg kg(-1), 46 mg kg(-1) and 57 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively) than (S)-PID (ED(50) values 20 mg kg(-1), 73 mg kg(-1) and 81 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],46,35777,DB00313,Valproic Acid
,12598414,ED(50),"3. In mice (S)-PID, (R)-PID and racemic PID were effective in preventing the 6 Hz seizures with (R)-PID being significantly (P < 0.05) more potent (ED(50) values 11 mg kg(-1), 46 mg kg(-1) and 57 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively) than (S)-PID (ED(50) values 20 mg kg(-1), 73 mg kg(-1) and 81 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],57,35778,DB00313,Valproic Acid
,12598414,ED(50),"3. In mice (S)-PID, (R)-PID and racemic PID were effective in preventing the 6 Hz seizures with (R)-PID being significantly (P < 0.05) more potent (ED(50) values 11 mg kg(-1), 46 mg kg(-1) and 57 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively) than (S)-PID (ED(50) values 20 mg kg(-1), 73 mg kg(-1) and 81 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],20,35779,DB00313,Valproic Acid
,12598414,ED(50),"3. In mice (S)-PID, (R)-PID and racemic PID were effective in preventing the 6 Hz seizures with (R)-PID being significantly (P < 0.05) more potent (ED(50) values 11 mg kg(-1), 46 mg kg(-1) and 57 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively) than (S)-PID (ED(50) values 20 mg kg(-1), 73 mg kg(-1) and 81 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],73,35780,DB00313,Valproic Acid
,12598414,ED(50),"3. In mice (S)-PID, (R)-PID and racemic PID were effective in preventing the 6 Hz seizures with (R)-PID being significantly (P < 0.05) more potent (ED(50) values 11 mg kg(-1), 46 mg kg(-1) and 57 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively) than (S)-PID (ED(50) values 20 mg kg(-1), 73 mg kg(-1) and 81 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],81,35781,DB00313,Valproic Acid
,12598414,ED(50),"(S)-PID, (R)-PID and racemic PID also blocked generalized seizures in the Frings mice (ED(50) values 16 mg kg(-1), 20 mg kg(-1) and 19 mg kg(-1) respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],16,35782,DB00313,Valproic Acid
,12598414,ED(50),"(S)-PID, (R)-PID and racemic PID also blocked generalized seizures in the Frings mice (ED(50) values 16 mg kg(-1), 20 mg kg(-1) and 19 mg kg(-1) respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],20,35783,DB00313,Valproic Acid
,12598414,ED(50),"(S)-PID, (R)-PID and racemic PID also blocked generalized seizures in the Frings mice (ED(50) values 16 mg kg(-1), 20 mg kg(-1) and 19 mg kg(-1) respectively).",Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12598414/),[mg] / [kg],19,35784,DB00313,Valproic Acid
,2095402,total plasma clearance,"The total plasma clearance of (E)-2-ene VPA in normal rats was 4.9 ml/min/kg and in bile-exteriorized rats, 7.7 ml/min/kg.",Pharmacokinetics and enterohepatic circulation of (E)-2-ene valproic acid in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095402/),[ml] / [kg·min],4.9,35962,DB00313,Valproic Acid
,2095402,total plasma clearance,"The total plasma clearance of (E)-2-ene VPA in normal rats was 4.9 ml/min/kg and in bile-exteriorized rats, 7.7 ml/min/kg.",Pharmacokinetics and enterohepatic circulation of (E)-2-ene valproic acid in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095402/),[ml] / [kg·min],7.7,35963,DB00313,Valproic Acid
,28697014,days to initiation of testing,"Animals treated with VPA had faster neurocognitive recovery (days to initiation of testing, mean ± SD: ISCS = 6.2 ± 1.6 vs ISCS + VPA = 3.6 ± 1.5; p = 0.002; days to task mastery: ISCS = 7.0 ± 1.0 vs ISCS + VPA = 4.8 ± 0.5; p = 0.03).","Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28697014/),,6.2,36402,DB00313,Valproic Acid
,28697014,days to initiation of testing,"Animals treated with VPA had faster neurocognitive recovery (days to initiation of testing, mean ± SD: ISCS = 6.2 ± 1.6 vs ISCS + VPA = 3.6 ± 1.5; p = 0.002; days to task mastery: ISCS = 7.0 ± 1.0 vs ISCS + VPA = 4.8 ± 0.5; p = 0.03).","Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28697014/),,3.6,36403,DB00313,Valproic Acid
,28697014,days to task mastery,"Animals treated with VPA had faster neurocognitive recovery (days to initiation of testing, mean ± SD: ISCS = 6.2 ± 1.6 vs ISCS + VPA = 3.6 ± 1.5; p = 0.002; days to task mastery: ISCS = 7.0 ± 1.0 vs ISCS + VPA = 4.8 ± 0.5; p = 0.03).","Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28697014/),,7.0,36404,DB00313,Valproic Acid
,28697014,days to task mastery,"Animals treated with VPA had faster neurocognitive recovery (days to initiation of testing, mean ± SD: ISCS = 6.2 ± 1.6 vs ISCS + VPA = 3.6 ± 1.5; p = 0.002; days to task mastery: ISCS = 7.0 ± 1.0 vs ISCS + VPA = 4.8 ± 0.5; p = 0.03).","Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28697014/),,4.8,36405,DB00313,Valproic Acid
,28697014,maximum VPA concentrations,"The mean ± SD maximum VPA concentrations, area under the curve, and half-life were 145 ± 38.2 mg/L, 616 ± 150 hour·mg/L, and 1.70 ± 0.12 hours.","Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28697014/),[mg] / [l],145,36406,DB00313,Valproic Acid
,28697014,area under the curve,"The mean ± SD maximum VPA concentrations, area under the curve, and half-life were 145 ± 38.2 mg/L, 616 ± 150 hour·mg/L, and 1.70 ± 0.12 hours.","Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28697014/),[h·mg] / [l],616,36407,DB00313,Valproic Acid
,28697014,half-life,"The mean ± SD maximum VPA concentrations, area under the curve, and half-life were 145 ± 38.2 mg/L, 616 ± 150 hour·mg/L, and 1.70 ± 0.12 hours.","Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28697014/),h,1.70,36408,DB00313,Valproic Acid
,11360028,T1/2,"Lamotrigine half-life (T1/2) and oral clearance (Cl/F) values were significantly lower and significantly higher, respectively, in patients comedicated with enzyme inducers than in those receiving valproic acid (T1/2 = 8.1 vs.",Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360028/),,8.1,38250,DB00313,Valproic Acid
,11360028,Cl/F,"41.7 hours respectively, P < 0.001; Cl/F = 0.11 vs. 0.04 L/h per kg respectively, P < 0.005, geometric means), whereas Cmax and Tmax values were comparable in the two groups.",Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360028/),[l] / [h·kg],0.11,38251,DB00313,Valproic Acid
,11360028,Cl/F,"41.7 hours respectively, P < 0.001; Cl/F = 0.11 vs. 0.04 L/h per kg respectively, P < 0.005, geometric means), whereas Cmax and Tmax values were comparable in the two groups.",Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360028/),[l] / [h·kg],0.04,38252,DB00313,Valproic Acid
,15509246,apparent oral clearance (CL/F),TPM apparent oral clearance (CL/F) was significantly higher in children taking enzyme-inducing AEDs (85.4 +/- 34.0 ml/h/kg) than in those receiving VPA (49.6 +/- 13.6 ml/h/kg) or neutral AEDs (46.5 +/- 12.8 ml/h/kg).,Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509246/),[ml] / [h·kg],85.4,38692,DB00313,Valproic Acid
,15509246,apparent oral clearance (CL/F),TPM apparent oral clearance (CL/F) was significantly higher in children taking enzyme-inducing AEDs (85.4 +/- 34.0 ml/h/kg) than in those receiving VPA (49.6 +/- 13.6 ml/h/kg) or neutral AEDs (46.5 +/- 12.8 ml/h/kg).,Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509246/),[ml] / [h·kg],49.6,38693,DB00313,Valproic Acid
,15509246,apparent oral clearance (CL/F),TPM apparent oral clearance (CL/F) was significantly higher in children taking enzyme-inducing AEDs (85.4 +/- 34.0 ml/h/kg) than in those receiving VPA (49.6 +/- 13.6 ml/h/kg) or neutral AEDs (46.5 +/- 12.8 ml/h/kg).,Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509246/),[ml] / [h·kg],46.5,38694,DB00313,Valproic Acid
,20089352,concentrations,"The subjects with one or two variant CYP2A6*4 alleles showed higher mean plasma VPA concentrations compared with non-*4 alleles [(3.4+/-0.4)microg kg ml(-1)mg(-1) vs. (3.6+/-0.4)microg kg ml(-1)mg(-1), p=0.0055].","The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20089352/),[kg·μg] / [ml],3.6,38896,DB00313,Valproic Acid
,2084224,total plasma clearance,"In the pregnant rats, the total plasma clearance decreased significantly (p less than 0.05) from 7.06 ml/min/kg of the control to 5.34 ml/min/kg, whereas the plasma elimination half-life of valproate did not change.",Effect of pregnancy on the disposition of valproate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084224/),[ml] / [kg·min],7.06,39799,DB00313,Valproic Acid
,2084224,total plasma clearance,"In the pregnant rats, the total plasma clearance decreased significantly (p less than 0.05) from 7.06 ml/min/kg of the control to 5.34 ml/min/kg, whereas the plasma elimination half-life of valproate did not change.",Effect of pregnancy on the disposition of valproate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084224/),[ml] / [kg·min],5.34,39800,DB00313,Valproic Acid
,2084224,Kp,Rapid placental transfer was observed and the Kp value of the fetus was 0.43.,Effect of pregnancy on the disposition of valproate in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2084224/),,0.43,39801,DB00313,Valproic Acid
,6149238,overall Cmin,"The overall Cmin of valproic acid with chlorpromazine (33.2 +/- 1.7 micrograms/ml, N = 25) was significantly (p less than 0.01) greater than without (27.1 +/- 1.4 micrograms/ml, N = 25).",The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[μg] / [ml],33.2,40333,DB00313,Valproic Acid
,6149238,overall Cmin,"The overall Cmin of valproic acid with chlorpromazine (33.2 +/- 1.7 micrograms/ml, N = 25) was significantly (p less than 0.01) greater than without (27.1 +/- 1.4 micrograms/ml, N = 25).",The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[μg] / [ml],27.1,40334,DB00313,Valproic Acid
,6149238,t1/2,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),h,15.4,40335,DB00313,Valproic Acid
,6149238,t1/2,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),h,13.5,40336,DB00313,Valproic Acid
,6149238,clearance,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[ml] / [h·kg],7.18,40337,DB00313,Valproic Acid
,6149238,clearance,The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine.,The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6149238/),[ml] / [h·kg],8.32,40338,DB00313,Valproic Acid
,12071334,serum concentration,There was a significant difference (P < 0.005) in the mean serum concentration (+/- S.D.) of valproate after 1 hr between conventional valproate (63.1 +/- 27.9 microg/ml) and slow-release formulation of valproate (45.7 +/- 19.5 microg/ml).,Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[μg] / [ml],63.1,40390,DB00313,Valproic Acid
,12071334,serum concentration,There was a significant difference (P < 0.005) in the mean serum concentration (+/- S.D.) of valproate after 1 hr between conventional valproate (63.1 +/- 27.9 microg/ml) and slow-release formulation of valproate (45.7 +/- 19.5 microg/ml).,Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[μg] / [ml],45.7,40391,DB00313,Valproic Acid
,12071334,serum concentrations,"Mean serum concentrations (+/- S.D.) of 4-en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow-release formulation of valproate (4-en: 29.5 +/- 14.0-->23.0 +/- 15.3 ng/ml, 3-OH: 488.5 +/- 234.0-->419.6 +/- 171.1 ng/ml, 4-OH: 404.3 +/- 124.7-->342.8 +/- 147.6 ng/ml, 5-OH: 102.8 +/- 54.4-->81.0 +/- 43.6 ng/ml).",Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[ng] / [ml],29.5,40392,DB00313,Valproic Acid
,12071334,serum concentrations,"Mean serum concentrations (+/- S.D.) of 4-en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow-release formulation of valproate (4-en: 29.5 +/- 14.0-->23.0 +/- 15.3 ng/ml, 3-OH: 488.5 +/- 234.0-->419.6 +/- 171.1 ng/ml, 4-OH: 404.3 +/- 124.7-->342.8 +/- 147.6 ng/ml, 5-OH: 102.8 +/- 54.4-->81.0 +/- 43.6 ng/ml).",Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[ng] / [ml],23.0,40393,DB00313,Valproic Acid
,12071334,serum concentrations,"Mean serum concentrations (+/- S.D.) of 4-en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow-release formulation of valproate (4-en: 29.5 +/- 14.0-->23.0 +/- 15.3 ng/ml, 3-OH: 488.5 +/- 234.0-->419.6 +/- 171.1 ng/ml, 4-OH: 404.3 +/- 124.7-->342.8 +/- 147.6 ng/ml, 5-OH: 102.8 +/- 54.4-->81.0 +/- 43.6 ng/ml).",Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[ng] / [ml],488.5,40394,DB00313,Valproic Acid
,12071334,serum concentrations,"Mean serum concentrations (+/- S.D.) of 4-en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow-release formulation of valproate (4-en: 29.5 +/- 14.0-->23.0 +/- 15.3 ng/ml, 3-OH: 488.5 +/- 234.0-->419.6 +/- 171.1 ng/ml, 4-OH: 404.3 +/- 124.7-->342.8 +/- 147.6 ng/ml, 5-OH: 102.8 +/- 54.4-->81.0 +/- 43.6 ng/ml).",Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[ng] / [ml],419.6,40395,DB00313,Valproic Acid
,12071334,serum concentrations,"Mean serum concentrations (+/- S.D.) of 4-en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow-release formulation of valproate (4-en: 29.5 +/- 14.0-->23.0 +/- 15.3 ng/ml, 3-OH: 488.5 +/- 234.0-->419.6 +/- 171.1 ng/ml, 4-OH: 404.3 +/- 124.7-->342.8 +/- 147.6 ng/ml, 5-OH: 102.8 +/- 54.4-->81.0 +/- 43.6 ng/ml).",Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[ng] / [ml],404.3,40396,DB00313,Valproic Acid
,12071334,serum concentrations,"Mean serum concentrations (+/- S.D.) of 4-en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow-release formulation of valproate (4-en: 29.5 +/- 14.0-->23.0 +/- 15.3 ng/ml, 3-OH: 488.5 +/- 234.0-->419.6 +/- 171.1 ng/ml, 4-OH: 404.3 +/- 124.7-->342.8 +/- 147.6 ng/ml, 5-OH: 102.8 +/- 54.4-->81.0 +/- 43.6 ng/ml).",Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[ng] / [ml],342.8,40397,DB00313,Valproic Acid
,12071334,serum concentrations,"Mean serum concentrations (+/- S.D.) of 4-en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow-release formulation of valproate (4-en: 29.5 +/- 14.0-->23.0 +/- 15.3 ng/ml, 3-OH: 488.5 +/- 234.0-->419.6 +/- 171.1 ng/ml, 4-OH: 404.3 +/- 124.7-->342.8 +/- 147.6 ng/ml, 5-OH: 102.8 +/- 54.4-->81.0 +/- 43.6 ng/ml).",Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[ng] / [ml],102.8,40398,DB00313,Valproic Acid
,12071334,serum concentrations,"Mean serum concentrations (+/- S.D.) of 4-en and hydroxy metabolites after 5 hr were significantly reduced after replacement with slow-release formulation of valproate (4-en: 29.5 +/- 14.0-->23.0 +/- 15.3 ng/ml, 3-OH: 488.5 +/- 234.0-->419.6 +/- 171.1 ng/ml, 4-OH: 404.3 +/- 124.7-->342.8 +/- 147.6 ng/ml, 5-OH: 102.8 +/- 54.4-->81.0 +/- 43.6 ng/ml).",Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071334/),[ng] / [ml],81.0,40399,DB00313,Valproic Acid
,20230843,ED(50),"Racemic-VCD, (2R,3S)-VCD and (2S,3S)-VCD showed a dose-related reversal of tactile allodynia with ED(50) values of 52, 61 and 39 mg/kg, respectively. (2S,3S)-VCD was significantly more potent than (2R,3S)-VCD but the opposite is true for its anticonvulsant-effect.","Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230843/),[mg] / [kg],52,41168,DB00313,Valproic Acid
,20230843,ED(50),"Racemic-VCD, (2R,3S)-VCD and (2S,3S)-VCD showed a dose-related reversal of tactile allodynia with ED(50) values of 52, 61 and 39 mg/kg, respectively. (2S,3S)-VCD was significantly more potent than (2R,3S)-VCD but the opposite is true for its anticonvulsant-effect.","Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230843/),[mg] / [kg],61,41169,DB00313,Valproic Acid
,20230843,ED(50),"Racemic-VCD, (2R,3S)-VCD and (2S,3S)-VCD showed a dose-related reversal of tactile allodynia with ED(50) values of 52, 61 and 39 mg/kg, respectively. (2S,3S)-VCD was significantly more potent than (2R,3S)-VCD but the opposite is true for its anticonvulsant-effect.","Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20230843/),[mg] / [kg],39,41170,DB00313,Valproic Acid
,16882100,minimum (C(min)),"In polytherapy patients on c. 32.1 mg/kg/day, steady-state (no missed doses) mean VPA minimum (C(min)) and maximum (C(max)) concentrations were 67 and 98 mg/L, respectively.",Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882100/),[mg] / [l],67,41313,DB00313,Valproic Acid
,16882100,maximum (C(max)) concentrations,"In polytherapy patients on c. 32.1 mg/kg/day, steady-state (no missed doses) mean VPA minimum (C(min)) and maximum (C(max)) concentrations were 67 and 98 mg/L, respectively.",Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882100/),[mg] / [l],98,41314,DB00313,Valproic Acid
,16882100,C(min),"When dose(s) were missed for 12, 18 and 24 h, mean C(min) fell to 37, 28 and 20 mg/L, respectively, below the threshold 50 mg/L VPA concentration generally required to maintain efficacy.",Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882100/),[mg] / [l],37,41315,DB00313,Valproic Acid
,16882100,C(min),"When dose(s) were missed for 12, 18 and 24 h, mean C(min) fell to 37, 28 and 20 mg/L, respectively, below the threshold 50 mg/L VPA concentration generally required to maintain efficacy.",Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882100/),[mg] / [l],28,41316,DB00313,Valproic Acid
,16882100,C(min),"When dose(s) were missed for 12, 18 and 24 h, mean C(min) fell to 37, 28 and 20 mg/L, respectively, below the threshold 50 mg/L VPA concentration generally required to maintain efficacy.",Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882100/),[mg] / [l],20,41317,DB00313,Valproic Acid
,16882100,C(max),"Replacing, then resuming the next regularly scheduled divalproex dose increased mean C(max) to 113, 117 and 129 mg/L upon replacement at 12, 18 and 24 h, respectively; a mean increment of 31 mg/L for replacement at 24 h.",Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882100/),[mg] / [l],113,41318,DB00313,Valproic Acid
,16882100,C(max),"Replacing, then resuming the next regularly scheduled divalproex dose increased mean C(max) to 113, 117 and 129 mg/L upon replacement at 12, 18 and 24 h, respectively; a mean increment of 31 mg/L for replacement at 24 h.",Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882100/),[mg] / [l],117,41319,DB00313,Valproic Acid
,16882100,C(max),"Replacing, then resuming the next regularly scheduled divalproex dose increased mean C(max) to 113, 117 and 129 mg/L upon replacement at 12, 18 and 24 h, respectively; a mean increment of 31 mg/L for replacement at 24 h.",Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882100/),[mg] / [l],129,41320,DB00313,Valproic Acid
,1940980,terminal half-lives,"Mean terminal half-lives were similar in plasma and whole blood (12.5 and 15.5 h, respectively), but were considerably longer than for free VPA (6.4 and 6.5 h, respectively; P less than 0.01).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),h,12.5,41562,DB00313,Valproic Acid
,1940980,terminal half-lives,"Mean terminal half-lives were similar in plasma and whole blood (12.5 and 15.5 h, respectively), but were considerably longer than for free VPA (6.4 and 6.5 h, respectively; P less than 0.01).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),h,15.5,41563,DB00313,Valproic Acid
,1940980,terminal half-lives,"Mean terminal half-lives were similar in plasma and whole blood (12.5 and 15.5 h, respectively), but were considerably longer than for free VPA (6.4 and 6.5 h, respectively; P less than 0.01).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),h,6.4,41564,DB00313,Valproic Acid
,1940980,terminal half-lives,"Mean terminal half-lives were similar in plasma and whole blood (12.5 and 15.5 h, respectively), but were considerably longer than for free VPA (6.4 and 6.5 h, respectively; P less than 0.01).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),h,6.5,41565,DB00313,Valproic Acid
,1940980,Plasma,"Plasma and whole blood clearance for total VPA was higher than reported in older infants and adults (17.8 and 28.9 ml/kg per hour) and was considerably higher for free VPA (127.6 and 188.8 ml/kg per hour, respectively).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),[ml] / [h·kg],17.8,41566,DB00313,Valproic Acid
,1940980,Plasma,"Plasma and whole blood clearance for total VPA was higher than reported in older infants and adults (17.8 and 28.9 ml/kg per hour) and was considerably higher for free VPA (127.6 and 188.8 ml/kg per hour, respectively).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),[ml] / [h·kg],28.9,41567,DB00313,Valproic Acid
,1940980,Plasma,"Plasma and whole blood clearance for total VPA was higher than reported in older infants and adults (17.8 and 28.9 ml/kg per hour) and was considerably higher for free VPA (127.6 and 188.8 ml/kg per hour, respectively).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),[ml] / [h·kg],127.6,41568,DB00313,Valproic Acid
,1940980,whole blood clearance,"Plasma and whole blood clearance for total VPA was higher than reported in older infants and adults (17.8 and 28.9 ml/kg per hour) and was considerably higher for free VPA (127.6 and 188.8 ml/kg per hour, respectively).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),[ml] / [h·kg],28.9,41569,DB00313,Valproic Acid
,1940980,whole blood clearance,"Plasma and whole blood clearance for total VPA was higher than reported in older infants and adults (17.8 and 28.9 ml/kg per hour) and was considerably higher for free VPA (127.6 and 188.8 ml/kg per hour, respectively).",Pharmacokinetics of total and free valproic acid during monotherapy in infants. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1940980/),[ml] / [h·kg],188.8,41570,DB00313,Valproic Acid
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB00313,Valproic Acid
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB00313,Valproic Acid
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB00313,Valproic Acid
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB00313,Valproic Acid
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB00313,Valproic Acid
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB00313,Valproic Acid
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB00313,Valproic Acid
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],2.9,44201,DB00313,Valproic Acid
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],5.1,44202,DB00313,Valproic Acid
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],89,44203,DB00313,Valproic Acid
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],119,44204,DB00313,Valproic Acid
,12959317,half-lives,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),h,17,44205,DB00313,Valproic Acid
,12959317,half-lives,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),h,20,44206,DB00313,Valproic Acid
,18028106,bioavailability (F),"However, the bioavailability (F) of acyclovir was 8.4% in group A versus 1.5% in group C.",Interaction between valproic acid and acyclovir after intravenous and oral administration in a rabbit model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18028106/),%,8.4,44441,DB00313,Valproic Acid
,18028106,bioavailability (F),"However, the bioavailability (F) of acyclovir was 8.4% in group A versus 1.5% in group C.",Interaction between valproic acid and acyclovir after intravenous and oral administration in a rabbit model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18028106/),%,1.5,44442,DB00313,Valproic Acid
,2907464,Total apparent plasma clearance,Total apparent plasma clearance was 8.67 ml/min.,Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907464/),[ml] / [min],8.67,44467,DB00313,Valproic Acid
,2907464,apparent plasma elimination half-life,"In these rats, the apparent plasma elimination half-life increased from 12.7 to 18.8 min and plasma clearance decreased from 11.4 to 7.41 ml/min.",Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907464/),min,12.7 to 18.8,44468,DB00313,Valproic Acid
,2907464,plasma clearance,"In these rats, the apparent plasma elimination half-life increased from 12.7 to 18.8 min and plasma clearance decreased from 11.4 to 7.41 ml/min.",Pharmacokinetics and enterohepatic circulation of 2-n-propyl-4-pentenoic acid in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907464/),[ml] / [min],11.4 to 7.41,44469,DB00313,Valproic Acid
,18503564,elimination half-life,"During repeated dosing, steady state is reached within 2 days, consistent with its elimination half-life of 6-10 h.",Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503564/),h,6-10,45117,DB00313,Valproic Acid
,15552635,steady-,"Mean steady-state valproic acid exposure, maximum concentration, and minimum concentration were 1771 mg x hr/L, 86.9 mg/L, and 55.5 mg/L for the morning dosing and 1728 mg x hr/L, 84.8 mg/L, and 57.4 mg/L for the evening dosing regimens, respectively.",Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552635/),[h·mg] / [l],1771,47549,DB00313,Valproic Acid
,15552635,steady-,"Mean steady-state valproic acid exposure, maximum concentration, and minimum concentration were 1771 mg x hr/L, 86.9 mg/L, and 55.5 mg/L for the morning dosing and 1728 mg x hr/L, 84.8 mg/L, and 57.4 mg/L for the evening dosing regimens, respectively.",Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552635/),[h·mg] / [l],1728,47550,DB00313,Valproic Acid
,15552635,maximum concentration,"Mean steady-state valproic acid exposure, maximum concentration, and minimum concentration were 1771 mg x hr/L, 86.9 mg/L, and 55.5 mg/L for the morning dosing and 1728 mg x hr/L, 84.8 mg/L, and 57.4 mg/L for the evening dosing regimens, respectively.",Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552635/),[mg] / [l],84.8,47551,DB00313,Valproic Acid
,15552635,minimum concentration,"Mean steady-state valproic acid exposure, maximum concentration, and minimum concentration were 1771 mg x hr/L, 86.9 mg/L, and 55.5 mg/L for the morning dosing and 1728 mg x hr/L, 84.8 mg/L, and 57.4 mg/L for the evening dosing regimens, respectively.",Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552635/),[mg] / [l],55.5,47552,DB00313,Valproic Acid
,15552635,minimum concentration,"Mean steady-state valproic acid exposure, maximum concentration, and minimum concentration were 1771 mg x hr/L, 86.9 mg/L, and 55.5 mg/L for the morning dosing and 1728 mg x hr/L, 84.8 mg/L, and 57.4 mg/L for the evening dosing regimens, respectively.",Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15552635/),[mg] / [l],57.4,47553,DB00313,Valproic Acid
,22476391,trough plasma concentration (C(S)),"The standardized trough plasma concentration (C(S)) of VPA was much lower in our patients with the UGT1A3*5 variant than in the wild type carriers (3.24 ± 1.05 vs. 4.68 ± 1.24 μg·kg·mL(-1)·mg(-1), P < 0.01).",Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22476391/),[kg·μg] / [mg·ml],3.24,47909,DB00313,Valproic Acid
,22476391,trough plasma concentration (C(S)),"The standardized trough plasma concentration (C(S)) of VPA was much lower in our patients with the UGT1A3*5 variant than in the wild type carriers (3.24 ± 1.05 vs. 4.68 ± 1.24 μg·kg·mL(-1)·mg(-1), P < 0.01).",Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22476391/),[kg·μg] / [mg·ml],4.68,47910,DB00313,Valproic Acid
,7667199,fe,"Valproyl glycine and valproyl GABA were partially excreted unchanged in the urine (fe = 50% and 34%, respectively), while the urinary metabolites of the amide derivatives were valproyl glycine and valproyl GABA.",Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667199/),%,50,50114,DB00313,Valproic Acid
,7667199,fe,"Valproyl glycine and valproyl GABA were partially excreted unchanged in the urine (fe = 50% and 34%, respectively), while the urinary metabolites of the amide derivatives were valproyl glycine and valproyl GABA.",Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667199/),%,34,50115,DB00313,Valproic Acid
,11802095,CL/F,Population estimates of CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.81 L/h and 78.1 +/- 5.1 L/kg.,Population pharmacokinetics of lamotrigine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802095/),[l] / [h],2.14,51797,DB00313,Valproic Acid
,11802095,V/F,Population estimates of CL/F and V/F for lamotrigine generated in the final model were 2.14 +/- 0.81 L/h and 78.1 +/- 5.1 L/kg.,Population pharmacokinetics of lamotrigine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11802095/),[l] / [kg],78.1,51798,DB00313,Valproic Acid
,17687269,AUEC_tracking,"Psychometric results were significant among the UGT2B7 genotype group (AUEC_tracking 261.5+/-298.9 in *1/*1, and 3,396.8+/-947 in *2/*2, P=0.047) when the two drugs were coadministered.",Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17687269/),,261.5,52633,DB00313,Valproic Acid
,17687269,AUEC_tracking,"Psychometric results were significant among the UGT2B7 genotype group (AUEC_tracking 261.5+/-298.9 in *1/*1, and 3,396.8+/-947 in *2/*2, P=0.047) when the two drugs were coadministered.",Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17687269/),,"3,396.8",52634,DB00313,Valproic Acid
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],69 to 151.3,52778,DB00313,Valproic Acid
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],11.3 to 26.7,52779,DB00313,Valproic Acid
,33336359,total plasma concentrations,"The total plasma concentrations ranged from 69 to 151.3 μg/mL for LEV, 11.3 to 26.7 μg/mL for PHT and 126 to 223 μg/mL for VPA.","Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),[μg] / [ml],126 to 223,52780,DB00313,Valproic Acid
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,4,52781,DB00313,Valproic Acid
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,19,52782,DB00313,Valproic Acid
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,17,52783,DB00313,Valproic Acid
,33336359,Free fraction,Free fraction ranged from 4% to 19% for PHT and 17% to 51% for VPA.,"Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336359/),%,51,52784,DB00313,Valproic Acid
,17727739,trough serum concentrations,"After the LTG escalation to 200 mg/day, mean trough serum concentrations of 8.0 microg/mL did not differ significantly from the 9.5 microg/mL after VPA withdrawal or the 9.2 microg/mL after 4 weeks of monotherapy at 500 mg/day.",Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17727739/),[μg] / [ml],8.0,53372,DB00313,Valproic Acid
,17727739,trough serum concentrations,"After the LTG escalation to 200 mg/day, mean trough serum concentrations of 8.0 microg/mL did not differ significantly from the 9.5 microg/mL after VPA withdrawal or the 9.2 microg/mL after 4 weeks of monotherapy at 500 mg/day.",Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17727739/),[μg] / [ml],9.5,53373,DB00313,Valproic Acid
,17727739,trough serum concentrations,"After the LTG escalation to 200 mg/day, mean trough serum concentrations of 8.0 microg/mL did not differ significantly from the 9.5 microg/mL after VPA withdrawal or the 9.2 microg/mL after 4 weeks of monotherapy at 500 mg/day.",Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17727739/),[μg] / [ml],9.2,53374,DB00313,Valproic Acid
,22171585,CL/F,"Eslicarbazepine CL/F was affected by bodyweight, dose of carbamazepine (D(CAR)) and co-administration of barbiturates or phenytoin (AED(PB)), as predicted by the equation CL/F = (2.36 + 0.00149 • D(CAR) + 1.41 • AED(PB)) • (weight/70)0.75, which means that CL/F is 2.36 L/h for a subject with a bodyweight of 70 kg and without concomitant carbamazepine and barbiturates/phenytoin.","Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22171585/),[l] / [h],2.36,53544,DB00313,Valproic Acid
,10365638,protein binding,Valproic acid is considered unremovable by hemodialysis because of the high protein binding of 90%-95%.,Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365638/),%,90,53968,DB00313,Valproic Acid
,10365638,protein binding,Valproic acid is considered unremovable by hemodialysis because of the high protein binding of 90%-95%.,Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365638/),%,95,53969,DB00313,Valproic Acid
,10365638,anion gap,The anion gap was 26 mmol/L (normal <12-14 mmol/L) and corresponded fairly well with this valproic acid level.,Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365638/),[mM] / [l],26,53970,DB00313,Valproic Acid
,10365638,plasma clearances,"The valproic acid plasma clearances during treatment were: 80 mL/min (hemodialysis); 40 mL/min (hemoperfusion by charcoal) and 80 mL/min (hemoperfusion by resin, only in the first hour).",Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365638/),[ml] / [min],80,53971,DB00313,Valproic Acid
,10365638,plasma clearances,"The valproic acid plasma clearances during treatment were: 80 mL/min (hemodialysis); 40 mL/min (hemoperfusion by charcoal) and 80 mL/min (hemoperfusion by resin, only in the first hour).",Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365638/),[ml] / [min],40,53972,DB00313,Valproic Acid
,10365638,protein binding,The protein binding of valproic acid in plasma was only 32% at the start and was 54% at the end of the two sessions.,Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365638/),%,32,53973,DB00313,Valproic Acid
,10365638,protein binding,The protein binding of valproic acid in plasma was only 32% at the start and was 54% at the end of the two sessions.,Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365638/),%,54,53974,DB00313,Valproic Acid
,25137440,flow rate,The chromatographic separation was achieved using a reversed-phase Zorbax SB-C18 column and a mobile phase of acetic acid in water (0.2% v/v) and acetonitrile (40:60 v/v) with a flow rate of 0.5 mL/min.,A simple validated RP-HPLC bioanalytical method for the quantitative determination of a novel valproic acid arylamide derivative in rat hepatic microsomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137440/),[ml] / [min],0.5,54094,DB00313,Valproic Acid
,25137440,recovery,The recovery of HO-AAVPA was measured between 91.36 and 97.98%.,A simple validated RP-HPLC bioanalytical method for the quantitative determination of a novel valproic acid arylamide derivative in rat hepatic microsomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137440/),%,91.36 and 97.98,54095,DB00313,Valproic Acid
,8689948,terminal elimination half-life,The disposition of VPA in maternal serum is best described by a biexponential function with a terminal elimination half-life of 2.13 +/- 0.49 hr and volume of distribution of 0.242 +/- 0.036 liter/kg.,The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689948/),h,2.13,57075,DB00313,Valproic Acid
,8689948,volume of distribution,The disposition of VPA in maternal serum is best described by a biexponential function with a terminal elimination half-life of 2.13 +/- 0.49 hr and volume of distribution of 0.242 +/- 0.036 liter/kg.,The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689948/),[l] / [kg],0.242,57076,DB00313,Valproic Acid
,8689948,AUCinfinityFA/AUCinfinityMA,There was significant fetal exposure to VPA after maternal dosing (mean AUCinfinityFA/AUCinfinityMA = 0.410 +/- 0.118).,The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689948/),,0.410,57077,DB00313,Valproic Acid
,8689948,terminal elimination half-life,"Similarly, the disposition of VPA in fetal serum after fetal dosing is best described by a biexponential decay with a terminal elimination half-life of 3.37 +/- 1.37 hr.",The pharmacokinetics of valproic acid in pregnant sheep after maternal and fetal intravenous bolus administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8689948/),h,3.37,57078,DB00313,Valproic Acid
,15569400,Ka,"Optimum PPK parameters were: Ka, 2.522+/-2.743 h(-1); Vs, 0.329+/-0.496 L/kg; and Kel, 0.0438+/-0.0384 h(-1).",Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15569400/),1/[h],2.522,57958,DB00313,Valproic Acid
,15569400,Vs,"Optimum PPK parameters were: Ka, 2.522+/-2.743 h(-1); Vs, 0.329+/-0.496 L/kg; and Kel, 0.0438+/-0.0384 h(-1).",Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15569400/),[l] / [kg],0.329,57959,DB00313,Valproic Acid
,15569400,Kel,"Optimum PPK parameters were: Ka, 2.522+/-2.743 h(-1); Vs, 0.329+/-0.496 L/kg; and Kel, 0.0438+/-0.0384 h(-1).",Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15569400/),1/[h],0.0438,57960,DB00313,Valproic Acid
,2114617,equilibrium association constants,The equilibrium association constants for the high- and intermediate-affinity sites were more than an order of magnitude higher with E-delta 2-VPA than with VPA (10(4)-10(6) versus 10(3) M-1).,Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2114617/),1/[M],10,58099,DB00313,Valproic Acid
,2114617,equilibrium association constants,The equilibrium association constants for the high- and intermediate-affinity sites were more than an order of magnitude higher with E-delta 2-VPA than with VPA (10(4)-10(6) versus 10(3) M-1).,Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2114617/),1/[M],10(3),58100,DB00313,Valproic Acid
,14673555,CL,The population CL as estimated by base model (no covariates) was 0.581 l h(-1) with inter-individual variability (C.V. %) of 17.4% and SD of residual error was 6.82 mg l(-1).,Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14673555/),[l] / [h],0.581,61129,DB00313,Valproic Acid
,31957880,Peak plasma concentration (Cmax ),"Peak plasma concentration (Cmax ) was obtained at 1-2 hours after dosing and ranged between 6.8 and 9.4 mg/L. (2S,3S)-SPD plasma concentration at 10 minutes after dosing (C10 ) ranged between 2.1 and 3.5 mg/mL, and its half-life ranged between 0.9 and 2.3 hours.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[mg] / [l],6.8 and 9.4,61555,DB00313,Valproic Acid
,31957880,plasma concentration at 10 minutes after dosing (C10 ),"Peak plasma concentration (Cmax ) was obtained at 1-2 hours after dosing and ranged between 6.8 and 9.4 mg/L. (2S,3S)-SPD plasma concentration at 10 minutes after dosing (C10 ) ranged between 2.1 and 3.5 mg/mL, and its half-life ranged between 0.9 and 2.3 hours.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[mg] / [ml],2.1 and 3.5,61556,DB00313,Valproic Acid
,31957880,half-life,"Peak plasma concentration (Cmax ) was obtained at 1-2 hours after dosing and ranged between 6.8 and 9.4 mg/L. (2S,3S)-SPD plasma concentration at 10 minutes after dosing (C10 ) ranged between 2.1 and 3.5 mg/mL, and its half-life ranged between 0.9 and 2.3 hours.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),h,0.9 and 2.3,61557,DB00313,Valproic Acid
,31957880,C10,"The highest C10 value, which may indicate rapid activity onset, and the highest Cmax were observed following administration of FA (40 mg/kg): C10 = 3.5 mg/L and Cmax = 9.5 mg/L.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[mg] / [l],3.5,61558,DB00313,Valproic Acid
,31957880,Cmax,"The highest C10 value, which may indicate rapid activity onset, and the highest Cmax were observed following administration of FA (40 mg/kg): C10 = 3.5 mg/L and Cmax = 9.5 mg/L.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[mg] / [l],9.5,61559,DB00313,Valproic Acid
,31957880,Cmax,"Following intramuscular dosing of (2S,3S)-SPD (12 mg/kg) to pigs of FA and FB , a Cmax value of 0.9 mg/L was obtained 0.42 and 0.75 hours after dosing, respectively.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[mg] / [l],0.9,61560,DB00313,Valproic Acid
,31957880,C10,"(2S,3S)-SPD C10 was 0.27 mg/L (FA ) and 0.49 mg/L (FB ). (2S,3S)-SPD clearance, volume of distribution, and half-life were 2 L/h/kg, 18-28 L/kg, and 6.1-9.7 hours, respectively.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[mg] / [l],0.27,61561,DB00313,Valproic Acid
,31957880,C10,"(2S,3S)-SPD C10 was 0.27 mg/L (FA ) and 0.49 mg/L (FB ). (2S,3S)-SPD clearance, volume of distribution, and half-life were 2 L/h/kg, 18-28 L/kg, and 6.1-9.7 hours, respectively.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[mg] / [l],0.49,61562,DB00313,Valproic Acid
,31957880,clearance,"(2S,3S)-SPD C10 was 0.27 mg/L (FA ) and 0.49 mg/L (FB ). (2S,3S)-SPD clearance, volume of distribution, and half-life were 2 L/h/kg, 18-28 L/kg, and 6.1-9.7 hours, respectively.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[l] / [h·kg],2,61563,DB00313,Valproic Acid
,31957880,volume of distribution,"(2S,3S)-SPD C10 was 0.27 mg/L (FA ) and 0.49 mg/L (FB ). (2S,3S)-SPD clearance, volume of distribution, and half-life were 2 L/h/kg, 18-28 L/kg, and 6.1-9.7 hours, respectively.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),[l] / [kg],18-28,61564,DB00313,Valproic Acid
,31957880,half-life,"(2S,3S)-SPD C10 was 0.27 mg/L (FA ) and 0.49 mg/L (FB ). (2S,3S)-SPD clearance, volume of distribution, and half-life were 2 L/h/kg, 18-28 L/kg, and 6.1-9.7 hours, respectively.","Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs-A CNS-active stereoisomer of SPD. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31957880/),h,6.1-9.7,61565,DB00313,Valproic Acid
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,2.65,61642,DB00313,Valproic Acid
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,3.52,61643,DB00313,Valproic Acid
,10864038,half-lives,"The half-lives of Ara-C, MTX, and ACNU were 2.65, 3.52, and 0.71 h, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),h,0.71,61644,DB00313,Valproic Acid
,10864038,concentrations,"The mean total and free VPA concentrations in plasma were 78.0+/-0.8 and 10.9-0.3 microg/ml, respectively.","Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10864038/),[μg] / [ml],10.9-0.3,61645,DB00313,Valproic Acid
,1682448,areas under the plasma concentration/time curve,"Their effect on bioavailability was observed as an increase in plasma levels of the active substance, with areas under the plasma concentration/time curve of 396.26 and 306.64 micrograms h mL-1 (formulas II and III, respectively) and 243.28 micrograms h mL-1 (formula I).",Rectal bioavailability of water-soluble drugs: sodium valproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682448/),[h·μg] / [ml],396.26,62427,DB00313,Valproic Acid
,1682448,areas under the plasma concentration/time curve,"Their effect on bioavailability was observed as an increase in plasma levels of the active substance, with areas under the plasma concentration/time curve of 396.26 and 306.64 micrograms h mL-1 (formulas II and III, respectively) and 243.28 micrograms h mL-1 (formula I).",Rectal bioavailability of water-soluble drugs: sodium valproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682448/),[h·μg] / [ml],306.64,62428,DB00313,Valproic Acid
,1682448,areas under the plasma concentration/time curve,"Their effect on bioavailability was observed as an increase in plasma levels of the active substance, with areas under the plasma concentration/time curve of 396.26 and 306.64 micrograms h mL-1 (formulas II and III, respectively) and 243.28 micrograms h mL-1 (formula I).",Rectal bioavailability of water-soluble drugs: sodium valproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682448/),[h·μg] / [ml],243.28,62429,DB00313,Valproic Acid
,1682448,time to peak plasma concentration,"The time to peak plasma concentration was also delayed with peaks at 30, 55 and 50 min with formulas I, II and III, respectively.",Rectal bioavailability of water-soluble drugs: sodium valproate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682448/),min,30,62430,DB00313,Valproic Acid
,1682448,time to peak plasma concentration,"The time to peak plasma concentration was also delayed with peaks at 30, 55 and 50 min with formulas I, II and III, respectively.",Rectal bioavailability of water-soluble drugs: sodium valproate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682448/),min,55,62431,DB00313,Valproic Acid
,1682448,time to peak plasma concentration,"The time to peak plasma concentration was also delayed with peaks at 30, 55 and 50 min with formulas I, II and III, respectively.",Rectal bioavailability of water-soluble drugs: sodium valproate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682448/),min,50,62432,DB00313,Valproic Acid
,31222537,apparent clearance (CL/F),"Average parameter estimates for valproic acid apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.14 L/h and 37.7 L (fixed), respectively.",Estimation of apparent clearance of valproic acid in adult Saudi patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222537/),[l] / [h],0.14,63153,DB00313,Valproic Acid
,31222537,apparent volume of distribution (V/F),"Average parameter estimates for valproic acid apparent clearance (CL/F) and apparent volume of distribution (V/F) were 0.14 L/h and 37.7 L (fixed), respectively.",Estimation of apparent clearance of valproic acid in adult Saudi patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222537/),l,37.7,63154,DB00313,Valproic Acid
,6773716,Clearance,Clearance declined 20% from 8.33 +/- 2.44 to 6.67 +/- 1.25 ml/hr/kd between the single-dose and the 500-mg/day steps (p = 0.05).,Valproic acid dosage and plasma protein binding and clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6773716/),[ml] / [h·kd],8.33,63209,DB00313,Valproic Acid
,6773716,Clearance,Clearance declined 20% from 8.33 +/- 2.44 to 6.67 +/- 1.25 ml/hr/kd between the single-dose and the 500-mg/day steps (p = 0.05).,Valproic acid dosage and plasma protein binding and clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6773716/),[ml] / [h·kd],6.67,63210,DB00313,Valproic Acid
,6773716,free fraction,"Clearance was unchanged between the 500- and 1,000-mg/day steps despite a 44% increase in mean free fraction (0.0703 +/- 0.0381 vs 0.1011 +/- 0.0438, p < 0.05), implying a balanced opposing decline in intrinsic clearance (from 89.2 +/0 71.0 to 72.0 +/- 20.8 ml/hr/kg; p = 0.025).",Valproic acid dosage and plasma protein binding and clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6773716/),,0.0703,63211,DB00313,Valproic Acid
,6773716,free fraction,"Clearance was unchanged between the 500- and 1,000-mg/day steps despite a 44% increase in mean free fraction (0.0703 +/- 0.0381 vs 0.1011 +/- 0.0438, p < 0.05), implying a balanced opposing decline in intrinsic clearance (from 89.2 +/0 71.0 to 72.0 +/- 20.8 ml/hr/kg; p = 0.025).",Valproic acid dosage and plasma protein binding and clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6773716/),,0.1011,63212,DB00313,Valproic Acid
,6773716,intrinsic clearance,"Clearance was unchanged between the 500- and 1,000-mg/day steps despite a 44% increase in mean free fraction (0.0703 +/- 0.0381 vs 0.1011 +/- 0.0438, p < 0.05), implying a balanced opposing decline in intrinsic clearance (from 89.2 +/0 71.0 to 72.0 +/- 20.8 ml/hr/kg; p = 0.025).",Valproic acid dosage and plasma protein binding and clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6773716/),[ml] / [h·kg],89.2,63213,DB00313,Valproic Acid
,6773716,intrinsic clearance,"Clearance was unchanged between the 500- and 1,000-mg/day steps despite a 44% increase in mean free fraction (0.0703 +/- 0.0381 vs 0.1011 +/- 0.0438, p < 0.05), implying a balanced opposing decline in intrinsic clearance (from 89.2 +/0 71.0 to 72.0 +/- 20.8 ml/hr/kg; p = 0.025).",Valproic acid dosage and plasma protein binding and clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6773716/),[ml] / [h·kg],72.0,63214,DB00313,Valproic Acid
,6773716,clearance,"In four subjects completing the 1,500-mg/day step, clearance increased from 6.76 +/- 1.48 ml/hr/kg (1,000- mg/day) to 8.20 +/- 1.62 ml/hr/kg, corresponding to a further increase in free fraction.",Valproic acid dosage and plasma protein binding and clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6773716/),[ml] / [h·kg],6.76,63215,DB00313,Valproic Acid
,6773716,clearance,"In four subjects completing the 1,500-mg/day step, clearance increased from 6.76 +/- 1.48 ml/hr/kg (1,000- mg/day) to 8.20 +/- 1.62 ml/hr/kg, corresponding to a further increase in free fraction.",Valproic acid dosage and plasma protein binding and clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6773716/),[ml] / [h·kg],8.20,63216,DB00313,Valproic Acid
,12576167,concentration at 1h (C(1h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],2.1,63306,DB00313,Valproic Acid
,12576167,concentration at 12h (C(12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],0.8,63307,DB00313,Valproic Acid
,12576167,area under the curve from 0 to 12h (AUC(0-12h)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),[μg] / [ml],17.1,63308,DB00313,Valproic Acid
,12576167,half-life (t(1/2)),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),h,8.1,63309,DB00313,Valproic Acid
,12576167,apparent oral clearance (CL/F),"Estimated pharmacokinetic values, normalized to a dose of 1 mgkg(-1) b.i.d., were: concentration at 1h (C(1h)) 2.1 microgram ml(-1), concentration at 12h (C(12h)) 0.8 microgram ml(-1), area under the curve from 0 to 12h (AUC(0-12h)) 17.1 microgram ml(-1)h, half-life (t(1/2)) 8.1h, and apparent oral clearance (CL/F) 0.97 mlmin(-1)kg(-1).",Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576167/),1/[mlmin],0.97,63310,DB00313,Valproic Acid
,29328514,Vd,The estimated Vd for one-compartment models ranged from 8.4 to 23.3 l.,A systematic review of population pharmacokinetics of valproic acid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29328514/),l,8.4 to 23.3,63560,DB00313,Valproic Acid
,29328514,peripheral volumes of distribution,"For two-compartment models, peripheral volumes of distribution ranged from 4.08 to 42.1 l.",A systematic review of population pharmacokinetics of valproic acid. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29328514/),l,4.08 to 42.1,63561,DB00313,Valproic Acid
,29328514,CLVPA,The estimated CLVPA ranged from 0.206 to 1.154 l h-1 and the inter-individual variability ranged from 13.40 to 35.90%.,A systematic review of population pharmacokinetics of valproic acid. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29328514/),[l] / [h],0.206 to 1.154,63562,DB00313,Valproic Acid
,9056061,area under the plasma concentration-time curve to 48 h (AUC (0.48 h)),"The area under the plasma concentration-time curve to 48 h (AUC (0.48 h)) was 408 +/- 114.5 (s.d.) mg l-1 h in the control phase and 398 +/- 108.6 mg l-1 h after charcoal and the t1/2 elimination was 20 +/- 6.8 h in the control phase, and 22 +/- 9.2 h after charcoal (NS).",The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056061/),[h·mg] / [l],408,64392,DB00313,Valproic Acid
,9056061,area under the plasma concentration-time curve to 48 h (AUC (0.48 h)),"The area under the plasma concentration-time curve to 48 h (AUC (0.48 h)) was 408 +/- 114.5 (s.d.) mg l-1 h in the control phase and 398 +/- 108.6 mg l-1 h after charcoal and the t1/2 elimination was 20 +/- 6.8 h in the control phase, and 22 +/- 9.2 h after charcoal (NS).",The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056061/),[h·mg] / [l],398,64393,DB00313,Valproic Acid
,9056061,t1/2 elimination,"The area under the plasma concentration-time curve to 48 h (AUC (0.48 h)) was 408 +/- 114.5 (s.d.) mg l-1 h in the control phase and 398 +/- 108.6 mg l-1 h after charcoal and the t1/2 elimination was 20 +/- 6.8 h in the control phase, and 22 +/- 9.2 h after charcoal (NS).",The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056061/),h,20,64394,DB00313,Valproic Acid
,9056061,t1/2 elimination,"The area under the plasma concentration-time curve to 48 h (AUC (0.48 h)) was 408 +/- 114.5 (s.d.) mg l-1 h in the control phase and 398 +/- 108.6 mg l-1 h after charcoal and the t1/2 elimination was 20 +/- 6.8 h in the control phase, and 22 +/- 9.2 h after charcoal (NS).",The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056061/),h,22,64395,DB00313,Valproic Acid
,8499581,Vmax1,"The maximum metabolic rate (Vmax) and the Michaelis-Menten constant (Km) for the primary (Vmax1, Km1) and the secondary (Vmax2, Km2) pathways were Vmax1 = 1.52 mumol min-1 kg-1, Km1 = 0.15 mumol ml-1, Vmax2 = 24.98 mumol min-1 kg-1 and Km2 = 11.70 mumol ml-1, respectively.",Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499581/),[μM] / [kg·min],1.52,64612,DB00313,Valproic Acid
,8499581,Km1,"The maximum metabolic rate (Vmax) and the Michaelis-Menten constant (Km) for the primary (Vmax1, Km1) and the secondary (Vmax2, Km2) pathways were Vmax1 = 1.52 mumol min-1 kg-1, Km1 = 0.15 mumol ml-1, Vmax2 = 24.98 mumol min-1 kg-1 and Km2 = 11.70 mumol ml-1, respectively.",Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499581/),[μM] / [ml],0.15,64613,DB00313,Valproic Acid
,8499581,Vmax2,"The maximum metabolic rate (Vmax) and the Michaelis-Menten constant (Km) for the primary (Vmax1, Km1) and the secondary (Vmax2, Km2) pathways were Vmax1 = 1.52 mumol min-1 kg-1, Km1 = 0.15 mumol ml-1, Vmax2 = 24.98 mumol min-1 kg-1 and Km2 = 11.70 mumol ml-1, respectively.",Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499581/),[μM] / [kg·min],24.98,64614,DB00313,Valproic Acid
,8499581,Km2,"The maximum metabolic rate (Vmax) and the Michaelis-Menten constant (Km) for the primary (Vmax1, Km1) and the secondary (Vmax2, Km2) pathways were Vmax1 = 1.52 mumol min-1 kg-1, Km1 = 0.15 mumol ml-1, Vmax2 = 24.98 mumol min-1 kg-1 and Km2 = 11.70 mumol ml-1, respectively.",Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8499581/),[μM] / [ml],11.70,64615,DB00313,Valproic Acid
,28819726,CL/F,Mean population estimates (% inter-individual variability) were 4.2 L/h (21%) for CL/F and 82 L (25%) for V d/F.,"Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28819726/),[l] / [h],4.2,66501,DB00313,Valproic Acid
,28819726,V d/F,Mean population estimates (% inter-individual variability) were 4.2 L/h (21%) for CL/F and 82 L (25%) for V d/F.,"Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28819726/),l,82,66502,DB00313,Valproic Acid
,8738857,area under the curve (AUC),"During the concurrent phase the coadministration of CHOL resulted in a decrease (p < 0.05) in the area under the curve (AUC) for VPA compared to VPA alone (415.2 +/- 113.2 mg*hr/l vs 489.2 +/- 153.0 mg*hr/l, respectively).",Effect of cholestyramine resin on single dose valproate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738857/),[h·mg] / [l],415.2,67781,DB00313,Valproic Acid
,8738857,area under the curve (AUC),"During the concurrent phase the coadministration of CHOL resulted in a decrease (p < 0.05) in the area under the curve (AUC) for VPA compared to VPA alone (415.2 +/- 113.2 mg*hr/l vs 489.2 +/- 153.0 mg*hr/l, respectively).",Effect of cholestyramine resin on single dose valproate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738857/),[h·mg] / [l],489.2,67782,DB00313,Valproic Acid
,8738857,AUC,"When the same dose of each drug was administered 3 hours apart, the AUC for VPA (454.8 +/- 123.1 mg*hr/l) was not significantly decreased when compared to VPA alone (489.2 +/- 153.0 mg*hr/l).",Effect of cholestyramine resin on single dose valproate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738857/),[h·mg] / [l],454.8,67783,DB00313,Valproic Acid
,8738857,AUC,"When the same dose of each drug was administered 3 hours apart, the AUC for VPA (454.8 +/- 123.1 mg*hr/l) was not significantly decreased when compared to VPA alone (489.2 +/- 153.0 mg*hr/l).",Effect of cholestyramine resin on single dose valproate pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738857/),[h·mg] / [l],489.2,67784,DB00313,Valproic Acid
,8738857,bioavailability,"Also, the bioavailability relative to VPA alone was 86.2% +/- 7.1 for the concurrent phase and 95.3% +/- 13.6 for the staggered phase.",Effect of cholestyramine resin on single dose valproate pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738857/),%,86.2,67785,DB00313,Valproic Acid
,8738857,bioavailability,"Also, the bioavailability relative to VPA alone was 86.2% +/- 7.1 for the concurrent phase and 95.3% +/- 13.6 for the staggered phase.",Effect of cholestyramine resin on single dose valproate pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738857/),%,95.3,67786,DB00313,Valproic Acid
,3920375,clearance,"Children (N = 16) receiving multiple AED therapy had a higher clearance (23.5 vs 13.0 ml/hr/kg, P less than 0.001), larger volume of distribution (0.30 vs 0.22 L/kg, P less than 0.01), and shorter half-life (9.4 vs 12.3 hours, P less than 0.01) than did those (n = 21) receiving VPA only.",Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920375/),[ml] / [h·kg],23.5,68041,DB00313,Valproic Acid
,3920375,clearance,"Children (N = 16) receiving multiple AED therapy had a higher clearance (23.5 vs 13.0 ml/hr/kg, P less than 0.001), larger volume of distribution (0.30 vs 0.22 L/kg, P less than 0.01), and shorter half-life (9.4 vs 12.3 hours, P less than 0.01) than did those (n = 21) receiving VPA only.",Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920375/),[ml] / [h·kg],13.0,68042,DB00313,Valproic Acid
,3920375,volume of distribution,"Children (N = 16) receiving multiple AED therapy had a higher clearance (23.5 vs 13.0 ml/hr/kg, P less than 0.001), larger volume of distribution (0.30 vs 0.22 L/kg, P less than 0.01), and shorter half-life (9.4 vs 12.3 hours, P less than 0.01) than did those (n = 21) receiving VPA only.",Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920375/),[l] / [kg],0.30,68043,DB00313,Valproic Acid
,3920375,volume of distribution,"Children (N = 16) receiving multiple AED therapy had a higher clearance (23.5 vs 13.0 ml/hr/kg, P less than 0.001), larger volume of distribution (0.30 vs 0.22 L/kg, P less than 0.01), and shorter half-life (9.4 vs 12.3 hours, P less than 0.01) than did those (n = 21) receiving VPA only.",Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920375/),[l] / [kg],0.22,68044,DB00313,Valproic Acid
,3920375,half-life,"Children (N = 16) receiving multiple AED therapy had a higher clearance (23.5 vs 13.0 ml/hr/kg, P less than 0.001), larger volume of distribution (0.30 vs 0.22 L/kg, P less than 0.01), and shorter half-life (9.4 vs 12.3 hours, P less than 0.01) than did those (n = 21) receiving VPA only.",Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920375/),h,9.4,68045,DB00313,Valproic Acid
,3920375,half-life,"Children (N = 16) receiving multiple AED therapy had a higher clearance (23.5 vs 13.0 ml/hr/kg, P less than 0.001), larger volume of distribution (0.30 vs 0.22 L/kg, P less than 0.01), and shorter half-life (9.4 vs 12.3 hours, P less than 0.01) than did those (n = 21) receiving VPA only.",Comparison of steady-state pharmacokinetics of valproic acid in children between monotherapy and multiple antiepileptic drug treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920375/),h,12.3,68046,DB00313,Valproic Acid
,32865063,absorption rate constant (Ka),"The absorption rate constant (Ka) was fixed at 2.38 hour-1, and the impact of covariates on clearance and apparent volume of distribution were also explored.","Impact of gender, albumin, and CYP2C19 polymorphisms on valproic acid in Chinese patients: a population pharmacokinetic model. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32865063/),1/[h],2.38,68795,DB00313,Valproic Acid
,32865063,objective function,"Medical records of 60 inpatients were reviewed prospectively and the objective function value (OFV) of the base model and final model were 851.813 and 817.622, respectively.","Impact of gender, albumin, and CYP2C19 polymorphisms on valproic acid in Chinese patients: a population pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32865063/),,851.813,68796,DB00313,Valproic Acid
,32865063,objective function,"Medical records of 60 inpatients were reviewed prospectively and the objective function value (OFV) of the base model and final model were 851.813 and 817.622, respectively.","Impact of gender, albumin, and CYP2C19 polymorphisms on valproic acid in Chinese patients: a population pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32865063/),,817.622,68797,DB00313,Valproic Acid
,7916169,elimination half-lives,"After withdrawal of sulthiame in 11 patients, short elimination half-lives (8.65 +/- 3.10 h) were estimated.",Pharmacokinetics of sulthiame in epileptic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7916169/),h,8.65,69627,DB00313,Valproic Acid
,6786896,half-life,"For 6 patients with 6 different anti-epileptic drug combinations, the mean VPA half-life was only 6.2 h, as compared to about 15 h after a single dose.",Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786896/),h,6.2,70229,DB00313,Valproic Acid
,6786896,half-life,"For 6 patients with 6 different anti-epileptic drug combinations, the mean VPA half-life was only 6.2 h, as compared to about 15 h after a single dose.",Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786896/),h,15,70230,DB00313,Valproic Acid
,6786896,plasma clearance,The mean plasma clearance in those patients was 16.4 ml/min.,Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786896/),[ml] / [min],16.4,70231,DB00313,Valproic Acid
,6786896,volume of distribution,"The volume of distribution was 0.14 l/kg, which did not differ from values found in single dose studies.",Valproic acid disposition in epileptic patients during combined antiepileptic maintenance therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786896/),[l] / [kg],0.14,70232,DB00313,Valproic Acid
,3924464,unbound fractions,The average unbound fractions in the elderly and young were 10.7% and 6.4%.,Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924464/),%,10.7,71930,DB00313,Valproic Acid
,3924464,unbound fractions,The average unbound fractions in the elderly and young were 10.7% and 6.4%.,Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924464/),%,6.4,71931,DB00313,Valproic Acid
,8218969,maximum concentration (F,"Relative to fasting conditions (F), when the tablet was given at the midpoint of the breakfast (NF), the maximum concentration (F: 34.6 +/- 8.9 micrograms ml-1 and NF: 40.9 +/- 7.3 micrograms ml-1; p = 0.014) and the mean cumulative amount absorbed up to time 6 h (F: 76.3 +/- 11.8% and NF: 90 +/- 10.4%; p = 0.0099) were significantly increased.",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),[μg] / [ml],34.6,73024,DB00313,Valproic Acid
,8218969,maximum concentration (F,"Relative to fasting conditions (F), when the tablet was given at the midpoint of the breakfast (NF), the maximum concentration (F: 34.6 +/- 8.9 micrograms ml-1 and NF: 40.9 +/- 7.3 micrograms ml-1; p = 0.014) and the mean cumulative amount absorbed up to time 6 h (F: 76.3 +/- 11.8% and NF: 90 +/- 10.4%; p = 0.0099) were significantly increased.",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),[μg] / [ml],40.9,73025,DB00313,Valproic Acid
,8218969,cumulative amount absorbed up to time 6 h,"Relative to fasting conditions (F), when the tablet was given at the midpoint of the breakfast (NF), the maximum concentration (F: 34.6 +/- 8.9 micrograms ml-1 and NF: 40.9 +/- 7.3 micrograms ml-1; p = 0.014) and the mean cumulative amount absorbed up to time 6 h (F: 76.3 +/- 11.8% and NF: 90 +/- 10.4%; p = 0.0099) were significantly increased.",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),%,76.3,73026,DB00313,Valproic Acid
,8218969,cumulative amount absorbed up to time 6 h,"Relative to fasting conditions (F), when the tablet was given at the midpoint of the breakfast (NF), the maximum concentration (F: 34.6 +/- 8.9 micrograms ml-1 and NF: 40.9 +/- 7.3 micrograms ml-1; p = 0.014) and the mean cumulative amount absorbed up to time 6 h (F: 76.3 +/- 11.8% and NF: 90 +/- 10.4%; p = 0.0099) were significantly increased.",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),%,90,73027,DB00313,Valproic Acid
,8218969,F,"Nevertheless, the extent of absorption (F: 46.7 +/- 9.9 mg l-1; NF: 48.7 +/- 7 mg l-1) was not significantly affected.",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),[mg] / [l],46.7,73028,DB00313,Valproic Acid
,8218969,NF,"Nevertheless, the extent of absorption (F: 46.7 +/- 9.9 mg l-1; NF: 48.7 +/- 7 mg l-1) was not significantly affected.",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),[mg] / [l],48.7,73029,DB00313,Valproic Acid
,8218969,area under the curve,"There was no change in the area under the curve (1129 micrograms.h ml-1), in the mean residence time (28 h), or in the elimination half-life (16 h).",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),[h·μg] / [ml],1129,73030,DB00313,Valproic Acid
,8218969,mean residence time,"There was no change in the area under the curve (1129 micrograms.h ml-1), in the mean residence time (28 h), or in the elimination half-life (16 h).",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),h,28,73031,DB00313,Valproic Acid
,8218969,elimination half-life,"There was no change in the area under the curve (1129 micrograms.h ml-1), in the mean residence time (28 h), or in the elimination half-life (16 h).",Influence of food intake on the pharmacokinetics of a sustained release formulation of sodium valproate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218969/),h,16,73032,DB00313,Valproic Acid
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.32,73970,DB00313,Valproic Acid
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.34,73971,DB00313,Valproic Acid
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.45,73972,DB00313,Valproic Acid
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.46,73973,DB00313,Valproic Acid
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.52,73974,DB00313,Valproic Acid
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.53,73975,DB00313,Valproic Acid
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.54,73976,DB00313,Valproic Acid
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB00313,Valproic Acid
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB00313,Valproic Acid
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB00313,Valproic Acid
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB00313,Valproic Acid
,20606310,Volume of distribution,Volume of distribution of topiramate was 0.518 l/kg.,A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [kg],0.518,78908,DB00313,Valproic Acid
,20606310,oral clearance,"For a typical patient oral clearance was estimated at 1.47 l/h, with interindividual variability of 39.2%.",A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [h],1.47,78909,DB00313,Valproic Acid
,8119045,bioavailability,The bioavailability of the oral formulation is about 98%.,Lamotrigine clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,98,80086,DB00313,Valproic Acid
,8119045,plasma protein binding,The degree of plasma protein binding is 56%.,Lamotrigine clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),%,56,80087,DB00313,Valproic Acid
,8119045,half-lives,Mean half-lives of lamotrigine in healthy volunteers (single and multiple doses) as well as in epileptic patients receiving lamotrigine monotherapy range from 22.8 to 37.4 hours.,Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,22.8 to 37.4,80088,DB00313,Valproic Acid
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,13.5 to 15,80089,DB00313,Valproic Acid
,8119045,half-life,"Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours).",Lamotrigine clinical pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8119045/),h,48.3 to 59,80090,DB00313,Valproic Acid
,9450162,maximum serum concentration,The mean maximum serum concentration after fasting (17.0 micrograms/ml) was virtually the same as after a meal (16.8 micrograms/ml).,Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450162/),[μg] / [ml],17.0,80488,DB00313,Valproic Acid
,9450162,maximum serum concentration,The mean maximum serum concentration after fasting (17.0 micrograms/ml) was virtually the same as after a meal (16.8 micrograms/ml).,Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450162/),[μg] / [ml],16.8,80489,DB00313,Valproic Acid
,9450162,terminal half-life,The rate of elimination was not affected (terminal half-life approximately 15 h).,Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450162/),h,15,80490,DB00313,Valproic Acid
,9450162,AUC0-infinity,The mean AUC0-infinity values were 468 micrograms/ml x h in fasting subjects and 458 micrograms/ml x h in postprandial subjects.,Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450162/),[μg] / [h·ml],468,80491,DB00313,Valproic Acid
,9450162,AUC0-infinity,The mean AUC0-infinity values were 468 micrograms/ml x h in fasting subjects and 458 micrograms/ml x h in postprandial subjects.,Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9450162/),[μg] / [h·ml],458,80492,DB00313,Valproic Acid
,6821439,half-life (t 1/2),"The half-life (t 1/2) at 24 days of age was 17.2 hours, clearance (Cl) 0.18 ml/min/kg, and volume of distribution (Vd) 0.28 liter/kg.",Pharmacokinetic study of valproic acid in a neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821439/),h,17.2,80779,DB00313,Valproic Acid
,6821439,clearance (Cl),"The half-life (t 1/2) at 24 days of age was 17.2 hours, clearance (Cl) 0.18 ml/min/kg, and volume of distribution (Vd) 0.28 liter/kg.",Pharmacokinetic study of valproic acid in a neonate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821439/),[ml] / [kg·min],0.18,80780,DB00313,Valproic Acid
,6821439,volume of distribution (Vd),"The half-life (t 1/2) at 24 days of age was 17.2 hours, clearance (Cl) 0.18 ml/min/kg, and volume of distribution (Vd) 0.28 liter/kg.",Pharmacokinetic study of valproic acid in a neonate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821439/),[l] / [kg],0.28,80781,DB00313,Valproic Acid
,6821439,clearance,"At 6 months of age, clearance had increased to 0.53 ml/min/kg, t 1/2 had decreased to 7.5 hours, while Vd was relatively unchanged (0.34 liter/kg).",Pharmacokinetic study of valproic acid in a neonate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821439/),[ml] / [kg·min],0.53,80782,DB00313,Valproic Acid
,6821439,t 1/2,"At 6 months of age, clearance had increased to 0.53 ml/min/kg, t 1/2 had decreased to 7.5 hours, while Vd was relatively unchanged (0.34 liter/kg).",Pharmacokinetic study of valproic acid in a neonate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821439/),h,7.5,80783,DB00313,Valproic Acid
,6821439,Vd,"At 6 months of age, clearance had increased to 0.53 ml/min/kg, t 1/2 had decreased to 7.5 hours, while Vd was relatively unchanged (0.34 liter/kg).",Pharmacokinetic study of valproic acid in a neonate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6821439/),[l] / [kg],0.34,80784,DB00313,Valproic Acid
,1970771,steady state plasma level,A 50 mg/kg bolus dose of sodium valproate was injected iv to Long Evans rats with and without (control) prior treatment by constant infusion of salicylate to keep it at steady state plasma level (about 250 micrograms/ml).,Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970771/),[μg] / [ml],250,81159,DB00313,Valproic Acid
,1970771,apparent dissociation constant,The apparent dissociation constant of plasma protein binding for valproic acid was increased from 0.287 to 1.204 mM in the presence of salicylic acid.,Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970771/),mM,0.287,81160,DB00313,Valproic Acid
,1970771,apparent dissociation constant,The apparent dissociation constant of plasma protein binding for valproic acid was increased from 0.287 to 1.204 mM in the presence of salicylic acid.,Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970771/),mM,1.204,81161,DB00313,Valproic Acid
,25220641,Ka,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),1/[h],0.83,82170,DB00313,Valproic Acid
,25220641,Vd,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [kg],0.67,82171,DB00313,Valproic Acid
,25220641,CL,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [h·kg],0.035,82172,DB00313,Valproic Acid
,25220641,MP,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.01,82173,DB00313,Valproic Acid
,25220641,MAE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.46,82174,DB00313,Valproic Acid
,25220641,MSE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),,0.39,82175,DB00313,Valproic Acid
,23707469,T(max),There were no significant differences in T(max) of VPA whatever the circadian-time of injections (T(max)=0.166 h).,Circadian variation of Valproic acid pharmacokinetics in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23707469/),h,0.166,82698,DB00313,Valproic Acid
,23707469,C(max),"However, there were relevant differences in C(max) between the four circadian groups (p<0.005), it varied between 386 ± 30.86 mg L(-1) in mice treated at 7 HALO and 824 ± 39.85 mg L(-1) in mice treated at 19 HALO.",Circadian variation of Valproic acid pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23707469/),[mg] / [l],386,82699,DB00313,Valproic Acid
,23707469,C(max),"However, there were relevant differences in C(max) between the four circadian groups (p<0.005), it varied between 386 ± 30.86 mg L(-1) in mice treated at 7 HALO and 824 ± 39.85 mg L(-1) in mice treated at 19 HALO.",Circadian variation of Valproic acid pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23707469/),[mg] / [l],824,82700,DB00313,Valproic Acid
,23707469,Cl(T),"Drug dosing at 7 HALO resulted in highest Cl(T) value: 0.405 ± 0.006 L h(-1)kg(-1), whereas Cl(T) was significantly slower when VPA was administered at 19 HALO (0.157 ± 0.009 L h(-1)kg(-1)) (p<0.0001).",Circadian variation of Valproic acid pharmacokinetics in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23707469/),[l] / [h],0.405,82701,DB00313,Valproic Acid
,23707469,Cl(T),"Drug dosing at 7 HALO resulted in highest Cl(T) value: 0.405 ± 0.006 L h(-1)kg(-1), whereas Cl(T) was significantly slower when VPA was administered at 19 HALO (0.157 ± 0.009 L h(-1)kg(-1)) (p<0.0001).",Circadian variation of Valproic acid pharmacokinetics in mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23707469/),[l] / [h],0.157,82702,DB00313,Valproic Acid
,23707469,AUC(0-∞),The AUC(0-∞) was significantly 2-fold higher when VPA was administered at 19 HALO (2216.65 ± 138.91 mg h(-1)L(-1)) as compared to the injection at 7 HALO (864.09 ± 16.82 mg h(-1)L(-1)) (p<0.0001).,Circadian variation of Valproic acid pharmacokinetics in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23707469/),[mg] / [h],2216.65,82703,DB00313,Valproic Acid
,23707469,AUC(0-∞),The AUC(0-∞) was significantly 2-fold higher when VPA was administered at 19 HALO (2216.65 ± 138.91 mg h(-1)L(-1)) as compared to the injection at 7 HALO (864.09 ± 16.82 mg h(-1)L(-1)) (p<0.0001).,Circadian variation of Valproic acid pharmacokinetics in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23707469/),[mg] / [h],864.09,82704,DB00313,Valproic Acid
,11095580,apparent intrinsic clearance,"However, PRB decreased the apparent intrinsic clearance of VPA (1.81 +/- 0.58 versus 1.23 +/- 0.23 ml/min; P =.025) by competitively inhibiting VPA elimination.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[ml] / [min],1.81,83248,DB00313,Valproic Acid
,11095580,apparent intrinsic clearance,"However, PRB decreased the apparent intrinsic clearance of VPA (1.81 +/- 0.58 versus 1.23 +/- 0.23 ml/min; P =.025) by competitively inhibiting VPA elimination.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[ml] / [min],1.23,83249,DB00313,Valproic Acid
,11095580,V(max),"VG formation (V(max) = 0.80 +/- 0.06 microg/min/mg of protein; K(m) = 173 +/- 28.8 microg/ml) was impaired by PRB in a competitive manner (K(i) = 876 +/- 559 microg/ml), consistent with the in vivo data.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[μg] / [mg·min],0.80,83250,DB00313,Valproic Acid
,11095580,K(m),"VG formation (V(max) = 0.80 +/- 0.06 microg/min/mg of protein; K(m) = 173 +/- 28.8 microg/ml) was impaired by PRB in a competitive manner (K(i) = 876 +/- 559 microg/ml), consistent with the in vivo data.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[μg] / [ml],173,83251,DB00313,Valproic Acid
,11095580,K(i),"VG formation (V(max) = 0.80 +/- 0.06 microg/min/mg of protein; K(m) = 173 +/- 28.8 microg/ml) was impaired by PRB in a competitive manner (K(i) = 876 +/- 559 microg/ml), consistent with the in vivo data.",Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data? ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095580/),[μg] / [ml],876,83252,DB00313,Valproic Acid
above,3126287,bioavailability,The bioavailability of VPA following dosing of both ointment was above 97%.,Percutaneous absorption of valproic acid and its plasma concentration after application of ointment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126287/),%,97,83307,DB00313,Valproic Acid
,12581229,t1/2,Mean talampanel t1/2 values were 3.0 h compared with 4.2 h in healthy volunteers.,"Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12581229/),h,3.0,84688,DB00313,Valproic Acid
,12581229,t1/2,Mean talampanel t1/2 values were 3.0 h compared with 4.2 h in healthy volunteers.,"Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12581229/),h,4.2,84689,DB00313,Valproic Acid
,12581229,t1/2,"After multiple-dose and steady-state, talampanel t1/2 values were increased to 5.6 h Talampanel and valproic acid (VPA) appear to inhibit each other's metabolism mutually.","Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12581229/),h,5.6,84690,DB00313,Valproic Acid
,15997234,ED50,"However, VPD (20-100 mg kg(- 1)), VCD (20-100 mg kg(- 1)) and DID (20-90 mg kg(- 1)) produced dose-related reversal of tactile allodynia with ED50 values of 61, 52 and 58 mgkg(- 1), respectively.",Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15997234/),1)·mgkg(-,61,84816,DB00313,Valproic Acid
,15997234,ED50,"However, VPD (20-100 mg kg(- 1)), VCD (20-100 mg kg(- 1)) and DID (20-90 mg kg(- 1)) produced dose-related reversal of tactile allodynia with ED50 values of 61, 52 and 58 mgkg(- 1), respectively.",Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15997234/),1)·mgkg(-,52,84817,DB00313,Valproic Acid
,15997234,ED50,"However, VPD (20-100 mg kg(- 1)), VCD (20-100 mg kg(- 1)) and DID (20-90 mg kg(- 1)) produced dose-related reversal of tactile allodynia with ED50 values of 61, 52 and 58 mgkg(- 1), respectively.",Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15997234/),1)·mgkg(-,58,84818,DB00313,Valproic Acid
,15997234,ED50,All the amides were more potent than VPA (ED50=269 mgkg(- 1)).,Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15997234/),1)·mgkg(-,269,84819,DB00313,Valproic Acid
,15954179,absolute recoveries,"The average absolute recoveries of valproic acid and the IS from spiked plasma samples were 96.1+/-4.2 and 95.6+/-2.7%, respectively.",Liquid chromatography/electrospray ionization mass spectrometry method for the quantification of valproic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15954179/),%,96.1,85451,DB00313,Valproic Acid
,15954179,absolute recoveries,"The average absolute recoveries of valproic acid and the IS from spiked plasma samples were 96.1+/-4.2 and 95.6+/-2.7%, respectively.",Liquid chromatography/electrospray ionization mass spectrometry method for the quantification of valproic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15954179/),%,95.6,85452,DB00313,Valproic Acid
,15954179,run time,A run time of 4.5 min for each sample made it possible to analyze more than 250 human plasma samples per day.,Liquid chromatography/electrospray ionization mass spectrometry method for the quantification of valproic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15954179/),min,4.5,85453,DB00313,Valproic Acid
,16421458,concentration/dose (C/D) ratio,"In females, the concentration/dose (C/D) ratio was 35.4% higher than in males (adjusted mean 0.144 ng/ml/mg for males versus 0.195 ng/ml/mg for females, respectively; P = 0.035).","Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16421458/),[ng] / [mg·ml],0.144,85590,DB00313,Valproic Acid
,16421458,concentration/dose (C/D) ratio,"In females, the concentration/dose (C/D) ratio was 35.4% higher than in males (adjusted mean 0.144 ng/ml/mg for males versus 0.195 ng/ml/mg for females, respectively; P = 0.035).","Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16421458/),[ng] / [mg·ml],0.195,85591,DB00313,Valproic Acid
,18043476,CL/F,The population estimate of CL/F from the base model was 5.14 L/h with interindividual variability of 50.20%.,Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043476/),[l] / [h],5.14,86360,DB00313,Valproic Acid
,10962217,elimination half-life,"The elimination half-life of VPA during the recovery phase was 100 h, which is some 6-12 times greater than values reported for this parameter in normal patients.",Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10962217/),h,100,86631,DB00313,Valproic Acid
,11565626,time lag,"A time lag of 1-2 h was observed in each patient, followed by rapid absorption, with the peak concentrations being recorded approximately 4 h after drug administration.",Pharmacokinetics of valproic acid in patients with bipolar disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565626/),h,1-2,87559,DB00313,Valproic Acid
,11565626,trough concentration,The average 12 h trough concentration was found to be 54.73+/-11.96 microg/ml.,Pharmacokinetics of valproic acid in patients with bipolar disorder. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565626/),[μg] / [ml],54.73,87560,DB00313,Valproic Acid
,11565626,terminal half-life,The plasma level decline was biphasic with a terminal half-life of 14.2+/-6.39 h.,Pharmacokinetics of valproic acid in patients with bipolar disorder. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565626/),h,14.2,87561,DB00313,Valproic Acid
,11565626,Total plasma clearance,Total plasma clearance was 0.095+/-0.035 ml/min/kg.,Pharmacokinetics of valproic acid in patients with bipolar disorder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565626/),[ml] / [kg·min],0.095,87562,DB00313,Valproic Acid
,11565626,steady-state apparent volume of distribution,The steady-state apparent volume of distribution was found to be 0.11+/-0.05 l/kg.,Pharmacokinetics of valproic acid in patients with bipolar disorder. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565626/),[l] / [kg],0.11,87563,DB00313,Valproic Acid
above,11565626,Css,"A positive correlation (r = 0.69) was found between the dose (mg/kg) and steady-state serum concentration (Css) of VPA and all patients, except one, had their Css above 50 microg/ml.",Pharmacokinetics of valproic acid in patients with bipolar disorder. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11565626/),[μg] / [ml],50,87564,DB00313,Valproic Acid
,32534880,trough,"Based on this model, we proposed dosage regimens to achieve trough lamotrigine concentrations within reference interval (2.5-15 mg/L).",Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32534880/),mg,2.5-15,88099,DB00313,Valproic Acid
,17270398,t(max),"Levetiracetam was rapidly absorbed following oral dosing, with median t(max) of 0.5 h.",Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270398/),h,0.5,91035,DB00313,Valproic Acid
,17270398,t(1/2),Dose proportional increases were observed for C(max) and AUC((0-12)) over the dose range; t(1/2) was 4.9 h.,Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17270398/),h,4.9,91036,DB00313,Valproic Acid
,3130892,steady-state concentration,"2 VPA alone had no effect on antipyrine clearance, urinary 6 beta-hydroxycortisol excretion and a battery of psychomotor function tests after 3 days' treatment despite achieving a mean steady-state concentration (90 +/- 6 mg 1(-1)) well within the target range (50-100 mg 1(-1)) for the drug.",Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3130892/),mg,90,92013,DB00313,Valproic Acid
,3130892,steady-state concentration,"2 VPA alone had no effect on antipyrine clearance, urinary 6 beta-hydroxycortisol excretion and a battery of psychomotor function tests after 3 days' treatment despite achieving a mean steady-state concentration (90 +/- 6 mg 1(-1)) well within the target range (50-100 mg 1(-1)) for the drug.",Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3130892/),mg,50-100,92014,DB00313,Valproic Acid
,6430313,Half-lives,"Half-lives (15.3 +/- 0.7 s.e. mean in the elderly vs 13.0 +/- 1.0 h in the young), volumes of distribution (0.16 +/- 0.01 l/kg in the elderly vs 0.14 +/- 0.01 l/kg in the young) and clearance (7.5 +/- 0.9 ml h-1 kg-1 in the elderly vs 7.7 +/- 0.6 ml h-1 kg-1 in the young) did not differ significantly between the two groups.",Pharmacokinetics of valproic acid in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),h,15.3,92302,DB00313,Valproic Acid
,6430313,Half-lives,"Half-lives (15.3 +/- 0.7 s.e. mean in the elderly vs 13.0 +/- 1.0 h in the young), volumes of distribution (0.16 +/- 0.01 l/kg in the elderly vs 0.14 +/- 0.01 l/kg in the young) and clearance (7.5 +/- 0.9 ml h-1 kg-1 in the elderly vs 7.7 +/- 0.6 ml h-1 kg-1 in the young) did not differ significantly between the two groups.",Pharmacokinetics of valproic acid in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),h,13.0,92303,DB00313,Valproic Acid
,6430313,volumes of distribution,"Half-lives (15.3 +/- 0.7 s.e. mean in the elderly vs 13.0 +/- 1.0 h in the young), volumes of distribution (0.16 +/- 0.01 l/kg in the elderly vs 0.14 +/- 0.01 l/kg in the young) and clearance (7.5 +/- 0.9 ml h-1 kg-1 in the elderly vs 7.7 +/- 0.6 ml h-1 kg-1 in the young) did not differ significantly between the two groups.",Pharmacokinetics of valproic acid in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),[l] / [kg],0.16,92304,DB00313,Valproic Acid
,6430313,volumes of distribution,"Half-lives (15.3 +/- 0.7 s.e. mean in the elderly vs 13.0 +/- 1.0 h in the young), volumes of distribution (0.16 +/- 0.01 l/kg in the elderly vs 0.14 +/- 0.01 l/kg in the young) and clearance (7.5 +/- 0.9 ml h-1 kg-1 in the elderly vs 7.7 +/- 0.6 ml h-1 kg-1 in the young) did not differ significantly between the two groups.",Pharmacokinetics of valproic acid in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),[l] / [kg],0.14,92305,DB00313,Valproic Acid
,6430313,clearance,"Half-lives (15.3 +/- 0.7 s.e. mean in the elderly vs 13.0 +/- 1.0 h in the young), volumes of distribution (0.16 +/- 0.01 l/kg in the elderly vs 0.14 +/- 0.01 l/kg in the young) and clearance (7.5 +/- 0.9 ml h-1 kg-1 in the elderly vs 7.7 +/- 0.6 ml h-1 kg-1 in the young) did not differ significantly between the two groups.",Pharmacokinetics of valproic acid in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),[ml] / [h·kg],7.5,92306,DB00313,Valproic Acid
,6430313,clearance,"Half-lives (15.3 +/- 0.7 s.e. mean in the elderly vs 13.0 +/- 1.0 h in the young), volumes of distribution (0.16 +/- 0.01 l/kg in the elderly vs 0.14 +/- 0.01 l/kg in the young) and clearance (7.5 +/- 0.9 ml h-1 kg-1 in the elderly vs 7.7 +/- 0.6 ml h-1 kg-1 in the young) did not differ significantly between the two groups.",Pharmacokinetics of valproic acid in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),[ml] / [h·kg],7.7,92307,DB00313,Valproic Acid
,6430313,clearance of the free drug (intrinsic clearance),The clearance of the free drug (intrinsic clearance) was reduced from 127.0 +/- 12 ml h-1 kg-1 (control value in the young) to 77.7 +/- 5.5 ml h-1 kg-1 (P less than 0.02).,Pharmacokinetics of valproic acid in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),[ml] / [h·kg],127.0,92308,DB00313,Valproic Acid
,6430313,clearance of the free drug (intrinsic clearance),The clearance of the free drug (intrinsic clearance) was reduced from 127.0 +/- 12 ml h-1 kg-1 (control value in the young) to 77.7 +/- 5.5 ml h-1 kg-1 (P less than 0.02).,Pharmacokinetics of valproic acid in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),[ml] / [h·kg],77.7,92309,DB00313,Valproic Acid
,6430313,fraction,Free VPA fraction was 9.5 +/- 0.6% in the elderly and 6.6 +/- 0.5% in the young (P less than 0.02).,Pharmacokinetics of valproic acid in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),%,9.5,92310,DB00313,Valproic Acid
,6430313,fraction,Free VPA fraction was 9.5 +/- 0.6% in the elderly and 6.6 +/- 0.5% in the young (P less than 0.02).,Pharmacokinetics of valproic acid in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430313/),%,6.6,92311,DB00313,Valproic Acid
,3148708,terminal half-life,The mean terminal half-life of VCD was 1.9 +/- 0.5 h and the total body clearance was 3.0 +/- 0.8 L/h.,"Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148708/),h,1.9,92998,DB00313,Valproic Acid
,3148708,total body clearance,The mean terminal half-life of VCD was 1.9 +/- 0.5 h and the total body clearance was 3.0 +/- 0.8 L/h.,"Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148708/),[l] / [h],3.0,92999,DB00313,Valproic Acid
,3148708,absolute bioavailability,"Following oral administration, the absolute bioavailability of VCD was 94 +/- 14%, and the terminal half-life was similar to that obtained after iv administration.","Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3148708/),,94,93000,DB00313,Valproic Acid
,16867166,terminal half-life,"The lowering of the valproic acid level in plasma was biphasic, with terminal half-life ranging between 8.8-30.9 hr.",Disposition of valproic acid in self-poisoned adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867166/),h,8.8-30.9,93042,DB00313,Valproic Acid
,16867166,apparent volume of distribution,The calculated apparent volume of distribution was 0.17-0.72 l/kg and could be affected by varied levels of doses as well as time of drug intake (data from interviews of patients) used for calculation and reduction in plasma protein binding at higher concentration of valproic acid.,Disposition of valproic acid in self-poisoned adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867166/),[l] / [kg],0.17-0.72,93043,DB00313,Valproic Acid
less,16548053,sample preparation time,"Because the proposed method combined a rapid water-phase derivatization with a fast, simple and solvent-free sample extraction and concentration technique of SPME, the sample preparation time was less than 25 min.",Development of water-phase derivatization followed by solid-phase microextraction and gas chromatography/mass spectrometry for fast determination of valproic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16548053/),min,25,94847,DB00313,Valproic Acid
,11302932,binding capacity (B(max1)),"Estimates of binding capacity (B(max1)) at the saturable site were higher in adults (91.8 microg/ml) when compared with lambs (44.9 microg/ml), whereas the opposite trend was observed for binding affinity [K(d1) = 9.6 microg/ml (adult) versus 3.2 microg/ml (lambs)].",Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302932/),[μg] / [ml],91.8,96399,DB00313,Valproic Acid
,11302932,binding capacity (B(max1)),"Estimates of binding capacity (B(max1)) at the saturable site were higher in adults (91.8 microg/ml) when compared with lambs (44.9 microg/ml), whereas the opposite trend was observed for binding affinity [K(d1) = 9.6 microg/ml (adult) versus 3.2 microg/ml (lambs)].",Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302932/),[μg] / [ml],44.9,96400,DB00313,Valproic Acid
,11302932,K(d1),"Estimates of binding capacity (B(max1)) at the saturable site were higher in adults (91.8 microg/ml) when compared with lambs (44.9 microg/ml), whereas the opposite trend was observed for binding affinity [K(d1) = 9.6 microg/ml (adult) versus 3.2 microg/ml (lambs)].",Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302932/),[μg] / [ml],9.6,96401,DB00313,Valproic Acid
,11302932,K(d1),"Estimates of binding capacity (B(max1)) at the saturable site were higher in adults (91.8 microg/ml) when compared with lambs (44.9 microg/ml), whereas the opposite trend was observed for binding affinity [K(d1) = 9.6 microg/ml (adult) versus 3.2 microg/ml (lambs)].",Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302932/),[μg] / [ml],3.2,96402,DB00313,Valproic Acid
,11302932,apparent V(max),This resulted in similar in vivo estimates of apparent V(max) [445.0 microg/min/kg (adult) versus 429.9 microg/min/kg (lambs)].,Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302932/),[μg] / [kg·min],445.0,96403,DB00313,Valproic Acid
,11302932,apparent V(max),This resulted in similar in vivo estimates of apparent V(max) [445.0 microg/min/kg (adult) versus 429.9 microg/min/kg (lambs)].,Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302932/),[μg] / [kg·min],429.9,96404,DB00313,Valproic Acid
,11302932,apparent K(m),"However, apparent K(m) estimates appeared to be higher in lambs [30.0 microg/ml (adult) versus 69.6 microg/ml (lambs)].",Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302932/),[μg] / [ml],30.0,96405,DB00313,Valproic Acid
,11302932,apparent K(m),"However, apparent K(m) estimates appeared to be higher in lambs [30.0 microg/ml (adult) versus 69.6 microg/ml (lambs)].",Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11302932/),[μg] / [ml],69.6,96406,DB00313,Valproic Acid
,30830506,relative bioavailability,In vivo pharmacokinetic studies of EVLF in rats demonstrated a 199% relative bioavailability compared to ERL suspension.,Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30830506/),%,199,96575,DB00313,Valproic Acid
,16981874,total apparent oral clearance,"Compared with the HC-free interval, HC intake was associated with a mean 21.5% increase in VPA total apparent oral clearance (from 8.0 +/- 5.2 to 9.7 +/- 6.4 ml/h/kg, p = 0.01) and a 45.2 % increase in VPA unbound apparent oral clearance (from 79 +/- 81 to 115 +/- 121 ml/h/kg, p = 0.029).",Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981874/),[ml] / [h·kg],8.0,99715,DB00313,Valproic Acid
,16981874,total apparent oral clearance,"Compared with the HC-free interval, HC intake was associated with a mean 21.5% increase in VPA total apparent oral clearance (from 8.0 +/- 5.2 to 9.7 +/- 6.4 ml/h/kg, p = 0.01) and a 45.2 % increase in VPA unbound apparent oral clearance (from 79 +/- 81 to 115 +/- 121 ml/h/kg, p = 0.029).",Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981874/),[ml] / [h·kg],9.7,99716,DB00313,Valproic Acid
,16981874,unbound apparent oral clearance,"Compared with the HC-free interval, HC intake was associated with a mean 21.5% increase in VPA total apparent oral clearance (from 8.0 +/- 5.2 to 9.7 +/- 6.4 ml/h/kg, p = 0.01) and a 45.2 % increase in VPA unbound apparent oral clearance (from 79 +/- 81 to 115 +/- 121 ml/h/kg, p = 0.029).",Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981874/),[ml] / [h·kg],79,99717,DB00313,Valproic Acid
,16981874,unbound apparent oral clearance,"Compared with the HC-free interval, HC intake was associated with a mean 21.5% increase in VPA total apparent oral clearance (from 8.0 +/- 5.2 to 9.7 +/- 6.4 ml/h/kg, p = 0.01) and a 45.2 % increase in VPA unbound apparent oral clearance (from 79 +/- 81 to 115 +/- 121 ml/h/kg, p = 0.029).",Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981874/),[ml] / [h·kg],115,99718,DB00313,Valproic Acid
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,2.8,99721,DB00313,Valproic Acid
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,13,99722,DB00313,Valproic Acid
,10604819,metabolite-to-parent drug ratio,"The metabolite-to-parent drug ratio shifted from a median value of 2.8 in group A to 13 in group B, and up to 29 in patients receiving polytherapy with FBM (p < 0.001).",Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604819/),,29,99723,DB00313,Valproic Acid
,28483293,CL/F,"The population estimates for valproic acid CL/F and V/F were 0.464 L/h and 23.3 L, respectively.",Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28483293/),[l] / [h],0.464,99837,DB00313,Valproic Acid
,28483293,V/F,"The population estimates for valproic acid CL/F and V/F were 0.464 L/h and 23.3 L, respectively.",Population Pharmacokinetics of Valproic Acid in Patients with Mania: Implication for Individualized Dosing Regimens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28483293/),l,23.3,99838,DB00313,Valproic Acid
,19674061,effective dose,"The pharmacokinetics of VCU was studied in a stereoselective manner following intraperitoneal (i.p.) administration to rats. (2S,3S)-VCU and (2R,3S)-VCU median effective dose ED(50) values were 29 mg/kg [95% confidence interval (CI) = 8-60 mg/kg] and 42 mg/kg (95% CI = 36-51 mg/kg) (MES) and 22 mg/kg (95% CI = 13-51 mg/kg) and 12 mg/kg (95%CI = 7-21 mg/kg) (scMet), respectively. (2S,3S)-VCU was more potent and had a wider safety margin (p < 0.05), defined as the protective index (PI = TD(50)/ED(50)), at both the MES (PI > 17) and scMet (PI > 23) tests than racemic-VCU or (R,S)-VCU (PI = 2.8 and 9.9, respectively).","Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19674061/),[mg] / [kg],29,100205,DB00313,Valproic Acid
,19674061,effective dose,"The pharmacokinetics of VCU was studied in a stereoselective manner following intraperitoneal (i.p.) administration to rats. (2S,3S)-VCU and (2R,3S)-VCU median effective dose ED(50) values were 29 mg/kg [95% confidence interval (CI) = 8-60 mg/kg] and 42 mg/kg (95% CI = 36-51 mg/kg) (MES) and 22 mg/kg (95% CI = 13-51 mg/kg) and 12 mg/kg (95%CI = 7-21 mg/kg) (scMet), respectively. (2S,3S)-VCU was more potent and had a wider safety margin (p < 0.05), defined as the protective index (PI = TD(50)/ED(50)), at both the MES (PI > 17) and scMet (PI > 23) tests than racemic-VCU or (R,S)-VCU (PI = 2.8 and 9.9, respectively).","Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19674061/),[mg] / [kg],42,100206,DB00313,Valproic Acid
,19674061,ED(50),"The pharmacokinetics of VCU was studied in a stereoselective manner following intraperitoneal (i.p.) administration to rats. (2S,3S)-VCU and (2R,3S)-VCU median effective dose ED(50) values were 29 mg/kg [95% confidence interval (CI) = 8-60 mg/kg] and 42 mg/kg (95% CI = 36-51 mg/kg) (MES) and 22 mg/kg (95% CI = 13-51 mg/kg) and 12 mg/kg (95%CI = 7-21 mg/kg) (scMet), respectively. (2S,3S)-VCU was more potent and had a wider safety margin (p < 0.05), defined as the protective index (PI = TD(50)/ED(50)), at both the MES (PI > 17) and scMet (PI > 23) tests than racemic-VCU or (R,S)-VCU (PI = 2.8 and 9.9, respectively).","Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19674061/),[mg] / [kg],29,100207,DB00313,Valproic Acid
,19674061,ED(50),"The pharmacokinetics of VCU was studied in a stereoselective manner following intraperitoneal (i.p.) administration to rats. (2S,3S)-VCU and (2R,3S)-VCU median effective dose ED(50) values were 29 mg/kg [95% confidence interval (CI) = 8-60 mg/kg] and 42 mg/kg (95% CI = 36-51 mg/kg) (MES) and 22 mg/kg (95% CI = 13-51 mg/kg) and 12 mg/kg (95%CI = 7-21 mg/kg) (scMet), respectively. (2S,3S)-VCU was more potent and had a wider safety margin (p < 0.05), defined as the protective index (PI = TD(50)/ED(50)), at both the MES (PI > 17) and scMet (PI > 23) tests than racemic-VCU or (R,S)-VCU (PI = 2.8 and 9.9, respectively).","Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19674061/),[mg] / [kg],42,100208,DB00313,Valproic Acid
,19674061,ED(50),"The pharmacokinetics of VCU was studied in a stereoselective manner following intraperitoneal (i.p.) administration to rats. (2S,3S)-VCU and (2R,3S)-VCU median effective dose ED(50) values were 29 mg/kg [95% confidence interval (CI) = 8-60 mg/kg] and 42 mg/kg (95% CI = 36-51 mg/kg) (MES) and 22 mg/kg (95% CI = 13-51 mg/kg) and 12 mg/kg (95%CI = 7-21 mg/kg) (scMet), respectively. (2S,3S)-VCU was more potent and had a wider safety margin (p < 0.05), defined as the protective index (PI = TD(50)/ED(50)), at both the MES (PI > 17) and scMet (PI > 23) tests than racemic-VCU or (R,S)-VCU (PI = 2.8 and 9.9, respectively).","Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19674061/),mg,22,100209,DB00313,Valproic Acid
,19674061,ED(50),"The pharmacokinetics of VCU was studied in a stereoselective manner following intraperitoneal (i.p.) administration to rats. (2S,3S)-VCU and (2R,3S)-VCU median effective dose ED(50) values were 29 mg/kg [95% confidence interval (CI) = 8-60 mg/kg] and 42 mg/kg (95% CI = 36-51 mg/kg) (MES) and 22 mg/kg (95% CI = 13-51 mg/kg) and 12 mg/kg (95%CI = 7-21 mg/kg) (scMet), respectively. (2S,3S)-VCU was more potent and had a wider safety margin (p < 0.05), defined as the protective index (PI = TD(50)/ED(50)), at both the MES (PI > 17) and scMet (PI > 23) tests than racemic-VCU or (R,S)-VCU (PI = 2.8 and 9.9, respectively).","Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19674061/),,12,100210,DB00313,Valproic Acid
,19674061,half-life,VCU was mainly eliminated by metabolism with a half-life of 2 h.,"Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): a chiral stereoisomer of valproic acid urea derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19674061/),h,2,100211,DB00313,Valproic Acid
,1362931,Urinary recovery,"Urinary recovery of base-labile (apparently glucuronide) conjugates in the bile-exteriorized rat was 28.8%, 12.0%, and 25.2% of the administered dose for VPA, CCA, and MCCA, respectively.","Pharmacokinetics and pharmacodynamics of valproate analogs in rats. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362931/),%,28.8,101169,DB00313,Valproic Acid
,1362931,Urinary recovery,"Urinary recovery of base-labile (apparently glucuronide) conjugates in the bile-exteriorized rat was 28.8%, 12.0%, and 25.2% of the administered dose for VPA, CCA, and MCCA, respectively.","Pharmacokinetics and pharmacodynamics of valproate analogs in rats. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362931/),%,12.0,101170,DB00313,Valproic Acid
,1362931,Urinary recovery,"Urinary recovery of base-labile (apparently glucuronide) conjugates in the bile-exteriorized rat was 28.8%, 12.0%, and 25.2% of the administered dose for VPA, CCA, and MCCA, respectively.","Pharmacokinetics and pharmacodynamics of valproate analogs in rats. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362931/),%,25.2,101171,DB00313,Valproic Acid
above,17960970,minimum valproic acid concentration,The ER + 500 dose was the only regimen that maintained the mean minimum valproic acid concentration above 50 mug/mL.,A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17960970/),[μg] / [ml],50,101630,DB00313,Valproic Acid
,6804223,t 1/2 alpha,"The half-life of the initial phase was t 1/2 alpha = 0.64 +/- 0.32 h, and the elimination half-life was calculated as t 1/2 beta = 11.55 +/- 2.33 h.",The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804223/),h,0.64,102434,DB00313,Valproic Acid
,6804223,t 1/2 beta,"The half-life of the initial phase was t 1/2 alpha = 0.64 +/- 0.32 h, and the elimination half-life was calculated as t 1/2 beta = 11.55 +/- 2.33 h.",The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804223/),h,11.55,102435,DB00313,Valproic Acid
,6804223,apparent volume of distribution was Vd beta,"The distribution volume of the central compartment was Vc = 9.9 +/- 0.78 L, the apparent volume of distribution was Vd beta = 18.2 +/- 6.2 L, and the distribution volume at steady state was Vss = 12.6 +/- 1.2 L.",The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804223/),l,18.2,102436,DB00313,Valproic Acid
,6804223,distribution volume at steady state was Vss,"The distribution volume of the central compartment was Vc = 9.9 +/- 0.78 L, the apparent volume of distribution was Vd beta = 18.2 +/- 6.2 L, and the distribution volume at steady state was Vss = 12.6 +/- 1.2 L.",The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804223/),l,12.6,102437,DB00313,Valproic Acid
,6804223,total clearance,The value for the average total clearance was Cltot = 51.1 +/- 11.9 ml/min.,The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804223/),[ml] / [min],51.1,102438,DB00313,Valproic Acid
,6804223,Cltot,The value for the average total clearance was Cltot = 51.1 +/- 11.9 ml/min.,The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6804223/),[ml] / [min],51.1,102439,DB00313,Valproic Acid
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],1.38,102510,DB00313,Valproic Acid
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],2.16,102511,DB00313,Valproic Acid
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],2.72,102512,DB00313,Valproic Acid
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],3.02,102513,DB00313,Valproic Acid
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],2.67,102514,DB00313,Valproic Acid
,27842261,trough levels,"In patients treated with carbamazepine alone, brivaracetam dose-dependently increased mean trough levels of carbamazepine epoxide from 1.38μg/mL on Day 1 pre-dose to 2.16μg/mL (+57%) on Day 8 (50mg bid), 2.72μg/mL (+97%) on Day 15 (100mg bid), 3.02μg/mL (+119%) on Day 22 (200mg bid), 2.67μg/mL (+94%) on Day 29 (100mg bid), and 1.22μg/mL (-12%) at ESV, respectively.","Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27842261/),[μg] / [ml],1.22,102515,DB00313,Valproic Acid
,11034263,clearance,"In dogs, (2S,3R)-VCD had a larger clearance (0.33 L/h x kg) and a larger volume of distribution (0.79 L/kg) than its two diastereomers (0.24-0.25 L/h x kg and 0.65 L/kg, respectively).","Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034263/),[l] / [h·kg],0.33,102524,DB00313,Valproic Acid
,11034263,volume of distribution,"In dogs, (2S,3R)-VCD had a larger clearance (0.33 L/h x kg) and a larger volume of distribution (0.79 L/kg) than its two diastereomers (0.24-0.25 L/h x kg and 0.65 L/kg, respectively).","Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034263/),[l] / [kg],0.79,102525,DB00313,Valproic Acid
,11034263,volume of distribution,"In dogs, (2S,3R)-VCD had a larger clearance (0.33 L/h x kg) and a larger volume of distribution (0.79 L/kg) than its two diastereomers (0.24-0.25 L/h x kg and 0.65 L/kg, respectively).","Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034263/),[l] / [h·kg],0.24-0.25,102526,DB00313,Valproic Acid
,11034263,volume of distribution,"In dogs, (2S,3R)-VCD had a larger clearance (0.33 L/h x kg) and a larger volume of distribution (0.79 L/kg) than its two diastereomers (0.24-0.25 L/h x kg and 0.65 L/kg, respectively).","Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034263/),[l] / [kg],0.65,102527,DB00313,Valproic Acid
,17496206,Hill coefficient (n),"Eadie-Hofstee plots of the VPAG formation rate (calculated from urinary excretion rate data for VPAG) were characteristic of autoactivation kinetics and provided estimates of the apparent maximum velocity of an enzymatic reaction (V(max)(app)), the substrate concentration resulting in 50% of V(max)(app) (S(50)(app)), and Hill coefficient (n) of 2.10 +/- 0.75 micromol/min/kg, 117 +/- 56 microM, and 1.34 +/- 0.14, respectively.",Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17496206/),[μM] / [kg·min],2.10,103102,DB00313,Valproic Acid
,17496206,Hill coefficient (n),"Eadie-Hofstee plots of the VPAG formation rate (calculated from urinary excretion rate data for VPAG) were characteristic of autoactivation kinetics and provided estimates of the apparent maximum velocity of an enzymatic reaction (V(max)(app)), the substrate concentration resulting in 50% of V(max)(app) (S(50)(app)), and Hill coefficient (n) of 2.10 +/- 0.75 micromol/min/kg, 117 +/- 56 microM, and 1.34 +/- 0.14, respectively.",Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17496206/),μM,117,103103,DB00313,Valproic Acid
,17496206,Hill coefficient (n),"Eadie-Hofstee plots of the VPAG formation rate (calculated from urinary excretion rate data for VPAG) were characteristic of autoactivation kinetics and provided estimates of the apparent maximum velocity of an enzymatic reaction (V(max)(app)), the substrate concentration resulting in 50% of V(max)(app) (S(50)(app)), and Hill coefficient (n) of 2.10 +/- 0.75 micromol/min/kg, 117 +/- 56 microM, and 1.34 +/- 0.14, respectively.",Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17496206/),,1.34,103104,DB00313,Valproic Acid
,17496206,V(max)(app),"Comparable estimates of V(max)(app) (2.63 +/- 0.33 micromol/min/kg), S(50)(app) (118 +/- 53 microM), and n (2.06 +/- 0.47) describing overall VPA elimination from plasma were obtained by fitting VPA unbound plasma concentration-time data to a two-compartment model with elimination described by the Hill equation.",Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17496206/),[μM] / [kg·min],2.63,103105,DB00313,Valproic Acid
,17496206,S(50)(app),"Comparable estimates of V(max)(app) (2.63 +/- 0.33 micromol/min/kg), S(50)(app) (118 +/- 53 microM), and n (2.06 +/- 0.47) describing overall VPA elimination from plasma were obtained by fitting VPA unbound plasma concentration-time data to a two-compartment model with elimination described by the Hill equation.",Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17496206/),μM,118,103106,DB00313,Valproic Acid
,17496206,n,"Comparable estimates of V(max)(app) (2.63 +/- 0.33 micromol/min/kg), S(50)(app) (118 +/- 53 microM), and n (2.06 +/- 0.47) describing overall VPA elimination from plasma were obtained by fitting VPA unbound plasma concentration-time data to a two-compartment model with elimination described by the Hill equation.",Kinetics of valproic acid glucuronidation: evidence for in vivo autoactivation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17496206/),,2.06,103107,DB00313,Valproic Acid
,797496,half-life,It has a relatively long half-life (in adults 2 to 3 days; in children shorter).,Clinical pharmacokinetics of anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/797496/),d,2 to 3,104851,DB00313,Valproic Acid
,20408498,trough concentrations,"As compared with values obtained while not receiving treatment with the carbapenem, mean plasma VPA trough concentrations decreased by 58% (from 51.7 [95% confidence interval {CI} 28.0-75.4] to 21.8 [95% CI 11.1-32.5] mg/L; p = 0.025).",Valproic acid-carbapenem interaction: report of six cases and a review of the literature. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20408498/),[mg] / [l],51.7,106262,DB00313,Valproic Acid
,20408498,trough concentrations,"As compared with values obtained while not receiving treatment with the carbapenem, mean plasma VPA trough concentrations decreased by 58% (from 51.7 [95% confidence interval {CI} 28.0-75.4] to 21.8 [95% CI 11.1-32.5] mg/L; p = 0.025).",Valproic acid-carbapenem interaction: report of six cases and a review of the literature. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20408498/),[mg] / [l],21.8,106263,DB00313,Valproic Acid
,20408498,clearance,Estimated mean VPA clearance increased by 191% (from 0.0158 [95% CI 0.0041-0.0275] to 0.0302 [95% CI 0.0169-0.0591] L/h/kg; p = 0.007).,Valproic acid-carbapenem interaction: report of six cases and a review of the literature. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20408498/),[l] / [h·kg],0.0158,106264,DB00313,Valproic Acid
,20408498,clearance,Estimated mean VPA clearance increased by 191% (from 0.0158 [95% CI 0.0041-0.0275] to 0.0302 [95% CI 0.0169-0.0591] L/h/kg; p = 0.007).,Valproic acid-carbapenem interaction: report of six cases and a review of the literature. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20408498/),[l] / [h·kg],0.0302,106265,DB00313,Valproic Acid
over,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,30,106800,DB00313,Valproic Acid
,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,5-7,106801,DB00313,Valproic Acid
,12812999,ED(50),"2 VTA lacked anticonvulsant activity, but VTD, DM-VTD and I-VTD possessed anticonvulsant activity in the Frings audiogenic seizure susceptible mice (ED(50) values of 52, 134 and 126 mg kg(-1), respectively).","Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12812999/),[mg] / [kg],52,106822,DB00313,Valproic Acid
,12812999,ED(50),"2 VTA lacked anticonvulsant activity, but VTD, DM-VTD and I-VTD possessed anticonvulsant activity in the Frings audiogenic seizure susceptible mice (ED(50) values of 52, 134 and 126 mg kg(-1), respectively).","Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12812999/),[mg] / [kg],134,106823,DB00313,Valproic Acid
,12812999,ED(50),"2 VTA lacked anticonvulsant activity, but VTD, DM-VTD and I-VTD possessed anticonvulsant activity in the Frings audiogenic seizure susceptible mice (ED(50) values of 52, 134 and 126 mg kg(-1), respectively).","Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12812999/),[mg] / [kg],126,106824,DB00313,Valproic Acid
,12812999,fraction,I-VTD's fraction metabolized to VTD was 29%.,"Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12812999/),%,29,106825,DB00313,Valproic Acid
,30826570,TID20,The experimentally determined TID20 value for TP427 was 11.71 mg/kg.,"New derivative of 1,2,4-triazole-3-thione (TP427) potentiates the anticonvulsant action of valproate, but not that of carbamazepine, phenytoin or phenobarbital in the mouse tonic-clonic seizure model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30826570/),[mg] / [kg],11.71,109717,DB00313,Valproic Acid
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,70,113444,DB00313,Valproic Acid
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,105,113445,DB00313,Valproic Acid
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,61.0,113446,DB00313,Valproic Acid
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,100.5,113447,DB00313,Valproic Acid
,6769666,Lp,"Lp values for treatments A, B and C were: 1.67 +/- 1.25 hr, 6.75 +/- 3.98 hr and 7.63 +/- 3.15 hr respectively.",Meal-dependent absorption of enteric-coated sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6769666/),h,1.67,113528,DB00313,Valproic Acid
,6769666,Lp,"Lp values for treatments A, B and C were: 1.67 +/- 1.25 hr, 6.75 +/- 3.98 hr and 7.63 +/- 3.15 hr respectively.",Meal-dependent absorption of enteric-coated sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6769666/),h,6.75,113529,DB00313,Valproic Acid
,6769666,Lp,"Lp values for treatments A, B and C were: 1.67 +/- 1.25 hr, 6.75 +/- 3.98 hr and 7.63 +/- 3.15 hr respectively.",Meal-dependent absorption of enteric-coated sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6769666/),h,7.63,113530,DB00313,Valproic Acid
,6769666,Lp,The mean Lp value was 8.1 +/- 1.6 hr and the mean bioavailability was 100%.,Meal-dependent absorption of enteric-coated sodium valproate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6769666/),h,8.1,113531,DB00313,Valproic Acid
,6769666,bioavailability,The mean Lp value was 8.1 +/- 1.6 hr and the mean bioavailability was 100%.,Meal-dependent absorption of enteric-coated sodium valproate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6769666/),%,100,113532,DB00313,Valproic Acid
,10082193,ED50,The ED50 value of ethosuximide was significantly increased from 108 to 158 mg/kg.,N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082193/),[mg] / [kg],108,114767,DB00313,Valproic Acid
,10082193,ED50,The ED50 value of ethosuximide was significantly increased from 108 to 158 mg/kg.,N(G)-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10082193/),[mg] / [kg],158,114768,DB00313,Valproic Acid
up to,6143468,time to the steady-state,"Due to the long half-life of phenobarbital its plasma concentrations change slowly, and time to the steady-state may be up to 30 days, if no loading dose is given.",Pharmacokinetics of antiepileptic drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),d,30,115019,DB00313,Valproic Acid
,6143468,half-lives,"Diazepam, clonazepam and nitrazepam are largely bound to plasma proteins and extensively metabolized with the half-lives of 20 to 60 hours.",Pharmacokinetics of antiepileptic drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6143468/),h,20 to 60,115020,DB00313,Valproic Acid
,14506315,ED(30),Vigabatrin inhibited the clonic pentetrazole-induced seizures and ED(30) of the drug was 879 mg/kg.,"Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],879,115573,DB00313,Valproic Acid
,14506315,ED(30),"Vigabatrin (at the subthreshold dose of 250 mg/kg) potentiated the protective activity of ethosuximide, reducing its ED(30) from 142 to 95 mg/kg against clonic seizures induced by pentetrazole, but simultaneously elevated its plasma level.","Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],142,115574,DB00313,Valproic Acid
,14506315,ED(30),"Vigabatrin (at the subthreshold dose of 250 mg/kg) potentiated the protective activity of ethosuximide, reducing its ED(30) from 142 to 95 mg/kg against clonic seizures induced by pentetrazole, but simultaneously elevated its plasma level.","Influence of vigabatrin, a novel antiepileptic drug, on the anticonvulsant activity of conventional antiepileptics in pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14506315/),[mg] / [kg],95,115575,DB00313,Valproic Acid
,30236821,elimination half-life (t1/2),"The elimination half-life (t1/2) was approximately 222 min, and the systemic clearance (CL) and apparent volume of distribution (Vd) were 2.20 mL/min/kg and 0.70 L/kg, respectively.",Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30236821/),min,222,115649,DB00313,Valproic Acid
,30236821,systemic clearance (CL),"The elimination half-life (t1/2) was approximately 222 min, and the systemic clearance (CL) and apparent volume of distribution (Vd) were 2.20 mL/min/kg and 0.70 L/kg, respectively.",Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30236821/),[ml] / [kg·min],2.20,115650,DB00313,Valproic Acid
,30236821,apparent volume of distribution (Vd),"The elimination half-life (t1/2) was approximately 222 min, and the systemic clearance (CL) and apparent volume of distribution (Vd) were 2.20 mL/min/kg and 0.70 L/kg, respectively.",Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30236821/),[l] / [kg],0.70,115651,DB00313,Valproic Acid
,30236821,absolute oral bioavailability,"The absolute oral bioavailability of HO-AAVPA was 33.8%, and the binding rate of HO-AAVPA with rat plasma proteins was between 66.2% and 83.0%.",Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30236821/),%,33.8,115652,DB00313,Valproic Acid
,30236821,binding rate,"The absolute oral bioavailability of HO-AAVPA was 33.8%, and the binding rate of HO-AAVPA with rat plasma proteins was between 66.2% and 83.0%.",Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30236821/),%,66.2,115653,DB00313,Valproic Acid
,30236821,binding rate,"The absolute oral bioavailability of HO-AAVPA was 33.8%, and the binding rate of HO-AAVPA with rat plasma proteins was between 66.2% and 83.0%.",Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30236821/),%,83.0,115654,DB00313,Valproic Acid
,6407454,T max,"In infants, after a single oral dose of 20 mg/kg body weight in the first morning meal, plasma kinetic data were as follows: T max 2.4 hr +/- 1.1; total DPA maximum plasma concentration: 94 micrograms/ml +/- 28; T 1/2: 12.4 hr +/- 4.9; the distribution volume was 0.25 l/kg +2- 0.07 and plasma clearance was 0.014 l/kg/hr +2- 0.004.",[Pharmacokinetic elements of sodium valproate. Use in febrile convulsions in children]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407454/),h,2.4,116474,DB00313,Valproic Acid
,6407454,maximum plasma concentration,"In infants, after a single oral dose of 20 mg/kg body weight in the first morning meal, plasma kinetic data were as follows: T max 2.4 hr +/- 1.1; total DPA maximum plasma concentration: 94 micrograms/ml +/- 28; T 1/2: 12.4 hr +/- 4.9; the distribution volume was 0.25 l/kg +2- 0.07 and plasma clearance was 0.014 l/kg/hr +2- 0.004.",[Pharmacokinetic elements of sodium valproate. Use in febrile convulsions in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407454/),[μg] / [ml],94,116475,DB00313,Valproic Acid
,6407454,T 1/2,"In infants, after a single oral dose of 20 mg/kg body weight in the first morning meal, plasma kinetic data were as follows: T max 2.4 hr +/- 1.1; total DPA maximum plasma concentration: 94 micrograms/ml +/- 28; T 1/2: 12.4 hr +/- 4.9; the distribution volume was 0.25 l/kg +2- 0.07 and plasma clearance was 0.014 l/kg/hr +2- 0.004.",[Pharmacokinetic elements of sodium valproate. Use in febrile convulsions in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407454/),h,12.4,116476,DB00313,Valproic Acid
,6407454,distribution volume,"In infants, after a single oral dose of 20 mg/kg body weight in the first morning meal, plasma kinetic data were as follows: T max 2.4 hr +/- 1.1; total DPA maximum plasma concentration: 94 micrograms/ml +/- 28; T 1/2: 12.4 hr +/- 4.9; the distribution volume was 0.25 l/kg +2- 0.07 and plasma clearance was 0.014 l/kg/hr +2- 0.004.",[Pharmacokinetic elements of sodium valproate. Use in febrile convulsions in children]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407454/),[l] / [kg],0.25,116477,DB00313,Valproic Acid
,6407454,plasma clearance,"In infants, after a single oral dose of 20 mg/kg body weight in the first morning meal, plasma kinetic data were as follows: T max 2.4 hr +/- 1.1; total DPA maximum plasma concentration: 94 micrograms/ml +/- 28; T 1/2: 12.4 hr +/- 4.9; the distribution volume was 0.25 l/kg +2- 0.07 and plasma clearance was 0.014 l/kg/hr +2- 0.004.",[Pharmacokinetic elements of sodium valproate. Use in febrile convulsions in children]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407454/),[l] / [h·kg],0.014,116478,DB00313,Valproic Acid
,23891703,Volume of distribution,Volume of distribution of TPM was estimated at 0.575 l/kg.,Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [kg],0.575,116785,DB00313,Valproic Acid
,23891703,CL/F,"Mean TPM CL/F during CBZ co-therapy was 2.46 l/h, which is higher for 60.8% than in patients not co-treated with CBZ.",Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891703/),[l] / [h],2.46,116786,DB00313,Valproic Acid
,1475789,half-lives,"After the treatment with carnitine, serum carnitine concentration was increased, and prolonged half-lives of VPA were corrected near to the normal range (from 12.2 +/- 4.2 hr to 9.7 +/- 2.2 hr; p < 0.05).",The effect of carnitine on the metabolism of valproic acid in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1475789/),h,12.2,116820,DB00313,Valproic Acid
,1475789,half-lives,"After the treatment with carnitine, serum carnitine concentration was increased, and prolonged half-lives of VPA were corrected near to the normal range (from 12.2 +/- 4.2 hr to 9.7 +/- 2.2 hr; p < 0.05).",The effect of carnitine on the metabolism of valproic acid in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1475789/),h,9.7,116821,DB00313,Valproic Acid
,23493631,CL/F,"Comparison between two groups showed that CL/F values in acutely manic patients were significantly higher than epileptic patients (10.35±5.77 vs. 7.70±2.63 ml/kg/h, P= 0.047).",Comparison of Valproic acid Clearance between Epileptic Patients and Patients with Acute Mania. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23493631/),[ml] / [h·kg],10.35,117218,DB00313,Valproic Acid
,23493631,CL/F,"Comparison between two groups showed that CL/F values in acutely manic patients were significantly higher than epileptic patients (10.35±5.77 vs. 7.70±2.63 ml/kg/h, P= 0.047).",Comparison of Valproic acid Clearance between Epileptic Patients and Patients with Acute Mania. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23493631/),[ml] / [h·kg],7.70,117219,DB00313,Valproic Acid
,12507057,elimination half-life,The elimination half-life was calculated to be 5.14 hours.,A case of levetiracetam (Keppra) poisoning with clinical and toxicokinetic data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507057/),h,5.14,117772,DB00313,Valproic Acid
,8294164,order of association constant (K),The order of association constant (K) for valproic acid-serum protein was 10(-2) l/mumol.,Can the serum protein binding of valproic acid limit the hepatic elimination? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8294164/),[l] / [μM],10(-2),118507,DB00313,Valproic Acid
,19843490,C(max),"For the MgV solution, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 59.75 (8.24) microg/mL, 0.542 (0.14) hours, 1099.67 (241.70) microg h/mL, 1156.30 (264.01) microg h/mL, 16.19 (2.36) hours, 9633.68 (1892.70) mL, 418.35 (92.01) mL/h, and 18.36 (1.44) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),[μg] / [ml],59.75,118721,DB00313,Valproic Acid
,19843490,MRT,"For the MgV solution, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 59.75 (8.24) microg/mL, 0.542 (0.14) hours, 1099.67 (241.70) microg h/mL, 1156.30 (264.01) microg h/mL, 16.19 (2.36) hours, 9633.68 (1892.70) mL, 418.35 (92.01) mL/h, and 18.36 (1.44) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),[ml] / [h],418.35,118722,DB00313,Valproic Acid
,19843490,MRT,"For the MgV solution, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 59.75 (8.24) microg/mL, 0.542 (0.14) hours, 1099.67 (241.70) microg h/mL, 1156.30 (264.01) microg h/mL, 16.19 (2.36) hours, 9633.68 (1892.70) mL, 418.35 (92.01) mL/h, and 18.36 (1.44) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),h,18.36,118723,DB00313,Valproic Acid
,19843490,C(max),"For the MgV suspension, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 55.04 (7.72) microg/mL, 0.773 (0.51) hour, 1057.76 (223.37) microg h/mL, 1111.09 (245.07) microg h/mL, 16.32 (2.20) hours, 1069.05 (1775.64) mL, 435.43 (99.59) mL/h, and 18.41 (1.43) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),[μg] / [ml],55.04,118724,DB00313,Valproic Acid
,19843490,MRT,"For the MgV suspension, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 55.04 (7.72) microg/mL, 0.773 (0.51) hour, 1057.76 (223.37) microg h/mL, 1111.09 (245.07) microg h/mL, 16.32 (2.20) hours, 1069.05 (1775.64) mL, 435.43 (99.59) mL/h, and 18.41 (1.43) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),[ml] / [h],435.43,118725,DB00313,Valproic Acid
,19843490,MRT,"For the MgV suspension, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 55.04 (7.72) microg/mL, 0.773 (0.51) hour, 1057.76 (223.37) microg h/mL, 1111.09 (245.07) microg h/mL, 16.32 (2.20) hours, 1069.05 (1775.64) mL, 435.43 (99.59) mL/h, and 18.41 (1.43) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),h,18.41,118726,DB00313,Valproic Acid
,19843490,C(max),"For the MgV enteric-coated tablets, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 54.88 (6.73) microg/mL, 2.79 (0.89) hours, 1100.79 (216.70) microg h/mL, 1163.61 (238.36) microg h/mL, 16.48 (2.10) hours, 9675.15 (1659.36) mL, 412.36 (85.24) mL/h, and 19.95 (1.53) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),[μg] / [ml],54.88,118727,DB00313,Valproic Acid
,19843490,MRT,"For the MgV enteric-coated tablets, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 54.88 (6.73) microg/mL, 2.79 (0.89) hours, 1100.79 (216.70) microg h/mL, 1163.61 (238.36) microg h/mL, 16.48 (2.10) hours, 9675.15 (1659.36) mL, 412.36 (85.24) mL/h, and 19.95 (1.53) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),[ml] / [h],412.36,118728,DB00313,Valproic Acid
,19843490,MRT,"For the MgV enteric-coated tablets, the mean (SD) pharmacokinetic parameters of C(max), T(max), AUC(0-72), AUC(0-infinity), t(1/2), V(d)/F, CL/F, and MRT were 54.88 (6.73) microg/mL, 2.79 (0.89) hours, 1100.79 (216.70) microg h/mL, 1163.61 (238.36) microg h/mL, 16.48 (2.10) hours, 9675.15 (1659.36) mL, 412.36 (85.24) mL/h, and 19.95 (1.53) hours, respectively.","A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19843490/),h,19.95,118729,DB00313,Valproic Acid
,11054983,elimination rate constant (kel),"High-flux hemodialysis was performed for four hours; the calculated elimination rate constant (kel) during the procedure was 0.2522 h-1 with a half-life (t1/2) of 2.74 hours compared with posthemodialysis kel of 0.0296 h-1 and t1/2 of 23.41 hours, suggesting that high-flux hemodialysis effectively eliminates valproic acid.",High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054983/),1/[h],0.2522,121649,DB00313,Valproic Acid
,11054983,half-life (t1/2),"High-flux hemodialysis was performed for four hours; the calculated elimination rate constant (kel) during the procedure was 0.2522 h-1 with a half-life (t1/2) of 2.74 hours compared with posthemodialysis kel of 0.0296 h-1 and t1/2 of 23.41 hours, suggesting that high-flux hemodialysis effectively eliminates valproic acid.",High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054983/),h,2.74,121650,DB00313,Valproic Acid
,11054983,kel,"High-flux hemodialysis was performed for four hours; the calculated elimination rate constant (kel) during the procedure was 0.2522 h-1 with a half-life (t1/2) of 2.74 hours compared with posthemodialysis kel of 0.0296 h-1 and t1/2 of 23.41 hours, suggesting that high-flux hemodialysis effectively eliminates valproic acid.",High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054983/),1/[h],0.0296,121651,DB00313,Valproic Acid
,11054983,t1/2,"High-flux hemodialysis was performed for four hours; the calculated elimination rate constant (kel) during the procedure was 0.2522 h-1 with a half-life (t1/2) of 2.74 hours compared with posthemodialysis kel of 0.0296 h-1 and t1/2 of 23.41 hours, suggesting that high-flux hemodialysis effectively eliminates valproic acid.",High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054983/),h,23.41,121652,DB00313,Valproic Acid
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],127.7,122128,DB00313,Valproic Acid
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],182.3,122129,DB00313,Valproic Acid
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],198.3,122130,DB00313,Valproic Acid
,6423010,overall bioavailability,"Results indicate that the sustained release formulation exhibited a more prolonged and uniform absorption rate, yielded more sustained plasma levels after ingestion, and showed an overall bioavailability of 0.84 (95 per cent C.I. = 0.72, 0.96) relative to an equivalent dose of a conventional tablet.",Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6423010/),,0.84,124200,DB00313,Valproic Acid
,20101186,Response rates,Response rates were 72.6% in the lithium group and 79.5% in the valproate group.,"Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),%,72.6,124463,DB00313,Valproic Acid
,20101186,Response rates,Response rates were 72.6% in the lithium group and 79.5% in the valproate group.,"Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),%,79.5,124464,DB00313,Valproic Acid
,20101186,Remission rates,"Remission rates were 58.5 and 71.9%, respectively.","Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),%,58.5,124465,DB00313,Valproic Acid
,20101186,Remission rates,"Remission rates were 58.5 and 71.9%, respectively.","Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),%,71.9,124466,DB00313,Valproic Acid
,20101186,time to treatment response,No intergroup differences were observed in median time to treatment response (21 days) or change in Clinical Global Impression Bipolar Disorder instrument or Montgomery and Asberg Depression Rating Scale scores.,"Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20101186/),d,21,124467,DB00313,Valproic Acid
,1552406,relative bioavailability,"The extent of absorption from sprinkle equaled that from syrup (relative bioavailability = 1.02), but absorption was slower (time to maximum concentration = 4.2 vs 0.9 hour; p less than 0.01).","Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552406/),,1.02,124667,DB00313,Valproic Acid
,1552406,time to maximum concentration,"The extent of absorption from sprinkle equaled that from syrup (relative bioavailability = 1.02), but absorption was slower (time to maximum concentration = 4.2 vs 0.9 hour; p less than 0.01).","Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552406/),h,4.2,124668,DB00313,Valproic Acid
,1552406,time to maximum concentration,"The extent of absorption from sprinkle equaled that from syrup (relative bioavailability = 1.02), but absorption was slower (time to maximum concentration = 4.2 vs 0.9 hour; p less than 0.01).","Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1552406/),h,0.9,124669,DB00313,Valproic Acid
,6421770,terminal half-life,"Following the administration of standard tablets, VPA concentrations reached a peak mean +/- SD of 105.4 +/- 9.0 micrograms/ml at 1 h and declined monoexponentially, with a terminal half-life of 14.9 +/- 2.4 h.",Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6421770/),h,14.9,125432,DB00313,Valproic Acid
,6421770,time lag,"Following the administration of an enteric-coated tablet, there was an average time lag of 2 h with a delayed peak serum concentration of 93.5 +/- 13.1 micrograms/ml at 6 h.",Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6421770/),h,2,125433,DB00313,Valproic Acid
,6421770,peak serum concentration,"Following the administration of an enteric-coated tablet, there was an average time lag of 2 h with a delayed peak serum concentration of 93.5 +/- 13.1 micrograms/ml at 6 h.",Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6421770/),[μg] / [ml],93.5,125434,DB00313,Valproic Acid
,16997532,oral bioavailability,"It showed a beneficial pharmacokinetic profile in rats, having a high oral bioavailability of 75% and satisfactory values of clearance and volume of distribution.","Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16997532/),%,75,126358,DB00313,Valproic Acid
,9452963,steady-state plasma concentration,"In another experiment, guinea pigs (n = 3) were given a constant i.v. infusion of VPA-Na to maintain a steady-state plasma concentration (58 micrograms/mL), followed by an i.v. bolus dose of bilirubin (2 mg/kg).",Effect of valproate on the pharmacokinetics of free and total plasma bilirubin in experimental hyperbilirubinemia in guinea pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452963/),[μg] / [ml],58,126722,DB00313,Valproic Acid
,9452963,binding constant (KD),"VPA displaced bilirubin from the high-affinity plasma protein binding site, with a binding constant (KD) of 5.7 x 10(-2)/microM.",Effect of valproate on the pharmacokinetics of free and total plasma bilirubin in experimental hyperbilirubinemia in guinea pigs. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9452963/),1/[μM],5.7 x 10(-2),126723,DB00313,Valproic Acid
,19054418,time,The median time from hospital admission to ivLEV was 36 min.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),min,36,126739,DB00313,Valproic Acid
,19054418,volume of distribution of central compartment,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [kg],0.45,126740,DB00313,Valproic Acid
,19054418,total body clearance,"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[l] / [h·kg],0.0476,126741,DB00313,Valproic Acid
,19054418,"distribution rate constants, central to peripheral compartment (k(12))","Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.24,126742,DB00313,Valproic Acid
,19054418,peripheral to central (k(21)),"Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h.",Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),1/[h],0.70,126743,DB00313,Valproic Acid
,19054418,maximal plasma concentration,Mean maximal plasma concentration was 85 (19) mg/L.,Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19054418/),[mg] / [l],85,126744,DB00313,Valproic Acid
,21186545,clearance,The typical mean value of the clearance of valproate estimated by the base model in our population was 0.3 77 I/h.,[Pharmacokinetic modelling of valproate in epileptic patients]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21186545/),[i] / [h],0.3 77,127437,DB00313,Valproic Acid
,6439443,elimination half-life,"Mean elimination half-life was 8.21 +/- 3.13 hours, mean apparent volume of distribution 0.1868 +/- 0.0641 L/kg and mean plasma clearance 0.0177 +/- 0.0099 L/kg/hour.",Steady-state valproate pharmacokinetics during long term therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6439443/),h,8.21,127741,DB00313,Valproic Acid
,6439443,apparent volume of distribution,"Mean elimination half-life was 8.21 +/- 3.13 hours, mean apparent volume of distribution 0.1868 +/- 0.0641 L/kg and mean plasma clearance 0.0177 +/- 0.0099 L/kg/hour.",Steady-state valproate pharmacokinetics during long term therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6439443/),[l] / [kg],0.1868,127742,DB00313,Valproic Acid
,6439443,plasma clearance,"Mean elimination half-life was 8.21 +/- 3.13 hours, mean apparent volume of distribution 0.1868 +/- 0.0641 L/kg and mean plasma clearance 0.0177 +/- 0.0099 L/kg/hour.",Steady-state valproate pharmacokinetics during long term therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6439443/),[l] / [h·kg],0.0177,127743,DB00313,Valproic Acid
,350128,half-life,"The drug had a relatively short half-life of 8.7 hours, necessitating administration in divided daily doses.",Valproic acid in epilepsy: clinical and pharmacological effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/350128/),h,8.7,127800,DB00313,Valproic Acid
,28497259,maximum tolerated dose,The maximum tolerated dose was 140 mg/kg.,Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28497259/),[mg] / [kg],140,128368,DB00313,Valproic Acid
,28497259,maximum tolerated dose,The maximum tolerated dose of intravenous valproic acid in healthy subjects is 140 mg/kg.,Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28497259/),[mg] / [kg],140,128369,DB00313,Valproic Acid
,28497259,maximum tolerated dose,This is significantly higher than the previously established maximum tolerated dose of 60-75 mg/kg.,Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28497259/),[mg] / [kg],60-75,128370,DB00313,Valproic Acid
,1682459,biliary excretion,"The biliary excretion of unchanged and conjugated valproic acid was 2.0 +/- 0.7 (s.e.m.) and 19.7 +/- 3.6 (s.e.m.)% of dose, respectively, and was almost completely reabsorbed in the enterohepatic recycling.",Pharmacokinetics of valproic acid in guinea-pigs with biliary abnormality. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682459/),%,2.0,128463,DB00313,Valproic Acid
,1682459,biliary excretion,"The biliary excretion of unchanged and conjugated valproic acid was 2.0 +/- 0.7 (s.e.m.) and 19.7 +/- 3.6 (s.e.m.)% of dose, respectively, and was almost completely reabsorbed in the enterohepatic recycling.",Pharmacokinetics of valproic acid in guinea-pigs with biliary abnormality. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1682459/),%,19.7,128464,DB00313,Valproic Acid
,9244143,clearance,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),[ml] / [kg·min],7.1,128899,DB00313,Valproic Acid
,9244143,clearance,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),[ml] / [kg·min],16,128900,DB00313,Valproic Acid
,9244143,volume of distribution (Vss),"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),[l] / [kg],0.78,128901,DB00313,Valproic Acid
,9244143,volume of distribution (Vss),"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),[l] / [kg],0.41,128902,DB00313,Valproic Acid
,9244143,half-life,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),h,1.1,128903,DB00313,Valproic Acid
,9244143,half-life,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),h,0.37,128904,DB00313,Valproic Acid
,9244143,mean residence time,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),h,1.8,128905,DB00313,Valproic Acid
,9244143,mean residence time,"The following PK parameters were obtained for valproyl glycinamide and valproyl glycine, respectively: clearance, 7.1 and 16 ml/ min/kg; volume of distribution (Vss), 0.78 and 0.41 l/kg; half-life, 1.1 and 0.37 h; and mean residence time, 1.8 and 0.4 h.",The disposition of valproyl glycinamide and valproyl glycine in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244143/),h,0.4,128906,DB00313,Valproic Acid
<,12576164,Maximum dose,Maximum dose was </=15mg/kg per infusion.,Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576164/),[mg] / [kg],15,129972,DB00313,Valproic Acid
,12576164,Maximum total,"Maximum total and unbound VPA concentrations were 94 and 14mg/l, respectively.",Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576164/),[mg] / [l],94,129973,DB00313,Valproic Acid
,12576164,unbound VPA concentrations,"Maximum total and unbound VPA concentrations were 94 and 14mg/l, respectively.",Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576164/),[mg] / [l],14,129974,DB00313,Valproic Acid
below,12576164,Total concentration,Total concentration fell below 50mg/l within 3h in induced and 6h in uninduced patients.,Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576164/),[mg] / [l],50,129975,DB00313,Valproic Acid
,12576164,distribution volume,The mean (S.D.) distribution volume was 0.21 (0.044)l/kg.,Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576164/),[l] / [kg],0.21,129976,DB00313,Valproic Acid
,22057163,ED(50),"In rats DEVA acted as a prodrug of VPA and had ED(50) values of 73 mg/kg and 158 mg/kg in the MES and the hippocampal kindling models, respectively.",Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057163/),[mg] / [kg],73,132765,DB00313,Valproic Acid
,22057163,ED(50),"In rats DEVA acted as a prodrug of VPA and had ED(50) values of 73 mg/kg and 158 mg/kg in the MES and the hippocampal kindling models, respectively.",Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057163/),[mg] / [kg],158,132766,DB00313,Valproic Acid
,3134567,concentration (Cmax),"The mean concentration (Cmax) and extent of absorption (area under the concentration-time curve) between 1 and 4 hours were 22.2 micrograms/ml and 59.3 micrograms.h/ml, respectively.",Bioavailability of a film-coated tablet of valproate in nonfasting volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134567/),[μg] / [ml],22.2,133593,DB00313,Valproic Acid
,3134567,extent of absorption (area under the concentration-time curve),"The mean concentration (Cmax) and extent of absorption (area under the concentration-time curve) between 1 and 4 hours were 22.2 micrograms/ml and 59.3 micrograms.h/ml, respectively.",Bioavailability of a film-coated tablet of valproate in nonfasting volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134567/),[μg] / [ml],22.2,133594,DB00313,Valproic Acid
,3134567,extent of absorption (area under the concentration-time curve),"The mean concentration (Cmax) and extent of absorption (area under the concentration-time curve) between 1 and 4 hours were 22.2 micrograms/ml and 59.3 micrograms.h/ml, respectively.",Bioavailability of a film-coated tablet of valproate in nonfasting volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3134567/),[h·μg] / [ml],59.3,133595,DB00313,Valproic Acid
,8112251,formation,"In the IPRL studies, VPA also significantly decreased formation of LZP glucuronide (from 0.72 +/- 0.14 to 0.22 +/- 0.15 ml/h/kg, p < 0.05), indicating that IPRL is a useful tool for evaluation of the effect of VPA on drugs eliminated by glucuronide conjugation.",Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112251/),m,0.,136538,DB00313,Valproic Acid
,16896786,serum concentration,The mean VPA serum concentration difference between 12 h and 24 h post-dose was approximately 40 mg/l.,"Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16896786/),,40,137096,DB00313,Valproic Acid
,15652736,trough serum concentrations,"Among the 67 patients with at least one lamotrigine trough serum concentration after initiation of therapy (pharmacokinetic population), mean trough serum concentrations at the end of the lamotrigine escalation phase at a lamotrigine daily dose of 200 mg (7.9 microg/mL, SD = 3.3) did not differ significantly from values during the valproate withdrawal phase (8.7 microg/mL, SD = 3.5) and the lamotrigine monotherapy phase at a lamotrigine dose of 500 mg daily (7.2 microg/mL, SD = 3.3).",A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652736/),[μg] / [ml],7.9,137398,DB00313,Valproic Acid
,15652736,trough serum concentrations,"Among the 67 patients with at least one lamotrigine trough serum concentration after initiation of therapy (pharmacokinetic population), mean trough serum concentrations at the end of the lamotrigine escalation phase at a lamotrigine daily dose of 200 mg (7.9 microg/mL, SD = 3.3) did not differ significantly from values during the valproate withdrawal phase (8.7 microg/mL, SD = 3.5) and the lamotrigine monotherapy phase at a lamotrigine dose of 500 mg daily (7.2 microg/mL, SD = 3.3).",A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652736/),[μg] / [ml],8.7,137399,DB00313,Valproic Acid
,15652736,trough serum concentrations,"Among the 67 patients with at least one lamotrigine trough serum concentration after initiation of therapy (pharmacokinetic population), mean trough serum concentrations at the end of the lamotrigine escalation phase at a lamotrigine daily dose of 200 mg (7.9 microg/mL, SD = 3.3) did not differ significantly from values during the valproate withdrawal phase (8.7 microg/mL, SD = 3.5) and the lamotrigine monotherapy phase at a lamotrigine dose of 500 mg daily (7.2 microg/mL, SD = 3.3).",A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15652736/),[μg] / [ml],7.2,137400,DB00313,Valproic Acid
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.045-0.070,137436,DB00313,Valproic Acid
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.028,137437,DB00313,Valproic Acid
,18641550,CL,"The administration of inducers led to a significant increase in mean LTG CL (values of 0.045-0.070 L/h/kg vs. 0.028 L/h/kg being reached in monotherapy), whereas VPA led to a significant decrease in CL (0.014 L/h/kg).",Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641550/),[l] / [h·kg],0.014,137438,DB00313,Valproic Acid
,25503589,CL/F,"Mean population estimates (% inter-individual variability) were 1.23 L/h (29%) for CL/F, 39.1 L (18%) for V CLB/F and 0.0706 h(-1) (26%) for Kem.",Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503589/),[l] / [h],1.23,137851,DB00313,Valproic Acid
,25503589,V CLB/F,"Mean population estimates (% inter-individual variability) were 1.23 L/h (29%) for CL/F, 39.1 L (18%) for V CLB/F and 0.0706 h(-1) (26%) for Kem.",Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503589/),l,39.1,137852,DB00313,Valproic Acid
,25503589,Kem,"Mean population estimates (% inter-individual variability) were 1.23 L/h (29%) for CL/F, 39.1 L (18%) for V CLB/F and 0.0706 h(-1) (26%) for Kem.",Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503589/),1/[h],0.0706,137853,DB00313,Valproic Acid
higher,25503589,C trough,"The AUC values for clobazam and N-CLB were found to increase by 100% when bodyweight increased from 10 to 60 kg, and the simulated C trough values were higher than the currently accepted target values (0.03-0.3 mg/L for clobazam and 0.3-3 mg/L for N-CLB).",Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503589/),[mg] / [l],0.03-0.3,137854,DB00313,Valproic Acid
,25503589,C trough,"The AUC values for clobazam and N-CLB were found to increase by 100% when bodyweight increased from 10 to 60 kg, and the simulated C trough values were higher than the currently accepted target values (0.03-0.3 mg/L for clobazam and 0.3-3 mg/L for N-CLB).",Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503589/),[mg] / [l],0.3-3,137855,DB00313,Valproic Acid
,17541590,maximum plasma concentration,"At a dose of 75 mg/kg, the maximum plasma concentration of VPA was 130.1 +/- 70.6 microg/ml (mean +/- standard deviation) for total drug and 53.3 +/- 44.4 microg/ml for free drug.",Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),[μg] / [ml],130.1,138173,DB00313,Valproic Acid
,17541590,maximum plasma concentration,"At a dose of 75 mg/kg, the maximum plasma concentration of VPA was 130.1 +/- 70.6 microg/ml (mean +/- standard deviation) for total drug and 53.3 +/- 44.4 microg/ml for free drug.",Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),[μg] / [ml],53.3,138174,DB00313,Valproic Acid
,17541590,plasma area under the curve (AUC),The mean plasma area under the curve (AUC) for total drug was 680 +/- 233 microg/ml h and for free drug 146 +/- 89 microg/ml hr.,Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),[μg] / [h·ml],680,138175,DB00313,Valproic Acid
,17541590,plasma area under the curve (AUC),The mean plasma area under the curve (AUC) for total drug was 680 +/- 233 microg/ml h and for free drug 146 +/- 89 microg/ml hr.,Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),[μg] / [h·ml],146,138176,DB00313,Valproic Acid
,17541590,maximum CSF concentration,The maximum CSF concentration occurred 2-3 h after administration and was 28.2 +/- 18.6 microg/ml.,Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),[μg] / [ml],28.2,138177,DB00313,Valproic Acid
,17541590,AUC,The CSF AUC for VPA was 108 +/- 52 microg/ml h.,Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),[μg] / [h·ml],108,138178,DB00313,Valproic Acid
,17541590,CSF penetration,The CSF penetration of VPA was 12.9 +/- 5.1% for total drug and 57.0 +/- 8.7% for free drug.,Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),%,12.9,138179,DB00313,Valproic Acid
,17541590,CSF penetration,The CSF penetration of VPA was 12.9 +/- 5.1% for total drug and 57.0 +/- 8.7% for free drug.,Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),%,57.0,138180,DB00313,Valproic Acid
,17541590,V (max),Disappearance from the plasma followed non-linear kinetics with a V (max) of 321.2 +/- 65.6 microg/kg/min and a K (m) of 17.2 +/- 13.7 mg/l.,Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),[μg] / [kg·min],321.2,138181,DB00313,Valproic Acid
,17541590,K (m),Disappearance from the plasma followed non-linear kinetics with a V (max) of 321.2 +/- 65.6 microg/kg/min and a K (m) of 17.2 +/- 13.7 mg/l.,Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541590/),[mg] / [l],17.2,138182,DB00313,Valproic Acid
,26805435,apparent clearance (CL/F),The apparent clearance (CL/F) estimated from the PK model was 2.19 L/h; it was found to increase significantly as a function of body weight.,"Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26805435/),[l] / [h],2.19,138421,DB00313,Valproic Acid
,23493451,dose,Mean VPA dose and VPA CL/F were 8.93±2.2 mg/kg/day and 0.65±0.55 l/hr respectively.,"Relationship between Patient Demographic Characteristics, Valproic Acid Dosage and Clearance in Adult Iranian Patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23493451/),[mg] / [d·kg],8.93,138900,DB00313,Valproic Acid
,23493451,CL/F,Mean VPA dose and VPA CL/F were 8.93±2.2 mg/kg/day and 0.65±0.55 l/hr respectively.,"Relationship between Patient Demographic Characteristics, Valproic Acid Dosage and Clearance in Adult Iranian Patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23493451/),[l] / [h],0.65,138901,DB00313,Valproic Acid
,23493451,plasma concentration,Mean total VPA plasma concentration was 54.51±23.74 mg/l.,"Relationship between Patient Demographic Characteristics, Valproic Acid Dosage and Clearance in Adult Iranian Patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23493451/),[mg] / [l],54.51,138902,DB00313,Valproic Acid
,21115653,trough concentrations,The primary purpose of this trial was to define and describe the toxicities of oral valproic acid (VPA) at doses required to maintain trough concentrations of 100 to 150 mcg/mL or 150 to 200 mcg/mL in children with refractory solid or central nervous system (CNS) tumors.,Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115653/),[mcg] / [ml],100 to 150,139599,DB00313,Valproic Acid
,21115653,trough concentrations,The primary purpose of this trial was to define and describe the toxicities of oral valproic acid (VPA) at doses required to maintain trough concentrations of 100 to 150 mcg/mL or 150 to 200 mcg/mL in children with refractory solid or central nervous system (CNS) tumors.,Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115653/),[mcg] / [ml],150 to 200,139600,DB00313,Valproic Acid
,21115653,trough concentrations,"Oral VPA, initially administered twice daily and subsequently three times daily, was continued without interruption to maintain trough concentrations of 100 to 150 mcg/mL.",Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115653/),[mcg] / [ml],100 to 150,139601,DB00313,Valproic Acid
,21115653,troughs,Dose-limiting somnolence and intratumoral hemorrhage were associated with VPA troughs of 100 to 150 mcg/mL.,Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115653/),[mcg] / [ml],100 to 150,139602,DB00313,Valproic Acid
,21115653,troughs,"Therefore, the final cohort of six children received VPA to maintain troughs of 75 to 100 mcg/mL and did not experience any dose-limiting toxicity.",Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115653/),[mcg] / [ml],75 to 100,139603,DB00313,Valproic Acid
,21115653,trough concentrations,VPA administered three times daily to maintain trough concentrations of 75 to 100 mcg/mL was well tolerated in children with refractory solid or CNS tumors.,Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115653/),[mcg] / [ml],75 to 100,139604,DB00313,Valproic Acid
,27218460,absolute bioavailabilities,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),%,76,139682,DB00313,Valproic Acid
,27218460,absolute bioavailabilities,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),%,96,139683,DB00313,Valproic Acid
,27218460,clearance,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),[l] / [h·kg],1.8-1.5,139684,DB00313,Valproic Acid
,27218460,half-life,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),[l] / [h·kg],1.8-1.5,139685,DB00313,Valproic Acid
,27218460,half-life,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),h,0.5-1.7,139686,DB00313,Valproic Acid
,27218460,brain-to-plasma AUC ratios,"The SPD brain-to-plasma AUC ratios were 1.86 (i.v.), 2.31 (i.p.), and 0.77 (i.m.).","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),,1.86,139687,DB00313,Valproic Acid
,27218460,brain-to-plasma AUC ratios,"The SPD brain-to-plasma AUC ratios were 1.86 (i.v.), 2.31 (i.p.), and 0.77 (i.m.).","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),,2.31,139688,DB00313,Valproic Acid
,27218460,brain-to-plasma AUC ratios,"The SPD brain-to-plasma AUC ratios were 1.86 (i.v.), 2.31 (i.p.), and 0.77 (i.m.).","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),,0.77,139689,DB00313,Valproic Acid
,25442425,effective dose (ED50 ),"Racemic EMC exhibited a potent activity in the soman-induced SE model when administered 5 and 20 min after seizure onset with median effective dose (ED50 ) values of 33 and 48 mg/kg, respectively. (2R)-IPC and (2S)-IPC exhibited ED50 values similar to those of racemic IPC in the mouse and rat MES and scMet models.",Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),[mg] / [kg],33,140158,DB00313,Valproic Acid
,25442425,effective dose (ED50 ),"Racemic EMC exhibited a potent activity in the soman-induced SE model when administered 5 and 20 min after seizure onset with median effective dose (ED50 ) values of 33 and 48 mg/kg, respectively. (2R)-IPC and (2S)-IPC exhibited ED50 values similar to those of racemic IPC in the mouse and rat MES and scMet models.",Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),[mg] / [kg],48,140159,DB00313,Valproic Acid
,25442425,ED50,Racemic IPC had an ED50 value of 107 mg/kg in the pilocarpine-induced SE model when given 30 min after seizure onset.,Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),[mg] / [kg],107,140160,DB00313,Valproic Acid
,25442425,clearance,Racemic EMC and IPC and their enantiomers had similar clearance (3.8-5.5 L/h/kg) and short half-life (<1 h).,Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),[l] / [h·kg],3.8-5.5,140161,DB00313,Valproic Acid
<,25442425,half-life,Racemic EMC and IPC and their enantiomers had similar clearance (3.8-5.5 L/h/kg) and short half-life (<1 h).,Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),h,1,140162,DB00313,Valproic Acid
,16730950,CL/F,"In the absence of enzyme inducing comedication, VPA CL/F in the elderly was similar to that found in non-elderly controls (9.7+/-4.6 versus 10.2+/-4.6mlh(-1)kg(-1)).",The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16730950/),1/[mlh],9.7,140265,DB00313,Valproic Acid
,16730950,CL/F,"In the absence of enzyme inducing comedication, VPA CL/F in the elderly was similar to that found in non-elderly controls (9.7+/-4.6 versus 10.2+/-4.6mlh(-1)kg(-1)).",The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16730950/),1/[mlh],10.2,140266,DB00313,Valproic Acid
,16730950,CL/F,"Elderly patients on enzyme inducing comedication, on the other hand, had lower CL/F values than enzyme induced younger controls (11.7+/-5.4 versus 16.0+/-6.3mlh(-1)kg(-1), p<0.05).",The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16730950/),1/[mlh],11.7,140267,DB00313,Valproic Acid
,16730950,CL/F,"Elderly patients on enzyme inducing comedication, on the other hand, had lower CL/F values than enzyme induced younger controls (11.7+/-5.4 versus 16.0+/-6.3mlh(-1)kg(-1), p<0.05).",The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16730950/),1/[mlh],16.0,140268,DB00313,Valproic Acid
,1777370,half-lives,"3. Nimodipine half-lives were shorter in enzyme-induced patients than in controls (3.9 +/- 2.0 h vs 9.1 +/- 3.4 h, means +/- s.d., P less than 0.01), but this difference could be artifactual since in the patients drug concentrations declined rapidly below the limit of assay, thus preventing identification of a possible slower terminal phase.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,3.9,140864,DB00313,Valproic Acid
,1777370,half-lives,"3. Nimodipine half-lives were shorter in enzyme-induced patients than in controls (3.9 +/- 2.0 h vs 9.1 +/- 3.4 h, means +/- s.d., P less than 0.01), but this difference could be artifactual since in the patients drug concentrations declined rapidly below the limit of assay, thus preventing identification of a possible slower terminal phase.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,9.1,140865,DB00313,Valproic Acid
,1777370,half-lives,"In valproate-treated patients, half-lives (8.2 +/- 1.8 h) were similar to those found in controls.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,8.2,140866,DB00313,Valproic Acid
,19076986,AUC,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[h·mg] / [l],7.794,141913,DB00313,Valproic Acid
,19076986,AUC,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[h·mg] / [l],5.038,141914,DB00313,Valproic Acid
,19076986,C(max),"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],1.911,141915,DB00313,Valproic Acid
,19076986,C(max),"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],1.383,141916,DB00313,Valproic Acid
,19076986,oral clearance,"CBZ, but not VPA, was associated with decreases in the MCB AUC by 35% [from 7.794 to 5.038 mg h l(-1); 95% confidence interval (CI) -4.84863, -0.66194; P = 0.01] and C(max) by 28% (from 1.911 to 1.383 mg l(-1); 95% CI -0.98197, -0.07518; P < 0.05), and an increase in its oral clearance by 41% (from 0.323 to 0.454 l h(-1) kg(-1); 95% CI 0.00086, 0.26171; P < 0.05) after 4 weeks of co-administration.",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[kg(-·l] / [h],0,141917,DB00313,Valproic Acid
,19076986,through concentrations,"MCB through concentrations were also decreased, on average by 41% (from 0.950 to 0.559 mg l(-1); 95% CI -0.77479, -0.03301; P < 0.05).",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],0.950,141918,DB00313,Valproic Acid
,19076986,through concentrations,"MCB through concentrations were also decreased, on average by 41% (from 0.950 to 0.559 mg l(-1); 95% CI -0.77479, -0.03301; P < 0.05).",Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076986/),[mg] / [l],0.559,141919,DB00313,Valproic Acid
,12558570,area under the curve (AUC),"Pharmacokinetic parameters of a single dose of LEV (1,500 mg) coadministered with steady-state concentrations of VPA (8 days of 500 mg, b.i.d.) did not differ significantly from the pharmacokinetics of LEV administered alone [area under the curve (AUC) of 397 and 400 microg/h/ml, respectively].","Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12558570/),[μg] / [h·ml],397,142573,DB00313,Valproic Acid
,12558570,area under the curve (AUC),"Pharmacokinetic parameters of a single dose of LEV (1,500 mg) coadministered with steady-state concentrations of VPA (8 days of 500 mg, b.i.d.) did not differ significantly from the pharmacokinetics of LEV administered alone [area under the curve (AUC) of 397 and 400 microg/h/ml, respectively].","Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12558570/),[μg] / [h·ml],400,142574,DB00313,Valproic Acid
,373773,half-life,"Valproate was rapidly eliminated in both species, the half-life being 90--120 min in dogs (T0.5 beta) and 50 min in mice.",Pharmacokinetics of sodium valproate in dog and mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/373773/),min,90--120,145564,DB00313,Valproic Acid
,373773,half-life,"Valproate was rapidly eliminated in both species, the half-life being 90--120 min in dogs (T0.5 beta) and 50 min in mice.",Pharmacokinetics of sodium valproate in dog and mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/373773/),min,50,145565,DB00313,Valproic Acid
,373773,T0.5 beta,"Valproate was rapidly eliminated in both species, the half-life being 90--120 min in dogs (T0.5 beta) and 50 min in mice.",Pharmacokinetics of sodium valproate in dog and mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/373773/),min,90--120,145566,DB00313,Valproic Acid
,373773,binding,The binding of valproate to serum proteins determined in dog serum was calculated to 88%.,Pharmacokinetics of sodium valproate in dog and mouse. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/373773/),%,88,145567,DB00313,Valproic Acid
,373773,pKa,"The pKa of valproate was determined to 4.56 and valproate is, therefore, nearly lipid-insoluble at pH 7.4.",Pharmacokinetics of sodium valproate in dog and mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/373773/),,4.56,145568,DB00313,Valproic Acid
,3126410,volume of distribution (V),"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),[l] / [kg],0.40,145872,DB00313,Valproic Acid
,3126410,serum clearance (Cl),"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),[ml] / [h·kg],14.4,145873,DB00313,Valproic Acid
,3126410,half-life (T1/2),"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),h,26.4,145874,DB00313,Valproic Acid
,3126410,V,"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),[l] / [kg],2.02,145875,DB00313,Valproic Acid
,3126410,Cl,"VPA pharmacokinetic measurements were as follows: for total VPA, volume of distribution (V) = 0.40 l/kg (range, 0.36 to 0.47 l/kg), serum clearance (Cl) = 14.4 ml/h/kg (5.5 to 18.2 ml/h/kg), half-life (T1/2) = 26.4 hours (8.6 to 48.5); for unbound VPA, V = 2.02 l/kg (1.14 to 2.44 l/kg), Cl = 108.9 ml/h/kg (42.0 to 252.0 ml/h/kg).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),[ml] / [h·kg],108.9,145876,DB00313,Valproic Acid
,3126410,T1/2,T1/2 = 17.6 hours (6.7 to 34.2).,"Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),h,17.6,145877,DB00313,Valproic Acid
,3126410,free fraction,"VPA free fraction ranged from 11.3 to 31.6% (mean, 19.2%).","Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3126410/),%,19.2,145878,DB00313,Valproic Acid
,17898646,volume,"Both volume and absorption rate constant were fixed (14 L and 1 hr, respectively).",Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),l,14,146382,DB00313,Valproic Acid
,17898646,absorption rate constant,"Both volume and absorption rate constant were fixed (14 L and 1 hr, respectively).",Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),h,1,146383,DB00313,Valproic Acid
,17898646,CL/F,The population CL/F was 0.843 L/hr.,Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898646/),[l] / [h],0.843,146384,DB00313,Valproic Acid
,3149565,bio-availability,"For most of these formulations bio-availability approaches 100%, while the absorption half-life varies from less than 30 minutes to 3 or 4 hours depending on the type of preparation used.",Clinical pharmacokinetics of valproic acid--1988. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3149565/),%,100,146909,DB00313,Valproic Acid
less,3149565,absorption half-life,"For most of these formulations bio-availability approaches 100%, while the absorption half-life varies from less than 30 minutes to 3 or 4 hours depending on the type of preparation used.",Clinical pharmacokinetics of valproic acid--1988. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3149565/),min,30,146910,DB00313,Valproic Acid
,3149565,absorption half-life,"For most of these formulations bio-availability approaches 100%, while the absorption half-life varies from less than 30 minutes to 3 or 4 hours depending on the type of preparation used.",Clinical pharmacokinetics of valproic acid--1988. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3149565/),h,3,146911,DB00313,Valproic Acid
,3149565,absorption half-life,"For most of these formulations bio-availability approaches 100%, while the absorption half-life varies from less than 30 minutes to 3 or 4 hours depending on the type of preparation used.",Clinical pharmacokinetics of valproic acid--1988. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3149565/),h,4,146912,DB00313,Valproic Acid
,3149565,volume of distribution,"Once absorbed, valproic acid is largely bound to plasma proteins and has a relatively small volume of distribution (0.1 to 0.4 L/kg).",Clinical pharmacokinetics of valproic acid--1988. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3149565/),[l] / [kg],0.1 to 0.4,146913,DB00313,Valproic Acid
,3149565,half-life,"At therapeutic doses, valproic acid half-life varies from 10 to 20 hours in adults, while it is significantly shorter (6 to 9 hours) in children.",Clinical pharmacokinetics of valproic acid--1988. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3149565/),h,10 to 20,146914,DB00313,Valproic Acid
,3149565,half-life,"At therapeutic doses, valproic acid half-life varies from 10 to 20 hours in adults, while it is significantly shorter (6 to 9 hours) in children.",Clinical pharmacokinetics of valproic acid--1988. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3149565/),h,6 to 9,146915,DB00313,Valproic Acid
,24041657,limit of detection (LOD),"The limit of detection (LOD) and the lower limit of quantification (LLOQ) was 0.03 and 0.07μg/mL, respectively with 100μL of plasma sample.",A rapid and highly sensitive UPLC-MS/MS method using pre-column derivatization with 2-picolylamine for intravenous and percutaneous pharmacokinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041657/),[μg] / [ml],0.03,147146,DB00313,Valproic Acid
,24041657,limit of detection (LOD),"The limit of detection (LOD) and the lower limit of quantification (LLOQ) was 0.03 and 0.07μg/mL, respectively with 100μL of plasma sample.",A rapid and highly sensitive UPLC-MS/MS method using pre-column derivatization with 2-picolylamine for intravenous and percutaneous pharmacokinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041657/),[μg] / [ml],0,147147,DB00313,Valproic Acid
,8603632,trough concentrations,"Mean plasma FBM trough concentrations on day 21 ranged from 26.9 mu g/ml (1,200 mg dose) to 76.8 mu g/ml (3,600-mg dose).",Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603632/),[g·mu] / [ml],26.9,147924,DB00313,Valproic Acid
,8603632,trough concentrations,"Mean plasma FBM trough concentrations on day 21 ranged from 26.9 mu g/ml (1,200 mg dose) to 76.8 mu g/ml (3,600-mg dose).",Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603632/),[g·mu] / [ml],76.8,147925,DB00313,Valproic Acid
,8603632,C max,Mean plasma VPA C max values were 32-42 mu g/ml in the various subgroups when VPA only was administered.,Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603632/),[g·mu] / [ml],32-42,147926,DB00313,Valproic Acid
,6795343,half-life,VPA was excreted in the neonates with a mean half-life of 47 +/- 15 hr (n = 8) which is approximately 4 times the mean value found in adult epileptics.,"Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6795343/),h,47,148806,DB00313,Valproic Acid
,9070595,oral,TPM oral and renal clearances (n = 8) were 25.9 +/- 4.6 and 11.6 +/- 3.2 ml/min during TPM monotherapy and were 29.8 +/- 4.2 and 12.4 +/- 2.7 ml/min during VPA concomitant therapy.,Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],25.9,149558,DB00313,Valproic Acid
,9070595,oral,TPM oral and renal clearances (n = 8) were 25.9 +/- 4.6 and 11.6 +/- 3.2 ml/min during TPM monotherapy and were 29.8 +/- 4.2 and 12.4 +/- 2.7 ml/min during VPA concomitant therapy.,Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],29.8,149559,DB00313,Valproic Acid
,9070595,renal clearances,TPM oral and renal clearances (n = 8) were 25.9 +/- 4.6 and 11.6 +/- 3.2 ml/min during TPM monotherapy and were 29.8 +/- 4.2 and 12.4 +/- 2.7 ml/min during VPA concomitant therapy.,Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],11.6,149560,DB00313,Valproic Acid
,9070595,renal clearances,TPM oral and renal clearances (n = 8) were 25.9 +/- 4.6 and 11.6 +/- 3.2 ml/min during TPM monotherapy and were 29.8 +/- 4.2 and 12.4 +/- 2.7 ml/min during VPA concomitant therapy.,Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],12.4,149561,DB00313,Valproic Acid
,9070595,oral clearance,"VPA oral clearance was 12.8 +/- 4.1 ml/min during monotherapy and was 13.8 +/- 4.0, 14.1 +/- 3.9, and 14.5 +/- 5.2 ml/min during coadministration of TPM 100, 200, and 400 mg every 12 h, respectively.",Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],12.8,149562,DB00313,Valproic Acid
,9070595,oral clearance,"VPA oral clearance was 12.8 +/- 4.1 ml/min during monotherapy and was 13.8 +/- 4.0, 14.1 +/- 3.9, and 14.5 +/- 5.2 ml/min during coadministration of TPM 100, 200, and 400 mg every 12 h, respectively.",Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],13.8,149563,DB00313,Valproic Acid
,9070595,oral clearance,"VPA oral clearance was 12.8 +/- 4.1 ml/min during monotherapy and was 13.8 +/- 4.0, 14.1 +/- 3.9, and 14.5 +/- 5.2 ml/min during coadministration of TPM 100, 200, and 400 mg every 12 h, respectively.",Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],14.1,149564,DB00313,Valproic Acid
,9070595,oral clearance,"VPA oral clearance was 12.8 +/- 4.1 ml/min during monotherapy and was 13.8 +/- 4.0, 14.1 +/- 3.9, and 14.5 +/- 5.2 ml/min during coadministration of TPM 100, 200, and 400 mg every 12 h, respectively.",Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9070595/),[ml] / [min],14.5,149565,DB00313,Valproic Acid
,6185649,plasma half-life,"The mean plasma half-life of valproate, using a one-compartment model, was 10.9 +/- 1.3 h (mean +/- SD).",Plasma concentrations of valproate during maintenance therapy in epileptic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6185649/),h,10.9,149798,DB00313,Valproic Acid
<,32362159,F1,Beeswax and compritol® tablets showed similar dissolution profiles to the marketed product Depakote® 500 ER tablets (F1 < 15 and F2 > 50).,Fabrication of extended-dissolution divalproex tablets: a green solvent-free granulation technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32362159/),,15,151066,DB00313,Valproic Acid
>,32362159,F2,Beeswax and compritol® tablets showed similar dissolution profiles to the marketed product Depakote® 500 ER tablets (F1 < 15 and F2 > 50).,Fabrication of extended-dissolution divalproex tablets: a green solvent-free granulation technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32362159/),,50,151067,DB00313,Valproic Acid
,32362159,relative bioavailability,"The in vivo pharmacokinetic study delineated relative bioavailability values for Beeswax and Compritol® tablets of 95.6% and 118%, respectively, compared to the marketed product.",Fabrication of extended-dissolution divalproex tablets: a green solvent-free granulation technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32362159/),%,95.6,151068,DB00313,Valproic Acid
,32362159,relative bioavailability,"The in vivo pharmacokinetic study delineated relative bioavailability values for Beeswax and Compritol® tablets of 95.6% and 118%, respectively, compared to the marketed product.",Fabrication of extended-dissolution divalproex tablets: a green solvent-free granulation technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32362159/),%,118,151069,DB00313,Valproic Acid
,2873993,effective half-life,The plasma concentration vs. time curve for delta 4-VPA in these animals was biexponential and the effective half-life values were 0.53 and 0.67 hr.,"Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873993/),h,0.53,151594,DB00313,Valproic Acid
,2873993,effective half-life,The plasma concentration vs. time curve for delta 4-VPA in these animals was biexponential and the effective half-life values were 0.53 and 0.67 hr.,"Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873993/),h,0.67,151595,DB00313,Valproic Acid
,24562047,concentration,"Analysis of variance showed a correlation of dose with LCM concentrations (r = 0.53, P < 0.001), and women had statistically higher mean LCM concentration than did men, 37.2 ± 23.6 versus 26.8 ± 12.9 μmol/L (P = 0.001).","Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24562047/),,26,153175,DB00313,Valproic Acid
,6440705,half-lives,"The calculated pharmacokinetic parameters for total VPA and free VPA were: half-lives of 7.5 +/- 1.6 hours and 5.0 +/- 1.5 hours, volumes of distribution of 0.189 +/- 0.038 l/kg and 1.51 +/- 0.98 l/kg, and clearances of 0.30 +/- 0.06 and 3.6 +/- 2.0 ml/min/kg., respectively.",Free valproic acid: steady-state pharmacokinetics in patients with intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440705/),h,7.5,153549,DB00313,Valproic Acid
,6440705,half-lives,"The calculated pharmacokinetic parameters for total VPA and free VPA were: half-lives of 7.5 +/- 1.6 hours and 5.0 +/- 1.5 hours, volumes of distribution of 0.189 +/- 0.038 l/kg and 1.51 +/- 0.98 l/kg, and clearances of 0.30 +/- 0.06 and 3.6 +/- 2.0 ml/min/kg., respectively.",Free valproic acid: steady-state pharmacokinetics in patients with intractable epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440705/),h,5.0,153550,DB00313,Valproic Acid
,6440705,volumes of distribution,"The calculated pharmacokinetic parameters for total VPA and free VPA were: half-lives of 7.5 +/- 1.6 hours and 5.0 +/- 1.5 hours, volumes of distribution of 0.189 +/- 0.038 l/kg and 1.51 +/- 0.98 l/kg, and clearances of 0.30 +/- 0.06 and 3.6 +/- 2.0 ml/min/kg., respectively.",Free valproic acid: steady-state pharmacokinetics in patients with intractable epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440705/),[l] / [kg],0.189,153551,DB00313,Valproic Acid
,6440705,volumes of distribution,"The calculated pharmacokinetic parameters for total VPA and free VPA were: half-lives of 7.5 +/- 1.6 hours and 5.0 +/- 1.5 hours, volumes of distribution of 0.189 +/- 0.038 l/kg and 1.51 +/- 0.98 l/kg, and clearances of 0.30 +/- 0.06 and 3.6 +/- 2.0 ml/min/kg., respectively.",Free valproic acid: steady-state pharmacokinetics in patients with intractable epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440705/),[l] / [kg],1.51,153552,DB00313,Valproic Acid
,6440705,clearances,"The calculated pharmacokinetic parameters for total VPA and free VPA were: half-lives of 7.5 +/- 1.6 hours and 5.0 +/- 1.5 hours, volumes of distribution of 0.189 +/- 0.038 l/kg and 1.51 +/- 0.98 l/kg, and clearances of 0.30 +/- 0.06 and 3.6 +/- 2.0 ml/min/kg., respectively.",Free valproic acid: steady-state pharmacokinetics in patients with intractable epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440705/),[ml] / [kg·min],0.30,153553,DB00313,Valproic Acid
,6440705,clearances,"The calculated pharmacokinetic parameters for total VPA and free VPA were: half-lives of 7.5 +/- 1.6 hours and 5.0 +/- 1.5 hours, volumes of distribution of 0.189 +/- 0.038 l/kg and 1.51 +/- 0.98 l/kg, and clearances of 0.30 +/- 0.06 and 3.6 +/- 2.0 ml/min/kg., respectively.",Free valproic acid: steady-state pharmacokinetics in patients with intractable epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440705/),[ml] / [kg·min],3.6,153554,DB00313,Valproic Acid
,9884091,steady-state concentration,Male Wistar rats received a 40 mg kg(-1) intravenous dose of PHT over 5 min either alone or in combination with an infusion of VPA resulting in a steady-state concentration of 115.5+/-4.9 microg ml(-1).,Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],115.5,153620,DB00313,Valproic Acid
,9884091,Vmax,"The pharmacokinetic parameters Vmax and Km were, respectively, 294+/-63 microg min(-1) and 7.8+/-2.4 microg ml(-1) in the absence of VPA and 562+/-40 microg min(-1) and 15.6+/-0.9 microg ml(-1) upon administration in combination with VPA.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [min],294,153621,DB00313,Valproic Acid
,9884091,Vmax,"The pharmacokinetic parameters Vmax and Km were, respectively, 294+/-63 microg min(-1) and 7.8+/-2.4 microg ml(-1) in the absence of VPA and 562+/-40 microg min(-1) and 15.6+/-0.9 microg ml(-1) upon administration in combination with VPA.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [min],562,153622,DB00313,Valproic Acid
,9884091,Km,"The pharmacokinetic parameters Vmax and Km were, respectively, 294+/-63 microg min(-1) and 7.8+/-2.4 microg ml(-1) in the absence of VPA and 562+/-40 microg min(-1) and 15.6+/-0.9 microg ml(-1) upon administration in combination with VPA.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],7.8,153623,DB00313,Valproic Acid
,9884091,Km,"The pharmacokinetic parameters Vmax and Km were, respectively, 294+/-63 microg min(-1) and 7.8+/-2.4 microg ml(-1) in the absence of VPA and 562+/-40 microg min(-1) and 15.6+/-0.9 microg ml(-1) upon administration in combination with VPA.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],15.6,153624,DB00313,Valproic Acid
,9884091,ke0,"The assessment of PHT concentrations at the effect site was based on the effect-compartment model, yielding mean ke0 values of 0.128 and 0.107 min(-1) in the presence and absence of VPA, respectively.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),1/[min],0.128,153625,DB00313,Valproic Acid
,9884091,ke0,"The assessment of PHT concentrations at the effect site was based on the effect-compartment model, yielding mean ke0 values of 0.128 and 0.107 min(-1) in the presence and absence of VPA, respectively.",Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),1/[min],0.107,153626,DB00313,Valproic Acid
,9884091,EC50%,A shift of EC50%TGS from 13.27+3.55 to 4.32+/-0.52 microg ml(-1) was observed upon combination with VPA (P<0.01).,Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],13.27,153627,DB00313,Valproic Acid
,9884091,EC50%,A shift of EC50%TGS from 13.27+3.55 to 4.32+/-0.52 microg ml(-1) was observed upon combination with VPA (P<0.01).,Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884091/),[μg] / [ml],4.32,153628,DB00313,Valproic Acid
,9109895,Dose-normalized Cmax,"Dose-normalized Cmax was higher in children taking valproate (18.2 +/- 5.0 ng/mL/mg) than in the induced children (14.8 +/- 6.9 ng/mL/mg), but the difference was not statistically significant.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ng] / [mg·ml],18.2,155190,DB00313,Valproic Acid
,9109895,Dose-normalized Cmax,"Dose-normalized Cmax was higher in children taking valproate (18.2 +/- 5.0 ng/mL/mg) than in the induced children (14.8 +/- 6.9 ng/mL/mg), but the difference was not statistically significant.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ng] / [mg·ml],14.8,155191,DB00313,Valproic Acid
,9109895,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time was significantly higher (p = 0.002) in children taking valproate (176.5 +/- 54.7 ng.hr/mL/mg) than in induced children (92.4 +/- 56.7 ng.hr/mL/mg).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[h·ng] / [mg·ml],176.5,155192,DB00313,Valproic Acid
,9109895,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time,Dose-normalized area under the plasma concentration-time curve from time zero to infinite time was significantly higher (p = 0.002) in children taking valproate (176.5 +/- 54.7 ng.hr/mL/mg) than in induced children (92.4 +/- 56.7 ng.hr/mL/mg).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[h·ng] / [mg·ml],92.4,155193,DB00313,Valproic Acid
,9109895,oral clearance,"Similarly, oral clearance in the children taking valproate (96 +/- 39 mL/min) was half that of the induced children (207 +/- 91 mL/min).",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ml] / [min],96,155194,DB00313,Valproic Acid
,9109895,oral clearance,"Similarly, oral clearance in the children taking valproate (96 +/- 39 mL/min) was half that of the induced children (207 +/- 91 mL/min).",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),[ml] / [min],207,155195,DB00313,Valproic Acid
,9109895,Half-life,"Half-life in children taking valproate (5.7 hr) was almost twice that for the induced children (3.2 hr), and the elimination rate constant was significantly lower (p < 0.02) for the children taking valproate than for the induced children.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),h,5.7,155196,DB00313,Valproic Acid
,9109895,Half-life,"Half-life in children taking valproate (5.7 hr) was almost twice that for the induced children (3.2 hr), and the elimination rate constant was significantly lower (p < 0.02) for the children taking valproate than for the induced children.",A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),h,3.2,155197,DB00313,Valproic Acid
,9109895,Volume of distribution,Volume of distribution was similar in the children taking valproate (52 +/- 9 L) and the induced children (59 +/- 29 L).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),l,52,155198,DB00313,Valproic Acid
,9109895,Volume of distribution,Volume of distribution was similar in the children taking valproate (52 +/- 9 L) and the induced children (59 +/- 29 L).,A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9109895/),l,59,155199,DB00313,Valproic Acid
,21416779,CL/F,"RESULTS; Population estimates of CL/F and V/F for VPA were 0.022 +/- 0.013 L/h and 0.217 +/- 0.134 L/kg, respectively.",Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21416779/),[l] / [h],0.022,156722,DB00313,Valproic Acid
,21416779,V/F,"RESULTS; Population estimates of CL/F and V/F for VPA were 0.022 +/- 0.013 L/h and 0.217 +/- 0.134 L/kg, respectively.",Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21416779/),[l] / [kg],0.217,156723,DB00313,Valproic Acid
,11198504,volume of distribution,"The volume of distribution and the serum clearance of valproate were approximately 0.245 L/kg and 25 mL/h/kg, respectively.",Intravenous valproate dosing in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11198504/),[l] / [kg],0.245,157020,DB00313,Valproic Acid
,11198504,serum clearance,"The volume of distribution and the serum clearance of valproate were approximately 0.245 L/kg and 25 mL/h/kg, respectively.",Intravenous valproate dosing in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11198504/),[ml] / [h·kg],25,157021,DB00313,Valproic Acid
,6782238,total clearance,"Valproate is shown to significantly increase the total clearance, i.e., 23.8 to 30.4 ml . min-1 .","Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6782238/),[ml] / [min],23.8 to 30.4,157403,DB00313,Valproic Acid
,6782238,volume of distribution,"kg-1 and volume of distribution, i.e., 0.92 to 1.25 liter .","Interaction between phenytoin, 5-(p-hydroxyphenyl)-5-phenylhydantoin and valproate in the rat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6782238/),l,0.92 to 1.25,157404,DB00313,Valproic Acid
,8287032,mean residence time (MRT),"VPDPH and VADPH were more rapidly eliminated from plasma and brain than DPH, giving smaller mean residence time (MRT) values (0.92 and 0.85 h) and much smaller cortex/plasma concentration ratio than those of DPH.",Pharmacokinetic analysis of phenytoin and its derivatives in plasma and brain in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287032/),h,0.92,157958,DB00313,Valproic Acid
,8287032,mean residence time (MRT),"VPDPH and VADPH were more rapidly eliminated from plasma and brain than DPH, giving smaller mean residence time (MRT) values (0.92 and 0.85 h) and much smaller cortex/plasma concentration ratio than those of DPH.",Pharmacokinetic analysis of phenytoin and its derivatives in plasma and brain in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287032/),h,0.85,157959,DB00313,Valproic Acid
,6766956,serum half-life,Pharmacokinetic evaluation of the data indicate a serum half-life of 12 hours.,Bioavailability of valproic acid under fasting/nonfasting regimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6766956/),h,12,158069,DB00313,Valproic Acid
,8345004,dissociation constant (K),"The mean values of the dissociation constant (K) and binding sites (n) were 460 mumol/l and 1.79, respectively, showing a variability of 86.6 and 38.7%, respectively, and a residual variability of 13.0%.",Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345004/),[μM] / [l],460,160481,DB00313,Valproic Acid
,8345004,binding sites (n),"The mean values of the dissociation constant (K) and binding sites (n) were 460 mumol/l and 1.79, respectively, showing a variability of 86.6 and 38.7%, respectively, and a residual variability of 13.0%.",Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345004/),,1.79,160482,DB00313,Valproic Acid
,18593524,time of maximum,The time of maximum or peak concentration (T(max)) of VPA DR soft gelatin capsules was 2.3 hours versus 3.7 hours with divalproex sodium DR tablets.,Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18593524/),h,2.3,161848,DB00313,Valproic Acid
,18593524,T(max),"AUC(0-t) and AUC(0-infinity) of VPA soft gelatin capsules were not affected in the non-fasting condition, but T(max) occurred at 6.1 hours compared to 2.3 hours fasting.",Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18593524/),h,6.1,161849,DB00313,Valproic Acid
,18593524,T(max),"AUC(0-t) and AUC(0-infinity) of VPA soft gelatin capsules were not affected in the non-fasting condition, but T(max) occurred at 6.1 hours compared to 2.3 hours fasting.",Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18593524/),h,2.3,161850,DB00313,Valproic Acid
,22943745,T(max),"Furthermore, the addition of aripiprazole did not change the median T(max) of lithium or valproate (4 h).",Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943745/),h,4,162135,DB00313,Valproic Acid
,367760,beta phase half-life,The beta phase half-life of VPA in rabbits after an i.v. dose (50 mg/kg) was 56 +/- 6 min.,Excretion of valproic acid into semen of rabbits and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/367760/),min,56,162224,DB00313,Valproic Acid
,11123499,half-life,"The plasma level of VPA declined with a half-life of 11.71 and 11.91 h, respectively.","Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11123499/),h,11.71,162534,DB00313,Valproic Acid
,11123499,half-life,"The plasma level of VPA declined with a half-life of 11.71 and 11.91 h, respectively.","Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11123499/),h,11.91,162535,DB00313,Valproic Acid
,17208410,maximum concentration (C(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),[mg] / [l],34.2,164845,DB00313,Valproic Acid
,17208410,maximum concentration (C(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),[mg] / [l],31.4,164846,DB00313,Valproic Acid
,17208410,maximum concentration (C(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),[mg] / [l],20.7,164847,DB00313,Valproic Acid
,17208410,time to C(max) (T(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),[mg] / [l],34.2,164848,DB00313,Valproic Acid
,17208410,time to C(max) (T(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),h,0.9,164849,DB00313,Valproic Acid
,17208410,time to C(max) (T(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),[mg] / [l],31.4,164850,DB00313,Valproic Acid
,17208410,time to C(max) (T(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),h,2.2,164851,DB00313,Valproic Acid
,17208410,time to C(max) (T(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),[mg] / [l],20.7,164852,DB00313,Valproic Acid
,17208410,time to C(max) (T(max)),"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),h,4.0,164853,DB00313,Valproic Acid
,17208410,lag-time,"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),h,1,164854,DB00313,Valproic Acid
,17208410,lag-time,"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),[mg] / [l],26.0,164855,DB00313,Valproic Acid
,17208410,lag-time,"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),h,3.4,164856,DB00313,Valproic Acid
,17208410,lag-time,"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),h,2,164857,DB00313,Valproic Acid
,17208410,lag-time,"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),[mg] / [l],11.8,164858,DB00313,Valproic Acid
,17208410,lag-time,"The rate of absorption, as characterized by maximum concentration (C(max)) and time to C(max) (T(max)), may be rank-ordered as: VPA syrup (34.2mg/L, 0.9h)>VPA capsule (31.4mg/L, 2.2h)>divalproex sodium sprinkle capsule (20.7mg/L, 4.0h; lag-time congruent with1h) congruent withdivalproex sodium enteric-coated delayed-release tablet (26.0mg/L, 3.4h; lag-time congruent with2h)>divalproex sodium extended-release (divalproex-ER) tablet (11.8mg/L, 19.7h).",Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208410/),h,19.7,164859,DB00313,Valproic Acid
,16415118,half-life,"Furthermore, the metabolite S-2-pentyl-4-pentynoic acid was found to be very stable in vivo, with an extended half-life of 4.2 h compared with that of VPA, 1.4 h.","S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415118/),h,4.2,165579,DB00313,Valproic Acid
,16415118,half-life,"Furthermore, the metabolite S-2-pentyl-4-pentynoic acid was found to be very stable in vivo, with an extended half-life of 4.2 h compared with that of VPA, 1.4 h.","S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415118/),h,1.4,165580,DB00313,Valproic Acid
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,6.3,165985,DB00313,Valproic Acid
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.2,165986,DB00313,Valproic Acid
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.5,165987,DB00313,Valproic Acid
,9029404,CS50,"CR 2039 [[4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenza m ide], in doses of 10, 50, and 100 mg/kg i.p., significantly elevated the threshold for electroconvulsions, increasing the CS50 (current strength 50% in mA) values from 6.3 to 7.2, 7.5, and 7.6 mA, respectively.","Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029404/),ma,7.6,165988,DB00313,Valproic Acid
,6411902,plasma protein binding,"Administration of 2-en-VPA in a dog showed that pharmacokinetics of this substance are similar to those of VPA, although plasma protein binding of 2-en-VPA (97%) is much higher than of VPA.",Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411902/),%,97,166868,DB00313,Valproic Acid
>,33230696,C/D ratio,"The Olanzapine concentration to dose (C/D) ratio was positively correlated with the percentage of improvement in the total PANSS (r = 0.46, p = 0.004), and a C/D ratio > 2.12 was identified as a positive predictor of a good response (percentage of improvement > 30%) after 2 months of treatment.",The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33230696/),,2.12,167263,DB00313,Valproic Acid
,10984013,maxima,"After administration of single doses of 100 mg, 150 mg and 300 mg sodium valproate the population mean curves reached their maxima of 4.3 microg/ml, 6.8 microg/ml and 12.8 microg/ml at 9 h, 9 h and 10 h, respectively.",Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984013/),[μg] / [ml],4.3,168524,DB00313,Valproic Acid
,10984013,maxima,"After administration of single doses of 100 mg, 150 mg and 300 mg sodium valproate the population mean curves reached their maxima of 4.3 microg/ml, 6.8 microg/ml and 12.8 microg/ml at 9 h, 9 h and 10 h, respectively.",Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984013/),[μg] / [ml],6.8,168525,DB00313,Valproic Acid
,10984013,maxima,"After administration of single doses of 100 mg, 150 mg and 300 mg sodium valproate the population mean curves reached their maxima of 4.3 microg/ml, 6.8 microg/ml and 12.8 microg/ml at 9 h, 9 h and 10 h, respectively.",Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984013/),[μg] / [ml],12.8,168526,DB00313,Valproic Acid
,8667473,Initial extraction ratio,Initial extraction ratio of the hemoperfusion cartridge was 0.54 with plasma clearance of 54.5 mL/min.,Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667473/),,0.54,169443,DB00313,Valproic Acid
,8667473,plasma clearance,Initial extraction ratio of the hemoperfusion cartridge was 0.54 with plasma clearance of 54.5 mL/min.,Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667473/),[ml] / [min],54.5,169444,DB00313,Valproic Acid
,8667473,elimination half-life,Valproic acid elimination half-life was 3 h during the 190 min hemoperfusion cycle.,Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667473/),h,3,169445,DB00313,Valproic Acid
,8667473,elimination half-life,Posthemoperfusion elimination half-life was 4.8 h with continued multiple-dose activated charcoal dosing.,Delayed peak serum valproic acid in massive divalproex overdose--treatment with charcoal hemoperfusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667473/),h,4.8,169446,DB00313,Valproic Acid
,786678,biological half lives,Elimination of the drug appeared to follow a monophasic exponential course; biological half lives were 8 to 15 hours.,Pharmacokinetics of di-n-propylacetate in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/786678/),h,8 to 15,172938,DB00313,Valproic Acid
,786678,relative distribution volumes,The drug appeared to have a relatively restricted distribution: calculated relative distribution volumes ranged from 0.15 to 0.40 1/kg.,Pharmacokinetics of di-n-propylacetate in epileptic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/786678/),[1] / [kg],0.15 to 0.40,172939,DB00313,Valproic Acid
,16569797,mean absorption time,"After VPA release in the intestine, approximately 63% of the dose was absorbed in less than 1 hour, that is, 2.9 hours (mean absorption time) from dosing.",Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569797/),h,1,173173,DB00313,Valproic Acid
,16569797,mean absorption time,"After VPA release in the intestine, approximately 63% of the dose was absorbed in less than 1 hour, that is, 2.9 hours (mean absorption time) from dosing.",Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569797/),h,2.9,173174,DB00313,Valproic Acid
,16569797,absorption half-lives,"VPA absorption was complete ( approximately 93% of dose) within 3 absorption half-lives ( approximately 4.5 h) post-absorption lag-time, that is, 6-7 hours from dosing.",Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569797/),h,4.5,173175,DB00313,Valproic Acid
,16569797,lag-time,"VPA absorption was complete ( approximately 93% of dose) within 3 absorption half-lives ( approximately 4.5 h) post-absorption lag-time, that is, 6-7 hours from dosing.",Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569797/),h,6-7,173176,DB00313,Valproic Acid
,16569797,lag-time,VPA absorption from enteric-coated divalproex-DR is rapid following a lag-time of approximately 2 hours and is complete within 6-7 hours of dosing.,Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569797/),h,2,173177,DB00313,Valproic Acid
,340640,serum protein binding,"The serum protein binding of valproate (di-n-propylacetate) has been determined at therapeutic concentrations by equilibrium dialysis in man (94.8%), dog (78.5%), rat (63.4%) and mouse (11.9%).","Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/340640/),%,94.8,173183,DB00313,Valproic Acid
,340640,serum protein binding,"The serum protein binding of valproate (di-n-propylacetate) has been determined at therapeutic concentrations by equilibrium dialysis in man (94.8%), dog (78.5%), rat (63.4%) and mouse (11.9%).","Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/340640/),%,78.5,173184,DB00313,Valproic Acid
,340640,serum protein binding,"The serum protein binding of valproate (di-n-propylacetate) has been determined at therapeutic concentrations by equilibrium dialysis in man (94.8%), dog (78.5%), rat (63.4%) and mouse (11.9%).","Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/340640/),%,63.4,173185,DB00313,Valproic Acid
,340640,serum protein binding,"The serum protein binding of valproate (di-n-propylacetate) has been determined at therapeutic concentrations by equilibrium dialysis in man (94.8%), dog (78.5%), rat (63.4%) and mouse (11.9%).","Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/340640/),%,11.9,173186,DB00313,Valproic Acid
,340640,half-life of elimination (T 0.5 (beta)),"After intravenous administration, serum concentrations declined biexponentially in both species, the half-life of elimination (T 0.5 (beta)) being 1.7 hours in dogs and 4.6 hours in rats.","Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/340640/),h,1.7,173187,DB00313,Valproic Acid
,340640,half-life of elimination (T 0.5 (beta)),"After intravenous administration, serum concentrations declined biexponentially in both species, the half-life of elimination (T 0.5 (beta)) being 1.7 hours in dogs and 4.6 hours in rats.","Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/340640/),h,4.6,173188,DB00313,Valproic Acid
,340640,hepatic extraction ratios,"Increased drug binding was associated with a decrease in the total clearance and in all species examined, the calculated hepatic extraction ratios (0.009-0,17) were smaller that the free fraction, indicating that valproate fits into the group of drugs with restrictive and liver blood flow independent elimination, i.e., only the unbound drug can be cleared.","Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/340640/),,"0.009-0,17",173189,DB00313,Valproic Acid
,18200330,CL,Typical mean value of CL of VPA estimated by the base model in our population was 0.368 l h(-1).,Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18200330/),[l] / [h],0.368,173865,DB00313,Valproic Acid
,9835504,steady-state plasma panipenem concentration,"VPA (50 mg/kg of body weight) or diclofenac (10 mg/kg of body weight) was administered intravenously under the steady-state plasma panipenem concentration of 4 microgram/ml, which had been achieved by a constant infusion rate.",Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9835504/),[μg] / [ml],4,176569,DB00313,Valproic Acid
,3136790,half-life,VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01).,"Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3136790/),h,6.4,176963,DB00313,Valproic Acid
,3136790,half-life,VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01).,"Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3136790/),h,20.5,176964,DB00313,Valproic Acid
,3136790,clearance,VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01).,"Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3136790/),[ml] / [h·kg],73.5,176965,DB00313,Valproic Acid
,3136790,clearance,VPM caused a prolongation of the CBZ-E half-life from 6.4 +/- 1.4 to 20.5 +/- 6.3 h and decreased CBZ-E clearance from 73.5 +/- 20.0 to 23.5 +/- 4.0 ml h-1 kg-1 (P less than 0.01).,"Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3136790/),[ml] / [h·kg],23.5,176966,DB00313,Valproic Acid
,6423377,serum half-life,"In this latter condition, a significant (p less than 0.05) increase in ESM serum half-life, from 44 to 54 h on average, and a significant (p less than 0.05) decrease in total body clearance, from 11.2 to 9.5 ml/min on average, were observed.",Valproic acid-ethosuximide interaction: a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6423377/),h,44 to 54,177179,DB00313,Valproic Acid
,6423377,total body clearance,"In this latter condition, a significant (p less than 0.05) increase in ESM serum half-life, from 44 to 54 h on average, and a significant (p less than 0.05) decrease in total body clearance, from 11.2 to 9.5 ml/min on average, were observed.",Valproic acid-ethosuximide interaction: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6423377/),[ml] / [min],11.2 to 9.5,177180,DB00313,Valproic Acid
,1868813,plasma levels,"""Active"" plasma levels ranged from approximately 300 ng/ml in the MES threshold test to approximately 1,300 ng/ml in the MES test.","Ralitoline: a reevaluation of anticonvulsant profile and determination of ""active"" plasma concentrations in comparison with prototype antiepileptic drugs in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868813/),[ng] / [ml],300,177484,DB00313,Valproic Acid
,1868813,plasma levels,"""Active"" plasma levels ranged from approximately 300 ng/ml in the MES threshold test to approximately 1,300 ng/ml in the MES test.","Ralitoline: a reevaluation of anticonvulsant profile and determination of ""active"" plasma concentrations in comparison with prototype antiepileptic drugs in mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868813/),[ng] / [ml],"1,300",177485,DB00313,Valproic Acid
,15118478,trough plasma levels,"Baseline and end point trough plasma levels were 80.1 +/- 20.4 and 73.1 +/- 24.2 microg/mL, respectively.","A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118478/),[μg] / [ml],80.1,178367,DB00313,Valproic Acid
,15118478,trough plasma levels,"Baseline and end point trough plasma levels were 80.1 +/- 20.4 and 73.1 +/- 24.2 microg/mL, respectively.","A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118478/),[μg] / [ml],73.1,178368,DB00313,Valproic Acid
,8823232,Oral clearance,Oral clearance of valproate was increased (from 7.2 +/- 1.1 ml/hr/kg before lamotrigine treatment to 9.0 +/- 2.0 ml/hr/kg on day 28; p < 0.05).,Bidirectional interaction of valproate and lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823232/),[ml] / [h·kg],7.2,179825,DB00313,Valproic Acid
,8823232,Oral clearance,Oral clearance of valproate was increased (from 7.2 +/- 1.1 ml/hr/kg before lamotrigine treatment to 9.0 +/- 2.0 ml/hr/kg on day 28; p < 0.05).,Bidirectional interaction of valproate and lamotrigine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823232/),[ml] / [h·kg],9.0,179826,DB00313,Valproic Acid
,12649109,overall response rate,This resulted in an overall response rate of only 2.2% (95% confidence interval 0.2% to 6.5%).,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),%,2.2,181628,DB00313,Valproic Acid
,12649109,time to tumour progression,The median time to tumour progression was 9 weeks in group A and 14.4 weeks in group B.,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),weeks,9,181629,DB00313,Valproic Acid
,12649109,time to tumour progression,The median time to tumour progression was 9 weeks in group A and 14.4 weeks in group B.,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),weeks,14.4,181630,DB00313,Valproic Acid
,12649109,progression-free survival rates,"Six-month progression-free survival rates were 26% in group A and 43% in group B. Grade 3-4 toxicities (percentage of patients in groups A and B) consisted of neutropenia (12.5% and 25.9%), diarrhoea (8.3% and 7.4%), asthenia (12.5% and 7.4%) and vomiting (0% and 7.4%).",Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),%,26,181631,DB00313,Valproic Acid
,12649109,progression-free survival rates,"Six-month progression-free survival rates were 26% in group A and 43% in group B. Grade 3-4 toxicities (percentage of patients in groups A and B) consisted of neutropenia (12.5% and 25.9%), diarrhoea (8.3% and 7.4%), asthenia (12.5% and 7.4%) and vomiting (0% and 7.4%).",Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),%,43,181632,DB00313,Valproic Acid
,12649109,clearance,The clearance of irinotecan was 12.4 and 14.4 l/h/m(2) in two patients who received no anticonvulsant.,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),[h·l] / [m(2],12.4,181633,DB00313,Valproic Acid
,12649109,clearance,The clearance of irinotecan was 12.4 and 14.4 l/h/m(2) in two patients who received no anticonvulsant.,Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),[h·l] / [m(2],14.4,181634,DB00313,Valproic Acid
,12649109,clearance,"In patients receiving valproic acid, the clearance of irinotecan was 17.2 +/- 4.4 l/h/m(2).",Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649109/),[h·l] / [m(2],17.2,181635,DB00313,Valproic Acid
,3146521,plasma elimination half-life,The plasma elimination half-life on GD 8 was 1.0 +/- 0.3 hr at 200 mg/kg and 2.3 +/- 0.7 hr at 600 mg/kg.,Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146521/),h,1.0,182252,DB00313,Valproic Acid
,3146521,plasma elimination half-life,The plasma elimination half-life on GD 8 was 1.0 +/- 0.3 hr at 200 mg/kg and 2.3 +/- 0.7 hr at 600 mg/kg.,Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146521/),h,2.3,182253,DB00313,Valproic Acid
,3146521,Maximal concentrations,"Maximal concentrations of total and free drug were 341 +/- 18 micrograms/ml and 181 +/- 11 micrograms/ml, respectively, in the low-dose group and 911 +/- 379 micrograms/ml and 542 +/- 224 micrograms/ml in the high-dose group.",Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146521/),[μg] / [ml],341,182254,DB00313,Valproic Acid
,3146521,Maximal concentrations,"Maximal concentrations of total and free drug were 341 +/- 18 micrograms/ml and 181 +/- 11 micrograms/ml, respectively, in the low-dose group and 911 +/- 379 micrograms/ml and 542 +/- 224 micrograms/ml in the high-dose group.",Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146521/),[μg] / [ml],181,182255,DB00313,Valproic Acid
,3146521,Maximal concentrations,"Maximal concentrations of total and free drug were 341 +/- 18 micrograms/ml and 181 +/- 11 micrograms/ml, respectively, in the low-dose group and 911 +/- 379 micrograms/ml and 542 +/- 224 micrograms/ml in the high-dose group.",Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146521/),[μg] / [ml],911,182256,DB00313,Valproic Acid
,3146521,Maximal concentrations,"Maximal concentrations of total and free drug were 341 +/- 18 micrograms/ml and 181 +/- 11 micrograms/ml, respectively, in the low-dose group and 911 +/- 379 micrograms/ml and 542 +/- 224 micrograms/ml in the high-dose group.",Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146521/),[μg] / [ml],542,182257,DB00313,Valproic Acid
,336377,time lag before absorption,"A time lag before absorption of 1 to 2 h was observed in each subject, and then absorption was rapid, peak concentrations being recorded 3 to 4 h after administration of the dose.",Disposition of valproic acid in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/336377/),h,1 to 2,182609,DB00313,Valproic Acid
,336377,terminal half-life,The plasma level decline was biphasic with a terminal half-life of 15.9 +/- 2.6 h in the single dose and 17.3 +/- 3.0 h in the multiple dose experiments.,Disposition of valproic acid in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/336377/),h,15.9,182610,DB00313,Valproic Acid
,336377,terminal half-life,The plasma level decline was biphasic with a terminal half-life of 15.9 +/- 2.6 h in the single dose and 17.3 +/- 3.0 h in the multiple dose experiments.,Disposition of valproic acid in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/336377/),h,17.3,182611,DB00313,Valproic Acid
,336377,Total plasma clearance,Total plasma clearance was 0.0064 +/- 0.0011 l/kg X h.,Disposition of valproic acid in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/336377/),[l] / [h·kg],0.0064,182612,DB00313,Valproic Acid
,336377,apparent volume of distribution,The apparent volume of distribution was small at 0.15 +/- 0.2 l/kg.,Disposition of valproic acid in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/336377/),[l] / [kg],0.15,182613,DB00313,Valproic Acid
,336377,steady state plasma concentration (Css),The mean steady state plasma concentration (Css) reached after 4 days was 81.3 +/- 13.0 microgram/ml.,Disposition of valproic acid in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/336377/),[μg] / [ml],81.3,182614,DB00313,Valproic Acid
,336377,Css,Css observed was lower than Css predicted (99.2 +/- 14.7 microgram/ml) from single dose kinetics (p less than 0.001).,Disposition of valproic acid in man. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/336377/),[μg] / [ml],99.2,182615,DB00313,Valproic Acid
,34214324,ka_pop,"Population PK-PD of VPA syrup at steady state level were ka_pop = 6.25/h, Vd_pop = 3.36 L, Cl_pop = 3.17·e-11 mL/min, IC50_pop = 1.85·e-6, correlation of Vd_pop and Cl_pop = 0.966.",Developing pharmacokinetics-pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214324/),1/[h],6.25,182962,DB00313,Valproic Acid
,34214324,Vd_pop,"Population PK-PD of VPA syrup at steady state level were ka_pop = 6.25/h, Vd_pop = 3.36 L, Cl_pop = 3.17·e-11 mL/min, IC50_pop = 1.85·e-6, correlation of Vd_pop and Cl_pop = 0.966.",Developing pharmacokinetics-pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214324/),l,3.36,182963,DB00313,Valproic Acid
,34214324,Cl_pop,"Population PK-PD of VPA syrup at steady state level were ka_pop = 6.25/h, Vd_pop = 3.36 L, Cl_pop = 3.17·e-11 mL/min, IC50_pop = 1.85·e-6, correlation of Vd_pop and Cl_pop = 0.966.",Developing pharmacokinetics-pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214324/),[ml] / [min],3.17,182964,DB00313,Valproic Acid
,34214324,IC50_pop,"Population PK-PD of VPA syrup at steady state level were ka_pop = 6.25/h, Vd_pop = 3.36 L, Cl_pop = 3.17·e-11 mL/min, IC50_pop = 1.85·e-6, correlation of Vd_pop and Cl_pop = 0.966.",Developing pharmacokinetics-pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34214324/),1/[(e)^6],1.85,182965,DB00313,Valproic Acid
,8723737,clearance,"The following PK parameters were obtained for VPD and VCD, respectively: clearance, 6.1 and 3 ml/min/kg; volume of distribution (Vss), 0.63 and 0.58 liter/kg; half-life (t1/2), 42 and 94 min; and mean residence time (MRT), 102 and 196 min.","Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),[ml] / [kg·min],6.1,182975,DB00313,Valproic Acid
,8723737,clearance,"The following PK parameters were obtained for VPD and VCD, respectively: clearance, 6.1 and 3 ml/min/kg; volume of distribution (Vss), 0.63 and 0.58 liter/kg; half-life (t1/2), 42 and 94 min; and mean residence time (MRT), 102 and 196 min.","Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),[ml] / [kg·min],3,182976,DB00313,Valproic Acid
,8723737,volume of distribution (Vss),"The following PK parameters were obtained for VPD and VCD, respectively: clearance, 6.1 and 3 ml/min/kg; volume of distribution (Vss), 0.63 and 0.58 liter/kg; half-life (t1/2), 42 and 94 min; and mean residence time (MRT), 102 and 196 min.","Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),[l] / [kg],0.63,182977,DB00313,Valproic Acid
,8723737,volume of distribution (Vss),"The following PK parameters were obtained for VPD and VCD, respectively: clearance, 6.1 and 3 ml/min/kg; volume of distribution (Vss), 0.63 and 0.58 liter/kg; half-life (t1/2), 42 and 94 min; and mean residence time (MRT), 102 and 196 min.","Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),[l] / [kg],0.58,182978,DB00313,Valproic Acid
,8723737,half-life (t1/2),"The following PK parameters were obtained for VPD and VCD, respectively: clearance, 6.1 and 3 ml/min/kg; volume of distribution (Vss), 0.63 and 0.58 liter/kg; half-life (t1/2), 42 and 94 min; and mean residence time (MRT), 102 and 196 min.","Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),min,42,182979,DB00313,Valproic Acid
,8723737,half-life (t1/2),"The following PK parameters were obtained for VPD and VCD, respectively: clearance, 6.1 and 3 ml/min/kg; volume of distribution (Vss), 0.63 and 0.58 liter/kg; half-life (t1/2), 42 and 94 min; and mean residence time (MRT), 102 and 196 min.","Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),min,94,182980,DB00313,Valproic Acid
,8723737,mean residence time (MRT),"The following PK parameters were obtained for VPD and VCD, respectively: clearance, 6.1 and 3 ml/min/kg; volume of distribution (Vss), 0.63 and 0.58 liter/kg; half-life (t1/2), 42 and 94 min; and mean residence time (MRT), 102 and 196 min.","Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),min,102,182981,DB00313,Valproic Acid
,8723737,mean residence time (MRT),"The following PK parameters were obtained for VPD and VCD, respectively: clearance, 6.1 and 3 ml/min/kg; volume of distribution (Vss), 0.63 and 0.58 liter/kg; half-life (t1/2), 42 and 94 min; and mean residence time (MRT), 102 and 196 min.","Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),min,196,182982,DB00313,Valproic Acid
,8723737,fraction metabolized,The fraction metabolized of VPD to VPA was 42%.,"Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. ",fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8723737/),%,42,182983,DB00313,Valproic Acid
,17579623,MTD,The MTD of infusional VPA was 60 mg kg(-1) day(-1).,Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579623/),[mg] / [day·kg],60,183772,DB00313,Valproic Acid
>,17579623,maximum serum,"Pharmacokinetic studies showed increased mean and maximum serum VPA concentrations >120 and >250 mg l(-1), respectively, in the 90 and 120 mg kg(-1) cohorts, correlating well with the incidence of dose-limiting toxicity (DLT).",Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579623/),[mg] / [l],120,183773,DB00313,Valproic Acid
>,17579623,maximum serum,"Pharmacokinetic studies showed increased mean and maximum serum VPA concentrations >120 and >250 mg l(-1), respectively, in the 90 and 120 mg kg(-1) cohorts, correlating well with the incidence of dose-limiting toxicity (DLT).",Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579623/),[mg] / [l],250,183774,DB00313,Valproic Acid
<,23906667,brain uptake,"The brain uptake of all three carboxylic acids was very low (<0.006%ID/cc, BA>VPA>PBA), which is consistent with the need for very high doses for therapeutic efficacy.","Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906667/),[%id] / [cc],0.006,185027,DB00313,Valproic Acid
,1490811,concentration maximum,The concentration maximum was reached earlier and higher in bile (60 +/- 22 min; 10.8 +/- 5.7 micrograms/ml) than in serum (73 +/- 28 min; 0.98 +/- 0.53 micrograms/ml).,The biliary and renal elimination of the new muscarinic-1-antagonist AWD 26-06 in volunteers with T-tube after cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490811/),min,60,185058,DB00313,Valproic Acid
,1490811,concentration maximum,The concentration maximum was reached earlier and higher in bile (60 +/- 22 min; 10.8 +/- 5.7 micrograms/ml) than in serum (73 +/- 28 min; 0.98 +/- 0.53 micrograms/ml).,The biliary and renal elimination of the new muscarinic-1-antagonist AWD 26-06 in volunteers with T-tube after cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490811/),[μg] / [ml],10.8,185059,DB00313,Valproic Acid
,1490811,concentration maximum,The concentration maximum was reached earlier and higher in bile (60 +/- 22 min; 10.8 +/- 5.7 micrograms/ml) than in serum (73 +/- 28 min; 0.98 +/- 0.53 micrograms/ml).,The biliary and renal elimination of the new muscarinic-1-antagonist AWD 26-06 in volunteers with T-tube after cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490811/),min,73,185060,DB00313,Valproic Acid
,1490811,concentration maximum,The concentration maximum was reached earlier and higher in bile (60 +/- 22 min; 10.8 +/- 5.7 micrograms/ml) than in serum (73 +/- 28 min; 0.98 +/- 0.53 micrograms/ml).,The biliary and renal elimination of the new muscarinic-1-antagonist AWD 26-06 in volunteers with T-tube after cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490811/),[μg] / [ml],0.98,185061,DB00313,Valproic Acid
,27414414,percent target attainment,"The percent target attainment for the non-critically ill group and critically ill group were 69.4 and 58.3% (p = 0.282) post-loading dose and 69.7 and 37.5% (p = 0.004) steady state, respectively.",Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27414414/),%,69.4,185269,DB00313,Valproic Acid
,27414414,percent target attainment,"The percent target attainment for the non-critically ill group and critically ill group were 69.4 and 58.3% (p = 0.282) post-loading dose and 69.7 and 37.5% (p = 0.004) steady state, respectively.",Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27414414/),%,58.3,185270,DB00313,Valproic Acid
,27414414,percent target attainment,"The percent target attainment for the non-critically ill group and critically ill group were 69.4 and 58.3% (p = 0.282) post-loading dose and 69.7 and 37.5% (p = 0.004) steady state, respectively.",Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27414414/),%,69.7,185271,DB00313,Valproic Acid
,27414414,percent target attainment,"The percent target attainment for the non-critically ill group and critically ill group were 69.4 and 58.3% (p = 0.282) post-loading dose and 69.7 and 37.5% (p = 0.004) steady state, respectively.",Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27414414/),%,37.5,185272,DB00313,Valproic Acid
,27414414,volume of distribution,"The volume of distribution was significantly different between the two groups (0.35 vs. 0.68 L/kg, p = < 0.0001).",Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27414414/),[l] / [kg],0.35,185273,DB00313,Valproic Acid
,27414414,volume of distribution,"The volume of distribution was significantly different between the two groups (0.35 vs. 0.68 L/kg, p = < 0.0001).",Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27414414/),[l] / [kg],0.68,185274,DB00313,Valproic Acid
,16012283,peak levels,VPA peak levels ranged from 520 to 1700 mg/L with a mean of 1127 mg/L.,"Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012283/),[mg] / [l],1127,185472,DB00313,Valproic Acid
,11331142,apparent elimination half life,Pharmacokinetic studies demonstrated that valproate has an apparent elimination half life of 17 minutes in rats after acute administration and that there is a nonlinear relationship between chronic dose and serum drug concentration.,Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11331142/),min,17,185877,DB00313,Valproic Acid
,9029743,clearance,"The clearance and volume of distribution of felbamate were 41.1 ml/h/kg and 908 ml/kg, respectively.",Population pharmacokinetics of felbamate in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029743/),[ml] / [h·kg],41.1,185907,DB00313,Valproic Acid
,9029743,volume of distribution,"The clearance and volume of distribution of felbamate were 41.1 ml/h/kg and 908 ml/kg, respectively.",Population pharmacokinetics of felbamate in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029743/),[ml] / [kg],908,185908,DB00313,Valproic Acid
,3094548,relative bioavailability,"The relative bioavailability of the enteric coated Leptilan tablets was 95.5 +/- 0.6%, 104.4 +/- 7.6%, and 100.7 +/- 2.4% (mean from experiments with 3 volunteers each) for the 150-, 300-, and 600-mg tablets respectively.",[Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094548/),%,95.5,186979,DB00313,Valproic Acid
,3094548,relative bioavailability,"The relative bioavailability of the enteric coated Leptilan tablets was 95.5 +/- 0.6%, 104.4 +/- 7.6%, and 100.7 +/- 2.4% (mean from experiments with 3 volunteers each) for the 150-, 300-, and 600-mg tablets respectively.",[Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094548/),%,104.4,186980,DB00313,Valproic Acid
,3094548,relative bioavailability,"The relative bioavailability of the enteric coated Leptilan tablets was 95.5 +/- 0.6%, 104.4 +/- 7.6%, and 100.7 +/- 2.4% (mean from experiments with 3 volunteers each) for the 150-, 300-, and 600-mg tablets respectively.",[Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094548/),%,100.7,186981,DB00313,Valproic Acid
,16026556,CL/F,"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],2.1,186996,DB00313,Valproic Acid
,16026556,CL/F,"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],1.2,186997,DB00313,Valproic Acid
,16026556,CL(r),"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],1.1,186998,DB00313,Valproic Acid
,16026556,CL(r),"Mean TPM CL/F and CL(r) were higher in the CBZ group than in controls (2.1 vs. 1.2 L/h and 1.1 vs. 0.6L/h, respectively; p < 0.05).",A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026556/),[l] / [h],0.6,186999,DB00313,Valproic Acid
,2111246,mean residence time,It had a mean residence time of 13.2 h and a terminal half-life of 9.3 h.,"Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111246/),h,13.2,187264,DB00313,Valproic Acid
,2111246,terminal half-life,It had a mean residence time of 13.2 h and a terminal half-life of 9.3 h.,"Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111246/),h,9.3,187265,DB00313,Valproic Acid
,17523712,bioavailability (area under the concentration-time curve [AUC] ratio,"For equal total daily dose comparisons, the divalproex ER/divalproex bioavailability (area under the concentration-time curve [AUC] ratio) was ~0.89 and when the divalproex ER dose was higher, the two regimens were equivalent (AUC ratio ~1.0).",Divalproex to divalproex extended release conversion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523712/),,0.89,187343,DB00313,Valproic Acid
,17523712,AUC ratio,"For equal total daily dose comparisons, the divalproex ER/divalproex bioavailability (area under the concentration-time curve [AUC] ratio) was ~0.89 and when the divalproex ER dose was higher, the two regimens were equivalent (AUC ratio ~1.0).",Divalproex to divalproex extended release conversion. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523712/),,1.0,187344,DB00313,Valproic Acid
,408478,periods,"The mean (+/- SD) periods obtained by cross-correlation analysis of individual plasma concentration-time plots were 30.7 (+/- 3.7) and 22.8 (+/- 3.6) hr for Animals 903 and 923, respectively.",Time-dependent kinetics III: diurnal oscillations in steady-state plasma valproic acid levels in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/408478/),h,30.7,187455,DB00313,Valproic Acid
,408478,periods,"The mean (+/- SD) periods obtained by cross-correlation analysis of individual plasma concentration-time plots were 30.7 (+/- 3.7) and 22.8 (+/- 3.6) hr for Animals 903 and 923, respectively.",Time-dependent kinetics III: diurnal oscillations in steady-state plasma valproic acid levels in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/408478/),h,22.8,187456,DB00313,Valproic Acid
,408478,amplitudes,The corresponding mean (+/- SD) amplitudes were 27.3 (+/- 12.6) and 17.4 (+/- 2.3)%.,Time-dependent kinetics III: diurnal oscillations in steady-state plasma valproic acid levels in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/408478/),%,27.3,187457,DB00313,Valproic Acid
,408478,amplitudes,The corresponding mean (+/- SD) amplitudes were 27.3 (+/- 12.6) and 17.4 (+/- 2.3)%.,Time-dependent kinetics III: diurnal oscillations in steady-state plasma valproic acid levels in rhesus monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/408478/),%,17.4,187458,DB00313,Valproic Acid
,3924587,blood-to-plasma concentration ratio,"In vitro study showed that the blood-to-plasma concentration ratio, ranging from 0.81 to 0.84, and the plasma unbound fraction (fu), ranging from 0.24 to 0.38, of valproic acid around therapeutic levels (50-100 micrograms/ml) were not significantly different among different age groups.",Changes in pharmacokinetics of valproic acid in guinea pigs from birth to maturity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924587/),,0.81 to 0.84,187794,DB00313,Valproic Acid
,3924587,plasma unbound fraction (fu),"In vitro study showed that the blood-to-plasma concentration ratio, ranging from 0.81 to 0.84, and the plasma unbound fraction (fu), ranging from 0.24 to 0.38, of valproic acid around therapeutic levels (50-100 micrograms/ml) were not significantly different among different age groups.",Changes in pharmacokinetics of valproic acid in guinea pigs from birth to maturity. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3924587/),,0.24 to 0.38,187795,DB00313,Valproic Acid
,8666331,rate constant,Acute administration of phenobarbital to the liver (1.12 mg) decreased the rate constant for canalicular egress of V-G (0.0489 +/- 0.0266 vs. 0.164 +/- 0.075 min(-1)).,Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],0.0489,188744,DB00313,Valproic Acid
,8666331,rate constant,Acute administration of phenobarbital to the liver (1.12 mg) decreased the rate constant for canalicular egress of V-G (0.0489 +/- 0.0266 vs. 0.164 +/- 0.075 min(-1)).,Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],0.164,188745,DB00313,Valproic Acid
,8666331,biliary excretion,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],1.06,188746,DB00313,Valproic Acid
,8666331,biliary excretion,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],2.76E-04,188747,DB00313,Valproic Acid
,8666331,V-G,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],5.63,188748,DB00313,Valproic Acid
,8666331,V-G,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),1/[min],1.74E-02,188749,DB00313,Valproic Acid
,8666331,apparent volume of distribution,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),ml,84.6,188750,DB00313,Valproic Acid
,8666331,apparent volume of distribution,"In vivo pretreatment with phenobarbital (75 mg/kg/d x 5 d) before liver isolation decreased the biliary excretion of both VPA (1.06E-04 +/- 0.27E-04 vs. 2.76E-04 +/- 0.45E-04 min(-1)) and V-G (5.63E- 03 +/- 1.98E-03 vs. 1.74E-02 +/- 0.5E-02 min(-1)), and increased the apparent volume of distribution of VPA (84.6 +/- 2.2 vs. 72.3 +/- 2.1 mL).",Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8666331/),ml,72.3,188751,DB00313,Valproic Acid
,10369622,Apparent volume of distribution (Vd),Apparent volume of distribution (Vd) following a 20 mg/kg loading dose was 0.29 L/kg.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[l] / [kg],0.29,190062,DB00313,Valproic Acid
,10369622,steady-state total concentrations,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],66,190063,DB00313,Valproic Acid
,10369622,steady-state total concentrations,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],92.4,190064,DB00313,Valproic Acid
,10369622,unbound concentration,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],44.6,190065,DB00313,Valproic Acid
,10369622,Clearance,Clearance ranged from 63-66 mL/h/kg.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[ml] / [h·kg],63-66,190066,DB00313,Valproic Acid
,10369622,Total,"Total and unbound steady-state VPA concentrations were 32.9 mg/L and 21.2 mg/L, respectively.",Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],32.9,190067,DB00313,Valproic Acid
,10369622,unbound steady-state VPA concentrations,"Total and unbound steady-state VPA concentrations were 32.9 mg/L and 21.2 mg/L, respectively.",Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],21.2,190068,DB00313,Valproic Acid
,10369622,Unbound fractions,Unbound fractions (48.3% and 66%) were significantly higher than normal.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),%,48.3,190069,DB00313,Valproic Acid
,10369622,Unbound fractions,Unbound fractions (48.3% and 66%) were significantly higher than normal.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),%,66,190070,DB00313,Valproic Acid
,7649598,Cmax,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [ml],1.73,190591,DB00313,Valproic Acid
,7649598,Cmax,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [ml],0.94,190592,DB00313,Valproic Acid
,7649598,AUC o-t,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [h·ml],76.19,190593,DB00313,Valproic Acid
,7649598,AUC o-t,The Cmax of CBZ was significantly lowered from 1.73 +/- 0.18 to 0.94 +/- 0.08 microgram/ml and the AUC o-t was significantly decreased from 76.19 +/- 6.20 to 52.66 +/- 1.84 micrograms/h/ml (P < 0.05).,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[μg] / [h·ml],52.66,190594,DB00313,Valproic Acid
,7649598,Tmax,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,5.60,190595,DB00313,Valproic Acid
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,16.80,190596,DB00313,Valproic Acid
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,44.88,190597,DB00313,Valproic Acid
,7649598,t1/2,"The pharmacokinetic parameters of CBZ that were altered in the presence of AMP were: the Tmax and t1/2 which was prolonged about threefold from 5.60 +/- 1.60 to 16.80 +/- 7.94 h and 44.88 +/- 4.50 to 125.07 +/- 29.09 h, respectively.",Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),h,125.07,190598,DB00313,Valproic Acid
,7649598,Vd,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[l] / [kg],2.19,190599,DB00313,Valproic Acid
,7649598,Vd,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[l] / [kg],3.85,190600,DB00313,Valproic Acid
,7649598,Cl,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[ml] / [min],34.07,190601,DB00313,Valproic Acid
,7649598,Cl,The Vd was marginally increased from 2.19 +/- 0.13 to 3.85 +/- 0.57 L/kg and the Cl was decreased from 34.07 +/- 3.78 to 25.26 +/- 5.15 mL/min.,Aminophylline alters pharmacokinetics of carbamazepine but not that of sodium valproate--a single dose pharmacokinetic study in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7649598/),[ml] / [min],25.26,190602,DB00313,Valproic Acid
,6985719,half-life,The drug was absorbed and excreted rapidly; the mean half-life was 9.6 hours.,Sodium valproate: pharmacokinetics and effectivensss in treating intractable seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6985719/),h,9.6,191690,DB00313,Valproic Acid
,1686245,hepatic extraction ratio,"The values of the hepatic extraction ratio in the control and pregnant rats were 39.9 and 22.4% at the steady state concentration of approximately 20 micrograms/ml, respectively.",Pharmacokinetic analysis of the disposition of valproate in pregnant rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686245/),%,39.9,191759,DB00313,Valproic Acid
,1686245,hepatic extraction ratio,"The values of the hepatic extraction ratio in the control and pregnant rats were 39.9 and 22.4% at the steady state concentration of approximately 20 micrograms/ml, respectively.",Pharmacokinetic analysis of the disposition of valproate in pregnant rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686245/),%,22.4,191760,DB00313,Valproic Acid
,1686245,steady state concentration,"The values of the hepatic extraction ratio in the control and pregnant rats were 39.9 and 22.4% at the steady state concentration of approximately 20 micrograms/ml, respectively.",Pharmacokinetic analysis of the disposition of valproate in pregnant rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686245/),[μg] / [ml],20,191761,DB00313,Valproic Acid
,2494154,elimination half-life,"Ideally, valproate is given in three to four doses per day, because the elimination half-life varies from 6 to 15 hours, depending on concomitantly administered drugs and metabolic variations.",The scope and use of valproate in epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2494154/),h,6 to 15,191799,DB00313,Valproic Acid
,328018,half-life,After withdrawal of DPA the half-life was about 14 h in adult patients.,Preliminary observations on valproic acid kinetics in patients with epilepsy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/328018/),h,14,192230,DB00313,Valproic Acid
,7735208,elimination half-life,"There was no difference in the elimination half-life of VPA determined by microdialysis, 1.09 +/- 0.22 h, or ultrafiltration, 1.22 +/- 0.21 h.",In vivo microdialysis for pharmacokinetic investigations: a plasma protein binding study of valproate in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735208/),h,1.09,194858,DB00313,Valproic Acid
,7735208,ultrafiltration,"There was no difference in the elimination half-life of VPA determined by microdialysis, 1.09 +/- 0.22 h, or ultrafiltration, 1.22 +/- 0.21 h.",In vivo microdialysis for pharmacokinetic investigations: a plasma protein binding study of valproate in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735208/),h,1.22,194859,DB00313,Valproic Acid
,7735208,AUC,"The AUC of VPA in dialysate was 15 +/- 4 micrograms.h/ml, which corresponded to 15% of that in ultrafiltrate (103 +/- 17 micrograms.h/ml).",In vivo microdialysis for pharmacokinetic investigations: a plasma protein binding study of valproate in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735208/),[h·μg] / [ml],15,194860,DB00313,Valproic Acid
,7735208,AUC,"The AUC of VPA in dialysate was 15 +/- 4 micrograms.h/ml, which corresponded to 15% of that in ultrafiltrate (103 +/- 17 micrograms.h/ml).",In vivo microdialysis for pharmacokinetic investigations: a plasma protein binding study of valproate in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735208/),[h·μg] / [ml],103,194861,DB00313,Valproic Acid
,7735208,relative recovery,The value was in good agreement with the in vitro relative recovery of VPA from plasma sample (15.8 +/- 1.2%).,In vivo microdialysis for pharmacokinetic investigations: a plasma protein binding study of valproate in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735208/),%,15.8,194862,DB00313,Valproic Acid
more,23328074,maximum tolerated dose (MTD),A pediatric study has established a maximum tolerated dose (MTD) for temsirolimus (Tem) of more than 150 mg/m intravenously/week.,Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328074/),[mg] / [m],150,194972,DB00313,Valproic Acid
,9725486,tmax,"The 14th day plasma time-course of radioactivity after PEV administrations was characterised by a slow absorption rate with a delayed peak (tmax 2 h, Cmax 7.52 +/- 1.35 microg eq./ml), followed by a plateau lasting up to 8 h.",14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725486/),h,2,195071,DB00313,Valproic Acid
,9725486,Cmax,"The 14th day plasma time-course of radioactivity after PEV administrations was characterised by a slow absorption rate with a delayed peak (tmax 2 h, Cmax 7.52 +/- 1.35 microg eq./ml), followed by a plateau lasting up to 8 h.",14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725486/),[eq·μg] / [ml],7.52,195072,DB00313,Valproic Acid
,9725486,Cmax,"After NaVP treatment, the main peak of radioactivity was observed 0.5 h after administration (Cmax 8.30 +/- 1.26 microg eq./ml) followed by a secondary peak due to biliary enterohepatic recycling.",14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725486/),[eq·μg] / [ml],8.30,195073,DB00313,Valproic Acid
,9725486,AUCtau,"Starting from 4 h onwards, radioactivity levels after PEV treatment were higher than those after NaVP (AUCtau = 113.3 h.microg eq./ml after PEV vs 71.9 h.microg eq./ml after NaVP), but concentrations declined with similar terminal half-lives (52.8 h for PEV and 49.7 h for NaVP).",14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725486/),[eq·h·μg] / [ml],113.3,195074,DB00313,Valproic Acid
,9725486,AUCtau,"Starting from 4 h onwards, radioactivity levels after PEV treatment were higher than those after NaVP (AUCtau = 113.3 h.microg eq./ml after PEV vs 71.9 h.microg eq./ml after NaVP), but concentrations declined with similar terminal half-lives (52.8 h for PEV and 49.7 h for NaVP).",14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725486/),[eq·h·μg] / [ml],71.9,195075,DB00313,Valproic Acid
,9725486,terminal half-lives,"Starting from 4 h onwards, radioactivity levels after PEV treatment were higher than those after NaVP (AUCtau = 113.3 h.microg eq./ml after PEV vs 71.9 h.microg eq./ml after NaVP), but concentrations declined with similar terminal half-lives (52.8 h for PEV and 49.7 h for NaVP).",14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725486/),h,52.8,195076,DB00313,Valproic Acid
,9725486,terminal half-lives,"Starting from 4 h onwards, radioactivity levels after PEV treatment were higher than those after NaVP (AUCtau = 113.3 h.microg eq./ml after PEV vs 71.9 h.microg eq./ml after NaVP), but concentrations declined with similar terminal half-lives (52.8 h for PEV and 49.7 h for NaVP).",14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9725486/),h,49.7,195077,DB00313,Valproic Acid
,10996503,plasma concentrations,LTG dose of 369+/-236 mg per day (8.1+/-5.9 mg/kg per day) achieved LTG plasma concentrations of 6.8+/-3.3 microg/ml.,Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[μg] / [ml],6.8,196945,DB00313,Valproic Acid
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0. 69,196946,DB00313,Valproic Acid
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],1.60,196947,DB00313,Valproic Acid
,10996503,oral clearance (Cl/F),"The observed LTG monotherapy, LTG+IND, and LTG+VPA oral clearance (Cl/F) were 0. 69+/-0.2, 1.60+/-0.65 and 0.2+/-0.05 ml/kg per min, respectively.",Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10996503/),[ml] / [kg·min],0.2,196948,DB00313,Valproic Acid
,10859159,steady-state fetal/maternal unbound VPA plasma concentration ratio,"During maternal drug infusion, the average steady-state fetal/maternal unbound VPA plasma concentration ratio was 0.81 +/- 0.09.","Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),,0.81,197029,DB00313,Valproic Acid
,10859159,placental clearance,Unbound maternal-to-fetal VPA placental clearance (69.0 +/- 20.2 ml/min/kg) was similar to that in the other direction (61.9 +/- 24.2 ml/min/kg); this indicates passive placental diffusion and intermediate placental permeability of VPA in sheep.,"Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),[ml] / [kg·min],69.0,197030,DB00313,Valproic Acid
,10859159,placental clearance,Unbound maternal-to-fetal VPA placental clearance (69.0 +/- 20.2 ml/min/kg) was similar to that in the other direction (61.9 +/- 24.2 ml/min/kg); this indicates passive placental diffusion and intermediate placental permeability of VPA in sheep.,"Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),[ml] / [kg·min],61.9,197031,DB00313,Valproic Acid
,10859159,unbound VPA,"Newborn unbound VPA clearance (0.66 +/- 0.28 ml/min/kg) was much lower than in the mother (5.4 +/- 2.7 ml/min/kg) or the fetus (62.1 +/- 22.4 ml/min/kg), and exhibited pronounced Michaelis-Menten characteristics.","Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),[ml] / [kg·min],0.66,197032,DB00313,Valproic Acid
,10859159,unbound VPA,"Newborn unbound VPA clearance (0.66 +/- 0.28 ml/min/kg) was much lower than in the mother (5.4 +/- 2.7 ml/min/kg) or the fetus (62.1 +/- 22.4 ml/min/kg), and exhibited pronounced Michaelis-Menten characteristics.","Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),[ml] / [kg·min],5.4,197033,DB00313,Valproic Acid
,10859159,unbound VPA,"Newborn unbound VPA clearance (0.66 +/- 0.28 ml/min/kg) was much lower than in the mother (5.4 +/- 2.7 ml/min/kg) or the fetus (62.1 +/- 22.4 ml/min/kg), and exhibited pronounced Michaelis-Menten characteristics.","Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),[ml] / [kg·min],62.1,197034,DB00313,Valproic Acid
,10859159,clearance,"Newborn unbound VPA clearance (0.66 +/- 0.28 ml/min/kg) was much lower than in the mother (5.4 +/- 2.7 ml/min/kg) or the fetus (62.1 +/- 22.4 ml/min/kg), and exhibited pronounced Michaelis-Menten characteristics.","Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),[ml] / [kg·min],0.66,197035,DB00313,Valproic Acid
,10859159,clearance,"Newborn unbound VPA clearance (0.66 +/- 0.28 ml/min/kg) was much lower than in the mother (5.4 +/- 2.7 ml/min/kg) or the fetus (62.1 +/- 22.4 ml/min/kg), and exhibited pronounced Michaelis-Menten characteristics.","Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),[ml] / [kg·min],5.4,197036,DB00313,Valproic Acid
,10859159,clearance,"Newborn unbound VPA clearance (0.66 +/- 0.28 ml/min/kg) was much lower than in the mother (5.4 +/- 2.7 ml/min/kg) or the fetus (62.1 +/- 22.4 ml/min/kg), and exhibited pronounced Michaelis-Menten characteristics.","Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),[ml] / [kg·min],62.1,197037,DB00313,Valproic Acid
,10859159,elimination half-life,The elimination half-life of the drug was much longer in the newborn (18.6 +/- 2.6 h) relative to the mother (5.6 +/- 1.4 h) and the fetus (4.6 +/- 1.9 h).,"Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),h,18.6,197038,DB00313,Valproic Acid
,10859159,elimination half-life,The elimination half-life of the drug was much longer in the newborn (18.6 +/- 2.6 h) relative to the mother (5.6 +/- 1.4 h) and the fetus (4.6 +/- 1.9 h).,"Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),h,5.6,197039,DB00313,Valproic Acid
,10859159,elimination half-life,The elimination half-life of the drug was much longer in the newborn (18.6 +/- 2.6 h) relative to the mother (5.6 +/- 1.4 h) and the fetus (4.6 +/- 1.9 h).,"Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859159/),h,4.6,197040,DB00313,Valproic Acid
,9756109,level:dose ratio,"The level:dose ratio increased with age, its mean value was 1.7 in children aged under 2 years, 2.1 in children aged 2.4 years and 3.3 in children aged 4.6 years.",Valproic acid clearance in children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9756109/),,1.7,197186,DB00313,Valproic Acid
,9756109,level:dose ratio,"The level:dose ratio increased with age, its mean value was 1.7 in children aged under 2 years, 2.1 in children aged 2.4 years and 3.3 in children aged 4.6 years.",Valproic acid clearance in children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9756109/),,2.1,197187,DB00313,Valproic Acid
,9756109,level:dose ratio,"The level:dose ratio increased with age, its mean value was 1.7 in children aged under 2 years, 2.1 in children aged 2.4 years and 3.3 in children aged 4.6 years.",Valproic acid clearance in children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9756109/),,3.3,197188,DB00313,Valproic Acid
,9756109,Cl,"The Cl values in these three age groups were 24.5+/-12.4 ml/kg/h, 19.9+/-6.1 ml/kg/h and 12.7+/-3.0 ml/kg/h, respectively.",Valproic acid clearance in children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9756109/),[ml] / [h·kg],24.5,197189,DB00313,Valproic Acid
,9756109,Cl,"The Cl values in these three age groups were 24.5+/-12.4 ml/kg/h, 19.9+/-6.1 ml/kg/h and 12.7+/-3.0 ml/kg/h, respectively.",Valproic acid clearance in children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9756109/),[ml] / [h·kg],19.9,197190,DB00313,Valproic Acid
,9756109,Cl,"The Cl values in these three age groups were 24.5+/-12.4 ml/kg/h, 19.9+/-6.1 ml/kg/h and 12.7+/-3.0 ml/kg/h, respectively.",Valproic acid clearance in children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9756109/),[ml] / [h·kg],12.7,197191,DB00313,Valproic Acid
,17516704,apparent elimination half-life (t((1/2))),In plasma after a single oral administration of oxcarbazepine the mean apparent elimination half-life (t((1/2))) of MHD in adults was 8-9h.,Overview of the clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),h,8-9,197924,DB00313,Valproic Acid
,17516704,ki [inhibition constant],"In vitro, MHD inhibits the cytochrome P450 (CYP) 2C19 (ki [inhibition constant] = 88 micromol/L).",Overview of the clinical pharmacokinetics of oxcarbazepine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),[μM] / [l],88,197925,DB00313,Valproic Acid
,31318844,retention rate,"The estimated retention rate with stiripentol therapy was higher, and the duration of retention was longer in the EM group than in the PM group (1378 versus 933 days, P < 0.001).",Impact of CYP2C19 Phenotypes on Clinical Efficacy of Stiripentol in Japanese Patients With Dravet Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318844/),d,1378,197953,DB00313,Valproic Acid
,31318844,duration of retention,"The estimated retention rate with stiripentol therapy was higher, and the duration of retention was longer in the EM group than in the PM group (1378 versus 933 days, P < 0.001).",Impact of CYP2C19 Phenotypes on Clinical Efficacy of Stiripentol in Japanese Patients With Dravet Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318844/),d,1378,197954,DB00313,Valproic Acid
,31318844,duration of retention,"The estimated retention rate with stiripentol therapy was higher, and the duration of retention was longer in the EM group than in the PM group (1378 versus 933 days, P < 0.001).",Impact of CYP2C19 Phenotypes on Clinical Efficacy of Stiripentol in Japanese Patients With Dravet Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31318844/),d,933,197955,DB00313,Valproic Acid
<,11082489,brain-to-unbound plasma concentration ratio,Delivery of valproic acid (VPA) to the human brain is relatively inefficient as reflected by a low brain-to-unbound plasma concentration ratio (< or =0.5) at steady state.,Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082489/),,0.5,198445,DB00313,Valproic Acid
,11082489,concentration ratio,"Probenecid co-infusion elevated the ICC-to-ECF concentration ratio to 4.2+/-0.44, which confirms the existence of an efflux transport system in brain parenchymal cells.",Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082489/),,4.2,198446,DB00313,Valproic Acid
below,11082489,-to-unbound plasma concentration ratio,"The ECF-to-unbound plasma concentration ratio was well below unity (0.029), indicating an uphill efflux transport of VPA across the BBB.",Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082489/),,unity,198447,DB00313,Valproic Acid
,11082489,-to-unbound plasma concentration ratio,"The ECF-to-unbound plasma concentration ratio was well below unity (0.029), indicating an uphill efflux transport of VPA across the BBB.",Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11082489/),,0.029,198448,DB00313,Valproic Acid
,6430363,fraction of,"The average fraction of valpromide that was transformed to valproic acid (fm) ranged from 30-55 per cent after all the oral and parenteral administrations, except for the enteric-coated tablet, which showed a very low bioavailability of valpromide.",Pharmacokinetics of valpromide in dogs after various modes of administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430363/),%,30-55,200091,DB00313,Valproic Acid
,27120710,CL/F,"The lowest LTG CL/F was found in patients comedicated with valproate (VPA) (mean, 0.0183 L/h per kg), followed by patients receiving VPA + enzyme inducers (0.0271 L/h per kg), patients on LTG monotherapy (0.0298 L/h per kg) and patients comedicated with enzyme inducers (0.056 L/h per kg) LTG CL/F correlated significantly with LTG dose (P < 0.01), but showed no significant relationship with gender, weight, and age.",An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120710/),[l] / [h·kg],0.0183,203606,DB00313,Valproic Acid
,27120710,CL/F,"The lowest LTG CL/F was found in patients comedicated with valproate (VPA) (mean, 0.0183 L/h per kg), followed by patients receiving VPA + enzyme inducers (0.0271 L/h per kg), patients on LTG monotherapy (0.0298 L/h per kg) and patients comedicated with enzyme inducers (0.056 L/h per kg) LTG CL/F correlated significantly with LTG dose (P < 0.01), but showed no significant relationship with gender, weight, and age.",An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120710/),[l] / [h·kg],0.0271,203607,DB00313,Valproic Acid
,27120710,CL/F,"The lowest LTG CL/F was found in patients comedicated with valproate (VPA) (mean, 0.0183 L/h per kg), followed by patients receiving VPA + enzyme inducers (0.0271 L/h per kg), patients on LTG monotherapy (0.0298 L/h per kg) and patients comedicated with enzyme inducers (0.056 L/h per kg) LTG CL/F correlated significantly with LTG dose (P < 0.01), but showed no significant relationship with gender, weight, and age.",An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120710/),[l] / [h·kg],0.0298,203608,DB00313,Valproic Acid
,27120710,CL/F,"The lowest LTG CL/F was found in patients comedicated with valproate (VPA) (mean, 0.0183 L/h per kg), followed by patients receiving VPA + enzyme inducers (0.0271 L/h per kg), patients on LTG monotherapy (0.0298 L/h per kg) and patients comedicated with enzyme inducers (0.056 L/h per kg) LTG CL/F correlated significantly with LTG dose (P < 0.01), but showed no significant relationship with gender, weight, and age.",An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27120710/),[l] / [h·kg],0.056,203609,DB00313,Valproic Acid
,24974473,trough concentration,"As compared to VPA group, the combination of CBZ significantly (P < 0.01) decreased the trough concentration of VPA [VPA group, (69.5 +/- 28.8) microg x mL(-1); VPA+CBZ group, (46.3 +/- 25.6) microg x mL(-1)] and does-adjusted VPA trough concentration [VPA group, (4.89 +/- 2.21) microg x mL(-1) x mg(-1) x kg(-1); VPA+CBZ group, (3.14 +/- 1.74) microg x mL(-1) x mg(-1) x kg(-1)].",[Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974473/),[μg] / [ml],69.5,205250,DB00313,Valproic Acid
,24974473,trough concentration,"As compared to VPA group, the combination of CBZ significantly (P < 0.01) decreased the trough concentration of VPA [VPA group, (69.5 +/- 28.8) microg x mL(-1); VPA+CBZ group, (46.3 +/- 25.6) microg x mL(-1)] and does-adjusted VPA trough concentration [VPA group, (4.89 +/- 2.21) microg x mL(-1) x mg(-1) x kg(-1); VPA+CBZ group, (3.14 +/- 1.74) microg x mL(-1) x mg(-1) x kg(-1)].",[Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974473/),[μg] / [ml],46.3,205251,DB00313,Valproic Acid
,24974473,trough concentration,"As compared to VPA group, the combination of CBZ significantly (P < 0.01) decreased the trough concentration of VPA [VPA group, (69.5 +/- 28.8) microg x mL(-1); VPA+CBZ group, (46.3 +/- 25.6) microg x mL(-1)] and does-adjusted VPA trough concentration [VPA group, (4.89 +/- 2.21) microg x mL(-1) x mg(-1) x kg(-1); VPA+CBZ group, (3.14 +/- 1.74) microg x mL(-1) x mg(-1) x kg(-1)].",[Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974473/),[μg] / [kg·mg·ml],4.89,205252,DB00313,Valproic Acid
,24974473,trough concentration,"As compared to VPA group, the combination of CBZ significantly (P < 0.01) decreased the trough concentration of VPA [VPA group, (69.5 +/- 28.8) microg x mL(-1); VPA+CBZ group, (46.3 +/- 25.6) microg x mL(-1)] and does-adjusted VPA trough concentration [VPA group, (4.89 +/- 2.21) microg x mL(-1) x mg(-1) x kg(-1); VPA+CBZ group, (3.14 +/- 1.74) microg x mL(-1) x mg(-1) x kg(-1)].",[Effects of carbamazepine on plasma concentrations of valproic acid and its toxic metabolite in epileptic patients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24974473/),[μg] / [kg·mg·ml],3.14,205253,DB00313,Valproic Acid
,1628592,intrinsic formation clearance (Clf),"The intrinsic formation clearance (Clf) of the 4-ene-VPA pathway showed a statistically significant dose-dependent increase (0.22, 0.33, 0.40 ml/h/kg).",Effect of valproate dose on formation of hepatotoxic metabolites. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628592/),[ml] / [h·kg],0.22,206017,DB00313,Valproic Acid
,1628592,intrinsic formation clearance (Clf),"The intrinsic formation clearance (Clf) of the 4-ene-VPA pathway showed a statistically significant dose-dependent increase (0.22, 0.33, 0.40 ml/h/kg).",Effect of valproate dose on formation of hepatotoxic metabolites. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628592/),[ml] / [h·kg],0.33,206018,DB00313,Valproic Acid
,1628592,intrinsic formation clearance (Clf),"The intrinsic formation clearance (Clf) of the 4-ene-VPA pathway showed a statistically significant dose-dependent increase (0.22, 0.33, 0.40 ml/h/kg).",Effect of valproate dose on formation of hepatotoxic metabolites. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628592/),[ml] / [h·kg],0.40,206019,DB00313,Valproic Acid
,29981400,oral clearance (CL/F),"For the final PPK model, the oral clearance (CL/F) of VPA was estimated to be 0.259 L/h with IIV of 13.3%.",Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29981400/),[l] / [h],0.259,206493,DB00313,Valproic Acid
,6807491,elimination half-life,Brain uptake of the drug was maximal at 1 min postinfusion and decayed rapidly with a mean elimination half-life of 41 min.,In vivo uptake of valproic acid into brain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6807491/),min,41,206507,DB00313,Valproic Acid
,6807491,volume of distribution,The volume of distribution was 0.125 1/kg.,In vivo uptake of valproic acid into brain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6807491/),[1] / [kg],0.125,206508,DB00313,Valproic Acid
,26309401,AUClast,"Systemic exposures and peak concentrations of VPA were slightly lower with treatment AMC + VPA than with treatment VPA (AUClast, 851.0 h·mg/L vs 889.6 h·mg/L; C max, 52.1 mg/L vs 53.0 mg/L).",Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309401/),[h·mg] / [l],851.0,206976,DB00313,Valproic Acid
,26309401,AUClast,"Systemic exposures and peak concentrations of VPA were slightly lower with treatment AMC + VPA than with treatment VPA (AUClast, 851.0 h·mg/L vs 889.6 h·mg/L; C max, 52.1 mg/L vs 53.0 mg/L).",Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309401/),[h·mg] / [l],889.6,206977,DB00313,Valproic Acid
,26309401,C max,"Systemic exposures and peak concentrations of VPA were slightly lower with treatment AMC + VPA than with treatment VPA (AUClast, 851.0 h·mg/L vs 889.6 h·mg/L; C max, 52.1 mg/L vs 53.0 mg/L).",Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309401/),[mg] / [l],52.1,206978,DB00313,Valproic Acid
,26309401,C max,"Systemic exposures and peak concentrations of VPA were slightly lower with treatment AMC + VPA than with treatment VPA (AUClast, 851.0 h·mg/L vs 889.6 h·mg/L; C max, 52.1 mg/L vs 53.0 mg/L).",Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309401/),[mg] / [l],53.0,206979,DB00313,Valproic Acid
,21192154,C(total),"The results show that the increment in C(total) (mg/mL) for every milligram-per-kilogram increment in dosage was decreased from 7 ± 3 to 4 ± 1 (mg/L) / (mg/kg) when the total VPA clearance (CL(total)) increased from 6.1 ± 2.6 to 9.0 ± 3.1 mL/kg per hour with the increasing dose in the 500 mg/d and 1000 mg/d groups, respectively (P < 0.05).",The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[mg] / [ml],7,207178,DB00313,Valproic Acid
,21192154,C(total),"The results show that the increment in C(total) (mg/mL) for every milligram-per-kilogram increment in dosage was decreased from 7 ± 3 to 4 ± 1 (mg/L) / (mg/kg) when the total VPA clearance (CL(total)) increased from 6.1 ± 2.6 to 9.0 ± 3.1 mL/kg per hour with the increasing dose in the 500 mg/d and 1000 mg/d groups, respectively (P < 0.05).",The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[mg] / [ml],4,207179,DB00313,Valproic Acid
,21192154,total VPA clearance (CL(total)),"The results show that the increment in C(total) (mg/mL) for every milligram-per-kilogram increment in dosage was decreased from 7 ± 3 to 4 ± 1 (mg/L) / (mg/kg) when the total VPA clearance (CL(total)) increased from 6.1 ± 2.6 to 9.0 ± 3.1 mL/kg per hour with the increasing dose in the 500 mg/d and 1000 mg/d groups, respectively (P < 0.05).",The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[ml] / [h·kg],6.1,207180,DB00313,Valproic Acid
,21192154,total VPA clearance (CL(total)),"The results show that the increment in C(total) (mg/mL) for every milligram-per-kilogram increment in dosage was decreased from 7 ± 3 to 4 ± 1 (mg/L) / (mg/kg) when the total VPA clearance (CL(total)) increased from 6.1 ± 2.6 to 9.0 ± 3.1 mL/kg per hour with the increasing dose in the 500 mg/d and 1000 mg/d groups, respectively (P < 0.05).",The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[ml] / [h·kg],9.0,207181,DB00313,Valproic Acid
,21192154,C(free),The increment in C(free) [0.6 ± 0.3 vs 0.5 ± 0.2 (mg/L) / (mg/kg)] and CL(free) (80.4 ± 41.5 vs 92.2 ± 47.6 ml/kg per hour) were not significantly different.,The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[l·mg] / [kg·mg],0.6,207182,DB00313,Valproic Acid
,21192154,C(free),The increment in C(free) [0.6 ± 0.3 vs 0.5 ± 0.2 (mg/L) / (mg/kg)] and CL(free) (80.4 ± 41.5 vs 92.2 ± 47.6 ml/kg per hour) were not significantly different.,The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[l·mg] / [kg·mg],0.5,207183,DB00313,Valproic Acid
,21192154,CL(free),The increment in C(free) [0.6 ± 0.3 vs 0.5 ± 0.2 (mg/L) / (mg/kg)] and CL(free) (80.4 ± 41.5 vs 92.2 ± 47.6 ml/kg per hour) were not significantly different.,The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[ml] / [h·kg],80.4,207184,DB00313,Valproic Acid
,21192154,CL(free),The increment in C(free) [0.6 ± 0.3 vs 0.5 ± 0.2 (mg/L) / (mg/kg)] and CL(free) (80.4 ± 41.5 vs 92.2 ± 47.6 ml/kg per hour) were not significantly different.,The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[ml] / [h·kg],92.2,207185,DB00313,Valproic Acid
,21192154,percent free,"Owing to the saturation of protein binding, percent free VPA was significantly increased from 8 ± 3 to 11 ± 3 when the dose was increased from 500 to 1000 mg/d (P < 0.05).",The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),,8,207186,DB00313,Valproic Acid
,21192154,percent free,"Owing to the saturation of protein binding, percent free VPA was significantly increased from 8 ± 3 to 11 ± 3 when the dose was increased from 500 to 1000 mg/d (P < 0.05).",The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),,11,207187,DB00313,Valproic Acid
,21192154,C(free),"Therefore, our study suggests that the therapeutic range of C(free) is 4 to 12 mg/L based on the therapeutic range of C(total) (45-100 mg/L) for general psychiatric conditions.",The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[mg] / [l],4 to 12,207188,DB00313,Valproic Acid
,21192154,C(total),"Therefore, our study suggests that the therapeutic range of C(free) is 4 to 12 mg/L based on the therapeutic range of C(total) (45-100 mg/L) for general psychiatric conditions.",The impact of dosage of sustained-release formulation on valproate clearance and plasma concentration in psychiatric patients: analysis based on routine therapeutic drug monitoring data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21192154/),[mg] / [l],45-100,207189,DB00313,Valproic Acid
,10849894,Cmax,"During Ramadan, a significant decrease was observed in the Cmax (56.22 +/- 5.32 mg/l in PR vs. 48.35 +/- 5.07 mg/l in R3; p < 0.05) and in the AUC(0.50 h) (1429.92 +/- 284.23 in PR vs. 1090.26 +/- 277.73 mg.h/l in R3; p < 0.05) for the 8:00 PM intake.",Influence of Ramadan on the pharmacokinetics of a single oral dose of valproic acid administered at two different times. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849894/),[mg] / [l],56.22,207333,DB00313,Valproic Acid
,10849894,Cmax,"During Ramadan, a significant decrease was observed in the Cmax (56.22 +/- 5.32 mg/l in PR vs. 48.35 +/- 5.07 mg/l in R3; p < 0.05) and in the AUC(0.50 h) (1429.92 +/- 284.23 in PR vs. 1090.26 +/- 277.73 mg.h/l in R3; p < 0.05) for the 8:00 PM intake.",Influence of Ramadan on the pharmacokinetics of a single oral dose of valproic acid administered at two different times. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849894/),[mg] / [l],48.35,207334,DB00313,Valproic Acid
,10849894,AUC(0.50 h),"During Ramadan, a significant decrease was observed in the Cmax (56.22 +/- 5.32 mg/l in PR vs. 48.35 +/- 5.07 mg/l in R3; p < 0.05) and in the AUC(0.50 h) (1429.92 +/- 284.23 in PR vs. 1090.26 +/- 277.73 mg.h/l in R3; p < 0.05) for the 8:00 PM intake.",Influence of Ramadan on the pharmacokinetics of a single oral dose of valproic acid administered at two different times. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849894/),[h·mg] / [l],1429.92,207335,DB00313,Valproic Acid
,10849894,AUC(0.50 h),"During Ramadan, a significant decrease was observed in the Cmax (56.22 +/- 5.32 mg/l in PR vs. 48.35 +/- 5.07 mg/l in R3; p < 0.05) and in the AUC(0.50 h) (1429.92 +/- 284.23 in PR vs. 1090.26 +/- 277.73 mg.h/l in R3; p < 0.05) for the 8:00 PM intake.",Influence of Ramadan on the pharmacokinetics of a single oral dose of valproic acid administered at two different times. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849894/),[h·mg] / [l],1090.26,207336,DB00313,Valproic Acid
,10849894,t1/2,"For the 5:00 AM intake, a significant decrease was observed in the t1/2 (12.15 +/- 1.45 h in PR vs. 9.55 +/- 1.97 h in R3; p < 0.05) and AUC(0.50 h) values (1241.29 +/- 239.01 mg.h/l in PR vs. 1019.21 +/- 256.86 mg.h/l in R3; p < 0.05).",Influence of Ramadan on the pharmacokinetics of a single oral dose of valproic acid administered at two different times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849894/),h,12.15,207337,DB00313,Valproic Acid
,10849894,t1/2,"For the 5:00 AM intake, a significant decrease was observed in the t1/2 (12.15 +/- 1.45 h in PR vs. 9.55 +/- 1.97 h in R3; p < 0.05) and AUC(0.50 h) values (1241.29 +/- 239.01 mg.h/l in PR vs. 1019.21 +/- 256.86 mg.h/l in R3; p < 0.05).",Influence of Ramadan on the pharmacokinetics of a single oral dose of valproic acid administered at two different times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849894/),h,9.55,207338,DB00313,Valproic Acid
,10849894,AUC(0.50 h),"For the 5:00 AM intake, a significant decrease was observed in the t1/2 (12.15 +/- 1.45 h in PR vs. 9.55 +/- 1.97 h in R3; p < 0.05) and AUC(0.50 h) values (1241.29 +/- 239.01 mg.h/l in PR vs. 1019.21 +/- 256.86 mg.h/l in R3; p < 0.05).",Influence of Ramadan on the pharmacokinetics of a single oral dose of valproic acid administered at two different times. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849894/),[h·mg] / [l],1241.29,207339,DB00313,Valproic Acid
,10849894,AUC(0.50 h),"For the 5:00 AM intake, a significant decrease was observed in the t1/2 (12.15 +/- 1.45 h in PR vs. 9.55 +/- 1.97 h in R3; p < 0.05) and AUC(0.50 h) values (1241.29 +/- 239.01 mg.h/l in PR vs. 1019.21 +/- 256.86 mg.h/l in R3; p < 0.05).",Influence of Ramadan on the pharmacokinetics of a single oral dose of valproic acid administered at two different times. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849894/),[h·mg] / [l],1019.21,207340,DB00313,Valproic Acid
,9255595,Bio-availability,Bio-availability approached 70%.,Pharmacokinetics and muscle histopathology of intramuscular valproate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255595/),%,70,208519,DB00313,Valproic Acid
,9255595,Half life,Half life of 120 min was calculated.,Pharmacokinetics and muscle histopathology of intramuscular valproate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255595/),min,120,208520,DB00313,Valproic Acid
,6440792,bioavailability,"Valpromide was biotransformed to valproic acid after the administration of the tablet and the solution with a bioavailability of 0.79 +/- 0.24 and 0.77 +/- 0.12, respectively, relative to a marketed tablet of valproic acid.",Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440792/),,0.79,209489,DB00313,Valproic Acid
,6440792,bioavailability,"Valpromide was biotransformed to valproic acid after the administration of the tablet and the solution with a bioavailability of 0.79 +/- 0.24 and 0.77 +/- 0.12, respectively, relative to a marketed tablet of valproic acid.",Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440792/),,0.77,209490,DB00313,Valproic Acid
,9330777,clearance (Cl),"Following i.v. administration (556 mg) to six dogs, VCGD had a clearance (Cl) value of 3.8 +/- 1.1 Lh-1 (mean +/- SD), a volume of distribution (Vss) of 15 +/- 2 L, and a half-life (t1/2) of 1.9 +/- 0.3 h.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),1/[lh],3.8,210911,DB00313,Valproic Acid
,9330777,volume of distribution (Vss),"Following i.v. administration (556 mg) to six dogs, VCGD had a clearance (Cl) value of 3.8 +/- 1.1 Lh-1 (mean +/- SD), a volume of distribution (Vss) of 15 +/- 2 L, and a half-life (t1/2) of 1.9 +/- 0.3 h.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),l,15,210912,DB00313,Valproic Acid
,9330777,half-life (t1/2),"Following i.v. administration (556 mg) to six dogs, VCGD had a clearance (Cl) value of 3.8 +/- 1.1 Lh-1 (mean +/- SD), a volume of distribution (Vss) of 15 +/- 2 L, and a half-life (t1/2) of 1.9 +/- 0.3 h.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),h,1.9,210913,DB00313,Valproic Acid
,9330777,Cl,"DIGD had Cl, Vss, and t1/2 values of 10 +/- 0.8 Lh-1, 19 +/- 3 L, and 1.6 +/- 0.2 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),1/[lh],10,210914,DB00313,Valproic Acid
,9330777,Vss,"DIGD had Cl, Vss, and t1/2 values of 10 +/- 0.8 Lh-1, 19 +/- 3 L, and 1.6 +/- 0.2 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),l,19,210915,DB00313,Valproic Acid
,9330777,t1/2,"DIGD had Cl, Vss, and t1/2 values of 10 +/- 0.8 Lh-1, 19 +/- 3 L, and 1.6 +/- 0.2 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),h,1.6,210916,DB00313,Valproic Acid
,9330777,fractions metabolized (fm),Both glycinamides were biotransformed to their glycine analogues with similar fractions metabolized (fm): 59 +/- 5% (VCGD) and 62 +/- 15% (DIGD).,Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),%,59,210917,DB00313,Valproic Acid
,9330777,fractions metabolized (fm),Both glycinamides were biotransformed to their glycine analogues with similar fractions metabolized (fm): 59 +/- 5% (VCGD) and 62 +/- 15% (DIGD).,Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),%,62,210918,DB00313,Valproic Acid
,9330777,t1/2,"Both VCGA and DIGA had higher Cl and lower Vss values than VCGD and DIGD and therefore their mean t1/2 values were 0.43 +/- 0.02 and 0.30 +/- 0.07 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),h,0.43,210919,DB00313,Valproic Acid
,9330777,t1/2,"Both VCGA and DIGA had higher Cl and lower Vss values than VCGD and DIGD and therefore their mean t1/2 values were 0.43 +/- 0.02 and 0.30 +/- 0.07 h, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),h,0.30,210920,DB00313,Valproic Acid
,9330777,fractions excreted unchanged (fe),"VCGA and DIGA were excreted mainly intact in the urine, with fractions excreted unchanged (fe) of 60 +/- 9 and 55 +/- 7%, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),%,60,210921,DB00313,Valproic Acid
,9330777,fractions excreted unchanged (fe),"VCGA and DIGA were excreted mainly intact in the urine, with fractions excreted unchanged (fe) of 60 +/- 9 and 55 +/- 7%, respectively.",Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9330777/),%,55,210922,DB00313,Valproic Acid
,24702251,AUC0-48 h,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[h·ng] / [ml],1410,210935,DB00313,Valproic Acid
,24702251,AUC0-48 h,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[h·ng] / [ml],1446,210936,DB00313,Valproic Acid
,24702251,Cmax,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[h·ng] / [ml],1446,210937,DB00313,Valproic Acid
,24702251,Cmax,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[ng] / [ml],93·4,210938,DB00313,Valproic Acid
,24702251,Cmax,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),[ng] / [ml],112·5,210939,DB00313,Valproic Acid
,24702251,AUC0-48 h,"The AUC0-48 h and Cmax of hydralazine were almost identical (1410 ± 560 vs. 1446 ± 509 ng h/mL and 93·4 ± 16·7 vs. 112·5 ± 42·1 ng/mL) in both groups with NAT2 genotype-adjusted doses, whereas the multidose parameters of valproate were not significantly affected neither by the selection of the NAT2 genotype (AUC0-48 h 2064 ± 455 vs.",Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),,2064,210940,DB00313,Valproic Acid
,24702251,Cmax,1896 ± 185 μg h/mL; Cmax 96·4 ± 21·1 vs.,Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702251/),,96·4,210941,DB00313,Valproic Acid
,19229380,clearance,"The typical mean value for carbamazepine clearance, estimated by the base model (without covariates), in our population was 3.43 l/h.",Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229380/),[l] / [h],3.43,211310,DB00313,Valproic Acid
,20444563,maximum concentration,Median maximum concentration at 30 min after infusion was 98.8 mcg/mL (range 67-161 mcg/mL).,Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444563/),[mcg] / [ml],98.8,211408,DB00313,Valproic Acid
,20444563,volume of distribution,Median volume of distribution was 0.20 L/kg (range 0.15-0.53 L/kg).,Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444563/),[l] / [kg],0.20,211409,DB00313,Valproic Acid
,20444563,half-life,Median half-life was 9.5 h (range 4.4-24.2 h).,Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444563/),h,9.5,211410,DB00313,Valproic Acid
,20444563,clearance,Median clearance was 0.02 L/h/kg (range 0.01-0.05 L/h/kg).,Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444563/),[l] / [h·kg],0.02,211411,DB00313,Valproic Acid
,20444563,Volume of distribution,Volume of distribution of 0.20 L/kg could be applied for initial intravenous administration with a favorable efficacy.,Pharmacokinetics and clinical application of intravenous valproate in Thai epileptic children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444563/),[l] / [kg],0.20,211412,DB00313,Valproic Acid
,20699076,Elimination half-life,Elimination half-life is from 11 to 20 h.,[Therapeutic drug monitoring of valproate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20699076/),h,11 to 20,211605,DB00313,Valproic Acid
,16918714,free fraction,"Mean total phenytoin concentration was 11.7 mg/l, free phenytoin 1.25 mg/l and phenytoin free fraction 0.107.","Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918714/),,0.107,212443,DB00313,Valproic Acid
,6419419,terminal half-lives,"The plasma level curves appeared to be biexponential, with terminal half-lives that averaged 16.6 h.",Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6419419/),h,16.6,213037,DB00313,Valproic Acid
,6419419,half-life,"One subject showed a remarkably long half-life (28-38 h) after each of the three doses, indicating the possibility of genetic differences between individuals in the disposition of VPA.",Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6419419/),h,28-38,213038,DB00313,Valproic Acid
,6419419,recovery,The mean recovery of VPA in 6-day urine represented 12-14% of the dose and ranged from 5.5 to 27.9% in different individuals.,Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6419419/),%,5.5 to 27.9,213039,DB00313,Valproic Acid
,30169477,apparent clearance (CL/F),"In the final model, apparent clearance (CL/F) of LTG was estimated to be 1.48 L/h; 500 mg valproic acid, oxcarbazepine, and UGT2B7-161TT genotype changed the CL/F by -46.2, +31.1, and -21.8%, respectively.",A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169477/),[l] / [h],1.48,216020,DB00313,Valproic Acid
,29403845,constant flow rate,"The mobile phase used was 10 mM ammonium formate-acetonitrile (5:95, v/v) at a constant flow rate of 0.8 mL/min monitored on triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) mode.",Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: Application of the method to support pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403845/),[ml] / [min],0.8,217893,DB00313,Valproic Acid
,29403845,run time,The injection volume used for LC-MS/MS analysis was 15 μL and the run time was 2.5 min.,Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: Application of the method to support pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403845/),min,2.5,217894,DB00313,Valproic Acid
,29403845,recoveries,"The method recoveries of asenapine (81.33%), valproic acid (81.70%), gliclazide (78.45%) and benzoic acid (79.73) from spiked plasma samples were consistent and reproducible.",Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: Application of the method to support pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403845/),%,81.33,217895,DB00313,Valproic Acid
,29403845,recoveries,"The method recoveries of asenapine (81.33%), valproic acid (81.70%), gliclazide (78.45%) and benzoic acid (79.73) from spiked plasma samples were consistent and reproducible.",Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: Application of the method to support pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403845/),%,81.70,217896,DB00313,Valproic Acid
,29403845,recoveries,"The method recoveries of asenapine (81.33%), valproic acid (81.70%), gliclazide (78.45%) and benzoic acid (79.73) from spiked plasma samples were consistent and reproducible.",Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: Application of the method to support pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403845/),%,78.45,217897,DB00313,Valproic Acid
,29403845,recoveries,"The method recoveries of asenapine (81.33%), valproic acid (81.70%), gliclazide (78.45%) and benzoic acid (79.73) from spiked plasma samples were consistent and reproducible.",Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: Application of the method to support pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403845/),,79.73,217898,DB00313,Valproic Acid
,6810290,t1/2 alpha,"After a single IV dose (50 mg/kg) to the mother, a rapid distribution phase (t1/2 alpha = 0.5 minute) was followed by a biphasic decline in concentration in maternal blood (t1/2 beta = 31 minutes, t1/2 gamma = 390 minutes).",Materno-fetal pharmacokinetics and fetal distribution of valproic acid in a pregnant rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6810290/),min,0.5,219563,DB00313,Valproic Acid
,6810290,t1/2 beta,"After a single IV dose (50 mg/kg) to the mother, a rapid distribution phase (t1/2 alpha = 0.5 minute) was followed by a biphasic decline in concentration in maternal blood (t1/2 beta = 31 minutes, t1/2 gamma = 390 minutes).",Materno-fetal pharmacokinetics and fetal distribution of valproic acid in a pregnant rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6810290/),min,31,219564,DB00313,Valproic Acid
,6810290,t1/2 gamma,"After a single IV dose (50 mg/kg) to the mother, a rapid distribution phase (t1/2 alpha = 0.5 minute) was followed by a biphasic decline in concentration in maternal blood (t1/2 beta = 31 minutes, t1/2 gamma = 390 minutes).",Materno-fetal pharmacokinetics and fetal distribution of valproic acid in a pregnant rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6810290/),min,390,219565,DB00313,Valproic Acid
,6810290,Terminal fetal/maternal ratios of blood concentration,Terminal fetal/maternal ratios of blood concentration of VPA were about 1.3.,Materno-fetal pharmacokinetics and fetal distribution of valproic acid in a pregnant rhesus monkey. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6810290/),,1.3,219566,DB00313,Valproic Acid
,3921078,free fraction,"The average free fraction of VPA obtained in this study, by using the EMIT technique, ranged from 1.5 to 11.5 per cent with a mean value of 4.9 per cent.",Pharmacokinetics of valproic acid in volunteers after a single dose study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921078/),%,1.5 to 11.5,221651,DB00313,Valproic Acid
,3921078,free fraction,"The average free fraction of VPA obtained in this study, by using the EMIT technique, ranged from 1.5 to 11.5 per cent with a mean value of 4.9 per cent.",Pharmacokinetics of valproic acid in volunteers after a single dose study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921078/),%,4.9,221652,DB00313,Valproic Acid
,6411107,elimination half-life,The median elimination half-life was 7.2 h in the young subjects but 14.9 h in the elderly patients (P less than 0.01).,Pharmacokinetics of valproic acid in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411107/),h,7.2,223593,DB00313,Valproic Acid
,6411107,elimination half-life,The median elimination half-life was 7.2 h in the young subjects but 14.9 h in the elderly patients (P less than 0.01).,Pharmacokinetics of valproic acid in young and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411107/),h,14.9,223594,DB00313,Valproic Acid
,6411107,clearance,"However, clearance did not differ significantly between groups, the values for young and old being 0.69 and 0.58 1/h respectively.",Pharmacokinetics of valproic acid in young and elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411107/),[1] / [h],0.69,223595,DB00313,Valproic Acid
,6411107,clearance,"However, clearance did not differ significantly between groups, the values for young and old being 0.69 and 0.58 1/h respectively.",Pharmacokinetics of valproic acid in young and elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411107/),[1] / [h],0.58,223596,DB00313,Valproic Acid
,20738383,ED(50),"α-F-TMCD was active in the two pain models, and was found to be equipotent to gabapentin in the SNL model (ED(50) = 37 and 32 mg/kg, respectively).","Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20738383/),[mg] / [kg],37,224631,DB00313,Valproic Acid
,20738383,ED(50),"α-F-TMCD was active in the two pain models, and was found to be equipotent to gabapentin in the SNL model (ED(50) = 37 and 32 mg/kg, respectively).","Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20738383/),[mg] / [kg],32,224632,DB00313,Valproic Acid
,9631937,recovery,It was found that the recovery was very close to 100% at 0.5 microl/minute and by in vitro studies it could be excluded that valproic acid binds to the dialysis equipment.,Validation of microdialysis sampling for subcutaneous extracellular valproic acid in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9631937/),%,100,224645,DB00313,Valproic Acid
,3920383,peak,Administered VPA was rapidly and completely absorbed into blood (peak 30 micrograms of VPA per ml at 0-2 hr).,"Disposition of beta-glucuronidase-resistant ""glucuronides"" of valproic acid after intrabiliary administration in the rat: intact absorption, fecal excretion and intestinal hydrolysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3920383/),μg,30,225316,DB00313,Valproic Acid
,29453075,Total C/D-ratios,Total C/D-ratios were reduced by 46% from before pregnancy to third trimester (0.48-0.29 μmol/L/mg).,Pharmacokinetic variability of valproate during pregnancy - Implications for the use of therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453075/),[μM] / [l·mg],0.48-0.29,225649,DB00313,Valproic Acid
,34255318,total clearance,The population mean value of lamotrigine total clearance generated in the final model (with covariates) was 2.12 L/hr.,Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34255318/),[l] / [h],2.12,226356,DB00313,Valproic Acid
,15013050,trough VPA concentrations,"Mean trough VPA concentrations at doses of 125, 250, 375 and 500 mg per day were 6.5, 13.9, 16.1 and 31.9 microg/ml, respectively.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],6.5,226806,DB00313,Valproic Acid
,15013050,trough VPA concentrations,"Mean trough VPA concentrations at doses of 125, 250, 375 and 500 mg per day were 6.5, 13.9, 16.1 and 31.9 microg/ml, respectively.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],13.9,226807,DB00313,Valproic Acid
,15013050,trough VPA concentrations,"Mean trough VPA concentrations at doses of 125, 250, 375 and 500 mg per day were 6.5, 13.9, 16.1 and 31.9 microg/ml, respectively.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],16.1,226808,DB00313,Valproic Acid
,15013050,trough VPA concentrations,"Mean trough VPA concentrations at doses of 125, 250, 375 and 500 mg per day were 6.5, 13.9, 16.1 and 31.9 microg/ml, respectively.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],31.9,226809,DB00313,Valproic Acid
,15013050,EC50 concentration,"Maximal theoretical inhibition of LTG oral clearance by VPA is approximately 65%, with an EC50 concentration value of approximately 5.6 microg/ml of VPA.",Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013050/),[μg] / [ml],5.6,226810,DB00313,Valproic Acid
,26088889,trough plasma concentration,"The standardized trough plasma concentration of VPA was much lower in those patients with a T allele at UGT2B7 C802T than in those with the CC genotype (TT, 2.11 ± 1.26; CT, 2.31 ± 1.25; CC, 3.02 ± 1.32 μg kg mL(-1) mg(-1), p < 0.01).",The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26088889/),[kg·μg] / [mg·ml],2.11,226853,DB00313,Valproic Acid
,26088889,trough plasma concentration,"The standardized trough plasma concentration of VPA was much lower in those patients with a T allele at UGT2B7 C802T than in those with the CC genotype (TT, 2.11 ± 1.26; CT, 2.31 ± 1.25; CC, 3.02 ± 1.32 μg kg mL(-1) mg(-1), p < 0.01).",The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26088889/),[kg·μg] / [mg·ml],2.31,226854,DB00313,Valproic Acid
,26088889,trough plasma concentration,"The standardized trough plasma concentration of VPA was much lower in those patients with a T allele at UGT2B7 C802T than in those with the CC genotype (TT, 2.11 ± 1.26; CT, 2.31 ± 1.25; CC, 3.02 ± 1.32 μg kg mL(-1) mg(-1), p < 0.01).",The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26088889/),[kg·μg] / [mg·ml],3.02,226855,DB00313,Valproic Acid
,17472600,Serum concentrations,"Serum concentrations of valproic acid at 0 h (50.7 +/- 19.4 vs 44.9 +/- 21.8 microg/mL, P < 0.05) and 24 h (52.3 +/- 19.54 vs 6.2 +/- 22.2 microg/mL, P < 0.05) were significantly higher during Selenica R than during Depakene R treatment, whereas the serum concentration of valproic acid at 8 h (49.7 +/- 19.2 vs 62.4 +/- 25.6 microg/mL, P < 0.01) was significantly lower during Selenica R treatment than during Depakene R treatment.",Different serum concentrations of steady-state valproic acid in two sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472600/),[μg] / [ml],50,227073,DB00313,Valproic Acid
,17472600,Serum concentrations,"Serum concentrations of valproic acid at 0 h (50.7 +/- 19.4 vs 44.9 +/- 21.8 microg/mL, P < 0.05) and 24 h (52.3 +/- 19.54 vs 6.2 +/- 22.2 microg/mL, P < 0.05) were significantly higher during Selenica R than during Depakene R treatment, whereas the serum concentration of valproic acid at 8 h (49.7 +/- 19.2 vs 62.4 +/- 25.6 microg/mL, P < 0.01) was significantly lower during Selenica R treatment than during Depakene R treatment.",Different serum concentrations of steady-state valproic acid in two sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472600/),[μg] / [ml],44.,227074,DB00313,Valproic Acid
,17472600,Serum concentrations,"Serum concentrations of valproic acid at 0 h (50.7 +/- 19.4 vs 44.9 +/- 21.8 microg/mL, P < 0.05) and 24 h (52.3 +/- 19.54 vs 6.2 +/- 22.2 microg/mL, P < 0.05) were significantly higher during Selenica R than during Depakene R treatment, whereas the serum concentration of valproic acid at 8 h (49.7 +/- 19.2 vs 62.4 +/- 25.6 microg/mL, P < 0.01) was significantly lower during Selenica R treatment than during Depakene R treatment.",Different serum concentrations of steady-state valproic acid in two sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472600/),μg,52.3,227075,DB00313,Valproic Acid
,17472600,Serum concentrations,"Serum concentrations of valproic acid at 0 h (50.7 +/- 19.4 vs 44.9 +/- 21.8 microg/mL, P < 0.05) and 24 h (52.3 +/- 19.54 vs 6.2 +/- 22.2 microg/mL, P < 0.05) were significantly higher during Selenica R than during Depakene R treatment, whereas the serum concentration of valproic acid at 8 h (49.7 +/- 19.2 vs 62.4 +/- 25.6 microg/mL, P < 0.01) was significantly lower during Selenica R treatment than during Depakene R treatment.",Different serum concentrations of steady-state valproic acid in two sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472600/),μg,6.2,227076,DB00313,Valproic Acid
,17472600,serum concentration,"Serum concentrations of valproic acid at 0 h (50.7 +/- 19.4 vs 44.9 +/- 21.8 microg/mL, P < 0.05) and 24 h (52.3 +/- 19.54 vs 6.2 +/- 22.2 microg/mL, P < 0.05) were significantly higher during Selenica R than during Depakene R treatment, whereas the serum concentration of valproic acid at 8 h (49.7 +/- 19.2 vs 62.4 +/- 25.6 microg/mL, P < 0.01) was significantly lower during Selenica R treatment than during Depakene R treatment.",Different serum concentrations of steady-state valproic acid in two sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472600/),,49,227077,DB00313,Valproic Acid
,17472600,serum concentration,"Serum concentrations of valproic acid at 0 h (50.7 +/- 19.4 vs 44.9 +/- 21.8 microg/mL, P < 0.05) and 24 h (52.3 +/- 19.54 vs 6.2 +/- 22.2 microg/mL, P < 0.05) were significantly higher during Selenica R than during Depakene R treatment, whereas the serum concentration of valproic acid at 8 h (49.7 +/- 19.2 vs 62.4 +/- 25.6 microg/mL, P < 0.01) was significantly lower during Selenica R treatment than during Depakene R treatment.",Different serum concentrations of steady-state valproic acid in two sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472600/),,62,227078,DB00313,Valproic Acid
,15199078,absolute bioavailability,"Conventional delayed-release, enteric-coated divalproex sodium tablet has an absolute bioavailability of approximately 100%.",Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199078/),%,100,227081,DB00313,Valproic Acid
,15199078,absolute bioavailability,The geometric mean absolute bioavailability of divalproex ER was 0.896.,Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199078/),,0.896,227082,DB00313,Valproic Acid
,15199078,duration of drug absorption,"The mean (coefficient of variation) duration of drug absorption from divalproex ER was 21.8 (17%) hours, and the zero-order absorption rate was 21.6 (24%) mg/h for a 500-mg tablet.",Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199078/),h,21.8,227083,DB00313,Valproic Acid
,15199078,zero-order absorption rate,"The mean (coefficient of variation) duration of drug absorption from divalproex ER was 21.8 (17%) hours, and the zero-order absorption rate was 21.6 (24%) mg/h for a 500-mg tablet.",Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199078/),[mg] / [h],21.6,227084,DB00313,Valproic Acid
,18201732,ED(50),"(R)-, (S)- and (R,S)-PID produced dose-related reversal of tactile allodynia with ED(50) values of 46, 48, 42 mg/kg, respectively.","Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201732/),[mg] / [kg],46,227608,DB00313,Valproic Acid
,18201732,ED(50),"(R)-, (S)- and (R,S)-PID produced dose-related reversal of tactile allodynia with ED(50) values of 46, 48, 42 mg/kg, respectively.","Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201732/),[mg] / [kg],48,227609,DB00313,Valproic Acid
,18201732,ED(50),"(R)-, (S)- and (R,S)-PID produced dose-related reversal of tactile allodynia with ED(50) values of 46, 48, 42 mg/kg, respectively.","Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18201732/),[mg] / [kg],42,227610,DB00313,Valproic Acid
,9795021,clearance,"The following similar PK parameters were obtained for TMCD and M-TMCD, respectively: clearance, 5 and 5.6 ml/min/kg; volume of distribution (Vss), 0.72 and 0.96 l/kg; half-life (t1/2), 1.1 and 1.","Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),[ml] / [kg·min],5,228273,DB00313,Valproic Acid
,9795021,clearance,"The following similar PK parameters were obtained for TMCD and M-TMCD, respectively: clearance, 5 and 5.6 ml/min/kg; volume of distribution (Vss), 0.72 and 0.96 l/kg; half-life (t1/2), 1.1 and 1.","Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),[ml] / [kg·min],5.6,228274,DB00313,Valproic Acid
,9795021,volume of distribution (Vss),"The following similar PK parameters were obtained for TMCD and M-TMCD, respectively: clearance, 5 and 5.6 ml/min/kg; volume of distribution (Vss), 0.72 and 0.96 l/kg; half-life (t1/2), 1.1 and 1.","Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),[l] / [kg],0.72,228275,DB00313,Valproic Acid
,9795021,volume of distribution (Vss),"The following similar PK parameters were obtained for TMCD and M-TMCD, respectively: clearance, 5 and 5.6 ml/min/kg; volume of distribution (Vss), 0.72 and 0.96 l/kg; half-life (t1/2), 1.1 and 1.","Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),[l] / [kg],0.96,228276,DB00313,Valproic Acid
,9795021,half-life (t1/2),"The following similar PK parameters were obtained for TMCD and M-TMCD, respectively: clearance, 5 and 5.6 ml/min/kg; volume of distribution (Vss), 0.72 and 0.96 l/kg; half-life (t1/2), 1.1 and 1.","Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),,1.1,228277,DB00313,Valproic Acid
,9795021,half-life (t1/2),"The following similar PK parameters were obtained for TMCD and M-TMCD, respectively: clearance, 5 and 5.6 ml/min/kg; volume of distribution (Vss), 0.72 and 0.96 l/kg; half-life (t1/2), 1.1 and 1.","Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),,1,228278,DB00313,Valproic Acid
,9795021,mean residence time (MRT),"2 h; and mean residence time (MRT), 2.41 and 2.8 h.","Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),h,2.41,228279,DB00313,Valproic Acid
,9795021,mean residence time (MRT),"2 h; and mean residence time (MRT), 2.41 and 2.8 h.","Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),h,2.8,228280,DB00313,Valproic Acid
,9795021,fraction metabolized,The fraction metabolized of M-TMCD to TMCD was 32%.,"Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. ",fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9795021/),%,32,228281,DB00313,Valproic Acid
,10390769,serum concentrations,"Mean serum concentrations of patients receiving CBZ were 8.2, 7.3 and 6.4 micrograms/ml for the 2, 4 and 6 hours samples, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],8.2,228745,DB00313,Valproic Acid
,10390769,serum concentrations,"Mean serum concentrations of patients receiving CBZ were 8.2, 7.3 and 6.4 micrograms/ml for the 2, 4 and 6 hours samples, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],7.3,228746,DB00313,Valproic Acid
,10390769,serum concentrations,"Mean serum concentrations of patients receiving CBZ were 8.2, 7.3 and 6.4 micrograms/ml for the 2, 4 and 6 hours samples, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],6.4,228747,DB00313,Valproic Acid
,10390769,serum concentrations,"Mean serum concentrations of CBZ in the group receiving CBZ + VAP were 7.8, 8.4 and 7.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],7.8,228748,DB00313,Valproic Acid
,10390769,serum concentrations,"Mean serum concentrations of CBZ in the group receiving CBZ + VAP were 7.8, 8.4 and 7.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],8.4,228749,DB00313,Valproic Acid
,10390769,serum concentrations,"Patients receiving VPA had mean serum concentrations of 92.8, 97.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],92.8,228750,DB00313,Valproic Acid
,10390769,serum concentrations,"Patients receiving VPA had mean serum concentrations of 92.8, 97.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),[μg] / [ml],97.8,228751,DB00313,Valproic Acid
,10390769,serum concentrations,"Those receiving CBZ + VPA had serum concentrations of 69.1, 70.6 and 55.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),,69.1,228752,DB00313,Valproic Acid
,10390769,serum concentrations,"Those receiving CBZ + VPA had serum concentrations of 69.1, 70.6 and 55.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),,70.6,228753,DB00313,Valproic Acid
,10390769,serum concentrations,"Those receiving CBZ + VPA had serum concentrations of 69.1, 70.6 and 55.8 micrograms/ml, respectively.",[The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10390769/),,55.8,228754,DB00313,Valproic Acid
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],235,230125,DB00313,Valproic Acid
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],197,230126,DB00313,Valproic Acid
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],172,230127,DB00313,Valproic Acid
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],164,230128,DB00313,Valproic Acid
,1436383,ED50,"Memantine increased the threshold for electroconvulsions, when administered at 1.0-6.0 mg/kg (i.p.) and given in subthreshold doses of 0.0156, 0.0625, 0.125 and 0.5 mg/kg (i.p.) potentiated the protective efficacy of valproate, against maximal electroshock (50 mA)-induced seizures in mice, lowering the ED50 from 235 to 197, 172, 164 and 130 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],130,230129,DB00313,Valproic Acid
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],206,230130,DB00313,Valproic Acid
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],103,230131,DB00313,Valproic Acid
,1436383,ED50,"Trihexyphenidyl, applied in doses of 30 and 50 mg/kg (i.p.), did not influence the electroconvulsive threshold per se but when combined with valproate, strongly enhanced its anticonvulsant activity against maximal electroshock-induced seizures lowering the ED50 from 206 to 103 and 46 mg/kg, respectively.",Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1436383/),[mg] / [kg],46,230132,DB00313,Valproic Acid
,15871637,maximum observed plasma concentration (C(max)),"Steady-state dosing of zonisamide (200mg twice daily) had no statistically significant effect on the mean (+/- SD) maximum observed plasma concentration (C(max)) [70.8 +/- 20.5 vs 69.2 +/- 27.0 microg/mL], area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)) [689.3 +/- 250.4 vs 661.8 +/- 251.3 microg . h/mL] or other evaluated pharmacokinetic parameters for valproic acid measured before and after zonisamide administration.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[μg] / [ml],70.8,230246,DB00313,Valproic Acid
,15871637,maximum observed plasma concentration (C(max)),"Steady-state dosing of zonisamide (200mg twice daily) had no statistically significant effect on the mean (+/- SD) maximum observed plasma concentration (C(max)) [70.8 +/- 20.5 vs 69.2 +/- 27.0 microg/mL], area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)) [689.3 +/- 250.4 vs 661.8 +/- 251.3 microg . h/mL] or other evaluated pharmacokinetic parameters for valproic acid measured before and after zonisamide administration.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[μg] / [ml],69.2,230247,DB00313,Valproic Acid
,15871637,area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)),"Steady-state dosing of zonisamide (200mg twice daily) had no statistically significant effect on the mean (+/- SD) maximum observed plasma concentration (C(max)) [70.8 +/- 20.5 vs 69.2 +/- 27.0 microg/mL], area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)) [689.3 +/- 250.4 vs 661.8 +/- 251.3 microg . h/mL] or other evaluated pharmacokinetic parameters for valproic acid measured before and after zonisamide administration.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[h·μg] / [ml],689.3,230248,DB00313,Valproic Acid
,15871637,area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)),"Steady-state dosing of zonisamide (200mg twice daily) had no statistically significant effect on the mean (+/- SD) maximum observed plasma concentration (C(max)) [70.8 +/- 20.5 vs 69.2 +/- 27.0 microg/mL], area under the plasma concentration-time curve from the time of dosing to 12 hours post-dose (AUC(12)) [689.3 +/- 250.4 vs 661.8 +/- 251.3 microg . h/mL] or other evaluated pharmacokinetic parameters for valproic acid measured before and after zonisamide administration.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[h·μg] / [ml],661.8,230249,DB00313,Valproic Acid
,15871637,oral clearance,"In the presence of valproic acid, mean zonisamide oral clearance (1.23 L/h) and elimination half-life (52.5 hours) are generally consistent with values reported for healthy volunteers receiving zonisamide monotherapy.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),[l] / [h],1.23,230250,DB00313,Valproic Acid
,15871637,elimination half-life,"In the presence of valproic acid, mean zonisamide oral clearance (1.23 L/h) and elimination half-life (52.5 hours) are generally consistent with values reported for healthy volunteers receiving zonisamide monotherapy.",Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871637/),h,52.5,230251,DB00313,Valproic Acid
,2111769,terminal half-life (t1/2,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),h,6.3,230256,DB00313,Valproic Acid
,2111769,terminal half-life (t1/2,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),h,9.0,230257,DB00313,Valproic Acid
,2111769,clearance,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),[ml] / [h·kg],90.6,230258,DB00313,Valproic Acid
,2111769,clearance,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),[ml] / [h·kg],63.2,230259,DB00313,Valproic Acid
,2111769,apparent volume of distribution,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),[l] / [kg],0.82,230260,DB00313,Valproic Acid
,2111769,apparent volume of distribution,"VPA caused a significant prolongation of CBZ-E terminal half-life (t1/2 from 6.3 +/- 1.2 to 9.0 +/- 2.0 h, mean values +/- SD) and decreased CBZ-E clearance (from 90.6 +/- 18.8 to 63.2 +/- 16.1 ml h-1 kg-1, mean values +/- SD) without affecting CBZ-E apparent volume of distribution (from 0.82 +/- 0.19 to 0.81 +/- 0.24 l kg-1, mean values +/- SD).","Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111769/),[l] / [kg],0.81,230261,DB00313,Valproic Acid
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,13,230405,DB00313,Valproic Acid
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,14,230406,DB00313,Valproic Acid
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,20,230407,DB00313,Valproic Acid
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],9.7,230408,DB00313,Valproic Acid
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],15.5,230409,DB00313,Valproic Acid
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],23.0,230410,DB00313,Valproic Acid
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],132.5,230411,DB00313,Valproic Acid
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],205.4,230412,DB00313,Valproic Acid
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],336.1,230413,DB00313,Valproic Acid
,24630050,plasma concentration,Stiripentol plasma concentration in the fixed-dose phase was 4-25 μg/mL.,Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24630050/),,4-25,231367,DB00313,Valproic Acid
,32187715,V1 /Vdss,Twenty compounds that have a human V1 /Vdss of 0.053-0.66 were selected from the literature.,"Applicability of the Øie-Tozer model to predict three types of distribution volume (Vd) in humans: Vd in central compartment, Vd at steady state, and Vd at beta phase. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187715/),,0.053-0.66,232486,DB00313,Valproic Acid
,8827398,half-life,"When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,20 to 30,232847,DB00313,Valproic Acid
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,50 to 70,232848,DB00313,Valproic Acid
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,25 to 35,232849,DB00313,Valproic Acid
,8827398,half-life,"It is highly (96%) bound to plasma proteins and it is eliminated primarily by cytochrome P450 3A-mediated oxidation, with a half-life of about 7 hours in healthy volunteers.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,7,232850,DB00313,Valproic Acid
,8947979,clearance,"While receiving propranolol 40 mg, VPA clearance was reduced from 1.66 L/hr to 1.19 L/hr and dropped to 1.08 L/hr on propranolol 80 mg.",A pharmacokinetic study to determine the drug interaction between valproate and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947979/),[l] / [h],1.66,233386,DB00313,Valproic Acid
,8947979,clearance,"While receiving propranolol 40 mg, VPA clearance was reduced from 1.66 L/hr to 1.19 L/hr and dropped to 1.08 L/hr on propranolol 80 mg.",A pharmacokinetic study to determine the drug interaction between valproate and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947979/),[l] / [h],1.19,233387,DB00313,Valproic Acid
,8947979,clearance,"While receiving propranolol 40 mg, VPA clearance was reduced from 1.66 L/hr to 1.19 L/hr and dropped to 1.08 L/hr on propranolol 80 mg.",A pharmacokinetic study to determine the drug interaction between valproate and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947979/),[l] / [h],1.08,233388,DB00313,Valproic Acid
,8947979,Plasma half-life,Plasma half-life of VPA ranged from 7.3-18 hours and did not change with coadministration of propranolol.,A pharmacokinetic study to determine the drug interaction between valproate and propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947979/),h,7.3-18,233389,DB00313,Valproic Acid
,11240599,Tmax,"The distribution of VPA to subdural CSF was rapid (Tmax, 3.5 h in two patients and 5.5 h in one patient) and subject to a minor delay in all three patients compared with that in the subcutaneous tissue ECF (Tmax, 2.5 h in all three patients), which in turn exhibited no evidence of a distribution delay compared with plasma.","Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240599/),h,3.5,234271,DB00313,Valproic Acid
,11240599,Tmax,"The distribution of VPA to subdural CSF was rapid (Tmax, 3.5 h in two patients and 5.5 h in one patient) and subject to a minor delay in all three patients compared with that in the subcutaneous tissue ECF (Tmax, 2.5 h in all three patients), which in turn exhibited no evidence of a distribution delay compared with plasma.","Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240599/),h,5.5,234272,DB00313,Valproic Acid
,11240599,Tmax,"The distribution of VPA to subdural CSF was rapid (Tmax, 3.5 h in two patients and 5.5 h in one patient) and subject to a minor delay in all three patients compared with that in the subcutaneous tissue ECF (Tmax, 2.5 h in all three patients), which in turn exhibited no evidence of a distribution delay compared with plasma.","Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240599/),h,2.5,234273,DB00313,Valproic Acid
,357068,half-lives (t1/2s),"Most patients had predicted half-lives (t1/2s) of 6 to 8 hr, independent of the plasma concentration of valproic acid.",Steady-state kinetics of valproic acid in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/357068/),h,6 to 8,235650,DB00313,Valproic Acid
,357068,t1/2s,Five patients had predicted t1/2s of 12 hr.,Steady-state kinetics of valproic acid in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/357068/),h,12,235651,DB00313,Valproic Acid
,28290002,degrees,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,36,239223,DB00313,Valproic Acid
,28290002,degrees,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,22,239224,DB00313,Valproic Acid
,28290002,CSF drug penetration,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,36,239225,DB00313,Valproic Acid
,28290002,CSF drug penetration,"For TMZ, the degrees of CSF drug penetration after intranasal and IV administration were 36 (32-57) and 22 (20-41)%, respectively.",Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28290002/),%,22,239226,DB00313,Valproic Acid
,16930590,ED(50),"Moreover, ACEA (at a subthreshold dose of 2.5 mg/kg; i.p.) co-administered with PMSF potentiated significantly the antielectroshock activity of valproate by reducing its ED(50) from 258.3 to 195.1 mg/kg (P<0.01).","Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16930590/),[mg] / [kg],258.3,239349,DB00313,Valproic Acid
,16930590,ED(50),"Moreover, ACEA (at a subthreshold dose of 2.5 mg/kg; i.p.) co-administered with PMSF potentiated significantly the antielectroshock activity of valproate by reducing its ED(50) from 258.3 to 195.1 mg/kg (P<0.01).","Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16930590/),[mg] / [kg],195.1,239350,DB00313,Valproic Acid
,8894115,fe,"(E)-2-ene valproyl glycinamide was partially excreted unchanged in the urine (fe = 7.4%), while its urinary metabolite was (E)-2-ene valproyl glycine.",Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894115/),%,7.4,240045,DB00313,Valproic Acid
,10197296,apparent oral clearance,The population mean apparent oral clearance of lamotrigine in adult patients receiving one concomitant enzyme-inducing antiepileptic drug and not valproic acid was estimated to be 1 mL/min/kg.,Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10197296/),[ml] / [kg·min],1,241375,DB00313,Valproic Acid
,6794365,time to attain a peak serum concentration,The time to attain a peak serum concentration was significantly delayed (p less than 0.005) from the 1.6 hours during fasting conditions to four hours after a standard meal.,Effects of food on valproic acid absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794365/),h,1.6,241740,DB00313,Valproic Acid
,6794365,time to attain a peak serum concentration,The time to attain a peak serum concentration was significantly delayed (p less than 0.005) from the 1.6 hours during fasting conditions to four hours after a standard meal.,Effects of food on valproic acid absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794365/),h,four,241741,DB00313,Valproic Acid
,6794365,peak serum concentrations,A statistically insignificant trend toward lower peak serum concentrations (54.6 micrograms/ml versus 49.4 micrograms/ml) was found under the nonfasting conditions.,Effects of food on valproic acid absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794365/),[μg] / [ml],54.6,241742,DB00313,Valproic Acid
,6794365,peak serum concentrations,A statistically insignificant trend toward lower peak serum concentrations (54.6 micrograms/ml versus 49.4 micrograms/ml) was found under the nonfasting conditions.,Effects of food on valproic acid absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794365/),[μg] / [ml],49.4,241743,DB00313,Valproic Acid
,16403497,effective dose (ED50),"Moreover, 2-PMPA administered i.p. at a constant dose of 150 mg/kg (the dose increasing the threshold for electroconvulsions) enhanced significantly the anticonvulsant action of valproate, by reducing its median effective dose (ED50) from 281.4 to 230.1 mg/kg (P<0.05).",2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403497/),[mg] / [kg],281.4,243510,DB00313,Valproic Acid
,16403497,effective dose (ED50),"Moreover, 2-PMPA administered i.p. at a constant dose of 150 mg/kg (the dose increasing the threshold for electroconvulsions) enhanced significantly the anticonvulsant action of valproate, by reducing its median effective dose (ED50) from 281.4 to 230.1 mg/kg (P<0.05).",2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403497/),[mg] / [kg],230.1,243511,DB00313,Valproic Acid
,2497766,plasma clearance,"2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1).",The effect of carbamazepine on valproic acid disposition in adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[l] / [h],0.90,243609,DB00313,Valproic Acid
,2497766,plasma clearance,"2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1).",The effect of carbamazepine on valproic acid disposition in adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[l] / [h],1.26,243610,DB00313,Valproic Acid
,2497766,clearance,"2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1).",The effect of carbamazepine on valproic acid disposition in adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[l] / [h],20.8,243611,DB00313,Valproic Acid
,2497766,clearance,"2. After CBZ administration, mean VPA plasma clearance increased from 0.90 +/- 0.18 s.d. to 1.26 +/- 0.24 l h-1 (P less than 0.05) as did clearance of free VPA (20.8 +/- 7.6 to 37.0 +/- 13.6 l h-1).",The effect of carbamazepine on valproic acid disposition in adult volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[l] / [h],37.0,243612,DB00313,Valproic Acid
,2497766,elimination rate constant,Mean VPA elimination rate constant increased from 0.051 +/- 0.011 to 0.067 +/- 0.011 h-1 (P less than 0.05) after CBZ administration.,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),1/[h],0.051,243613,DB00313,Valproic Acid
,2497766,elimination rate constant,Mean VPA elimination rate constant increased from 0.051 +/- 0.011 to 0.067 +/- 0.011 h-1 (P less than 0.05) after CBZ administration.,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),1/[h],0.067,243614,DB00313,Valproic Acid
,2497766,area under the serum concentration vs time curve,3. Mean area under the serum concentration vs time curve decreased from 675.0 +/- 130.5 to 475.7 +/- 75.7 mg l-1 h (P less than 0.05) after CBZ administration.,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[h·mg] / [l],675.0,243615,DB00313,Valproic Acid
,2497766,area under the serum concentration vs time curve,3. Mean area under the serum concentration vs time curve decreased from 675.0 +/- 130.5 to 475.7 +/- 75.7 mg l-1 h (P less than 0.05) after CBZ administration.,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[h·mg] / [l],475.7,243616,DB00313,Valproic Acid
,2497766,half-life,Mean serum VPA half-life decreased from 14.0 +/- 2.4 to 10.6 +/- 1.4 h (P less than 0.05).,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),h,14.0,243617,DB00313,Valproic Acid
,2497766,half-life,Mean serum VPA half-life decreased from 14.0 +/- 2.4 to 10.6 +/- 1.4 h (P less than 0.05).,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),h,10.6,243618,DB00313,Valproic Acid
,2497766,trough concentrations,Mean serum VPA trough concentrations decreased from 44.0 +/- 16.7 to 27.0 +/- 10.4 micrograms ml-1 (P less than 0.05).,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[μg] / [ml],44.0,243619,DB00313,Valproic Acid
,2497766,trough concentrations,Mean serum VPA trough concentrations decreased from 44.0 +/- 16.7 to 27.0 +/- 10.4 micrograms ml-1 (P less than 0.05).,The effect of carbamazepine on valproic acid disposition in adult volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2497766/),[μg] / [ml],27.0,243620,DB00313,Valproic Acid
,34082013,penetration ratio,"The pharmacokinetic results demonstrated that the VPA penetration ratio of the BBB, determined by the area under the concentration curve (AUC) ratio of VPA (AUCbrain/AUCblood), was approximately 0.36.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,0.36,245826,DB00313,Valproic Acid
,34082013,area under the concentration curve (AUC) ratio,"The pharmacokinetic results demonstrated that the VPA penetration ratio of the BBB, determined by the area under the concentration curve (AUC) ratio of VPA (AUCbrain/AUCblood), was approximately 0.36.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,0.36,245827,DB00313,Valproic Acid
,34082013,penetration ratios,"After treatment with the G. elata extract (1 and 3 g/kg, p.o. for 5 consecutive days), the VPA penetration ratios were significantly enhanced to 1.47 and 1.02, respectively.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,1.47,245828,DB00313,Valproic Acid
,34082013,penetration ratios,"After treatment with the G. elata extract (1 and 3 g/kg, p.o. for 5 consecutive days), the VPA penetration ratios were significantly enhanced to 1.47 and 1.02, respectively.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,1.02,245829,DB00313,Valproic Acid
,34082013,penetration ratio,"Instead, the VPA penetration ratio in the brain was suppressed back to 0.38.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,0.38,245830,DB00313,Valproic Acid
<,30412268,trough concentration,"In our cohort, half the patients had a trough concentration <50 mg/L.",Simulations of Valproate Doses Based on an External Evaluation of Pediatric Population Pharmacokinetic Models. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30412268/),[mg] / [l],50,246423,DB00313,Valproic Acid
,12142639,peak concentration (Cmax),"The peak concentration (Cmax) of CZP and the time intervals from dosing to Cmax (Tmax) were 20.9 ng/mL to 113.8 ng/mL and 1 hour to 1.5 hours, respectively.",Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142639/),[ng] / [ml],20.9,246667,DB00313,Valproic Acid
,12142639,time intervals from dosing to Cmax (Tmax),"The peak concentration (Cmax) of CZP and the time intervals from dosing to Cmax (Tmax) were 20.9 ng/mL to 113.8 ng/mL and 1 hour to 1.5 hours, respectively.",Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142639/),[ng] / [ml],113.8,246668,DB00313,Valproic Acid
,12142639,time intervals from dosing to Cmax (Tmax),"The peak concentration (Cmax) of CZP and the time intervals from dosing to Cmax (Tmax) were 20.9 ng/mL to 113.8 ng/mL and 1 hour to 1.5 hours, respectively.",Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142639/),h,1,246669,DB00313,Valproic Acid
,12142639,time intervals from dosing to Cmax (Tmax),"The peak concentration (Cmax) of CZP and the time intervals from dosing to Cmax (Tmax) were 20.9 ng/mL to 113.8 ng/mL and 1 hour to 1.5 hours, respectively.",Pharmacokinetic and pharmacodynamic effects of clonazepam in children with epilepsy treated with valproate: a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12142639/),h,1.5,246670,DB00313,Valproic Acid
,2119396,time to reach peak (tmax),"Compared to enteric-coated tablets, Sprinkle capsules had earlier absorption onset, 1 versus 2.6 hours (P less than .05), slightly slower absorption rate, time to reach peak (tmax) of 4.0 versus 3.4 hours (P less than .1), and lower maximum peak plasma drug concentration (Cmax), 20.7 versus 25.9 mcg/mL (P less than .05).",Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119396/),h,4.0,246937,DB00313,Valproic Acid
,2119396,time to reach peak (tmax),"Compared to enteric-coated tablets, Sprinkle capsules had earlier absorption onset, 1 versus 2.6 hours (P less than .05), slightly slower absorption rate, time to reach peak (tmax) of 4.0 versus 3.4 hours (P less than .1), and lower maximum peak plasma drug concentration (Cmax), 20.7 versus 25.9 mcg/mL (P less than .05).",Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119396/),h,3.4,246938,DB00313,Valproic Acid
,2119396,maximum peak plasma drug concentration (Cmax),"Compared to enteric-coated tablets, Sprinkle capsules had earlier absorption onset, 1 versus 2.6 hours (P less than .05), slightly slower absorption rate, time to reach peak (tmax) of 4.0 versus 3.4 hours (P less than .1), and lower maximum peak plasma drug concentration (Cmax), 20.7 versus 25.9 mcg/mL (P less than .05).",Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119396/),[mcg] / [ml],20.7,246939,DB00313,Valproic Acid
,2119396,maximum peak plasma drug concentration (Cmax),"Compared to enteric-coated tablets, Sprinkle capsules had earlier absorption onset, 1 versus 2.6 hours (P less than .05), slightly slower absorption rate, time to reach peak (tmax) of 4.0 versus 3.4 hours (P less than .1), and lower maximum peak plasma drug concentration (Cmax), 20.7 versus 25.9 mcg/mL (P less than .05).",Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119396/),[mcg] / [ml],25.9,246940,DB00313,Valproic Acid
,2119396,Time to reach peak concentration,"Time to reach peak concentration was 2.7 hours for tablet (fasting), 3.3 hours for capsule (fasting), and 4.8 hours for capsule (nonfasting) (P less than .05).",Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119396/),h,2.7,246941,DB00313,Valproic Acid
,2119396,Time to reach peak concentration,"Time to reach peak concentration was 2.7 hours for tablet (fasting), 3.3 hours for capsule (fasting), and 4.8 hours for capsule (nonfasting) (P less than .05).",Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119396/),h,3.3,246942,DB00313,Valproic Acid
,2119396,Time to reach peak concentration,"Time to reach peak concentration was 2.7 hours for tablet (fasting), 3.3 hours for capsule (fasting), and 4.8 hours for capsule (nonfasting) (P less than .05).",Absorption characteristics of a new valproate formulation: divalproex sodium-coated particles in capsules (Depakote Sprinkle). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119396/),h,4.8,246943,DB00313,Valproic Acid
,18435754,ED(50),DBU emerged as the most potent compound having an MES-ED(50)of 186 mg/kg (mice) and 64 mg/kg (rats) and an scMet-ED(50)of 66 mg/kg (mice) and 26 mg/kg (rats).,"Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435754/),[mg] / [kg],66,249093,DB00313,Valproic Acid
,18435754,ED(50),DBU emerged as the most potent compound having an MES-ED(50)of 186 mg/kg (mice) and 64 mg/kg (rats) and an scMet-ED(50)of 66 mg/kg (mice) and 26 mg/kg (rats).,"Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435754/),mg,26,249094,DB00313,Valproic Acid
,18435754,half-life,DBU was eliminated by metabolism with a half-life of 4.5 h.,"Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: a potential for a second generation drug to valproic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18435754/),h,4.5,249095,DB00313,Valproic Acid
,3106614,peak plasma VPA concentration (Cmax),"By using VI, the highest values of the mean of the peak plasma VPA concentration (Cmax) (49.8 +/- 2.6 micrograms/ml) and the mean of the area under the plasma concentration-time curve (AUC) (90.0 +/- 3.7 h X micrograms/ml) were obtained.",Pharmaceutical evaluation of hollow type suppositories. V. Preparation of valproic acid suppository and rectal absorption of valproic acid in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3106614/),[μg] / [ml],49.8,249335,DB00313,Valproic Acid
,3106614,area under the plasma concentration-time curve (AUC),"By using VI, the highest values of the mean of the peak plasma VPA concentration (Cmax) (49.8 +/- 2.6 micrograms/ml) and the mean of the area under the plasma concentration-time curve (AUC) (90.0 +/- 3.7 h X micrograms/ml) were obtained.",Pharmaceutical evaluation of hollow type suppositories. V. Preparation of valproic acid suppository and rectal absorption of valproic acid in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3106614/),[h·μg] / [ml],90.0,249336,DB00313,Valproic Acid
,3106614,bioavailability (EBA),"The Cmax and the AUC were lower with III than with IV, VI or VII but the extent of bioavailability (EBA) of III was about 80%.",Pharmaceutical evaluation of hollow type suppositories. V. Preparation of valproic acid suppository and rectal absorption of valproic acid in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3106614/),%,80,249337,DB00313,Valproic Acid
,25380628,CL/F,Typical value of PB CL/F for final model was estimated at 0.314 l/h.,Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25380628/),[l] / [h],0.314,249519,DB00313,Valproic Acid
,29340733,oral clearance (CL/F),"For the final model, the oral clearance (CL/F) of LTG was estimated to be 0.705 L/h with inter-individual variability (IIV) of 21.3%.",Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29340733/),[l] / [h],0.705,249880,DB00313,Valproic Acid
,6434296,absolute bioavailabilities,"There were no significant differences between the absolute bioavailabilities of the three intraperitoneal doses, which ranged between 40 and 49%.",Disposition of progabide and valproic acid following intraperitoneal administration in rhesus monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434296/),%,40 and 49,250005,DB00313,Valproic Acid
,9357093,peak plasma concentration,"The peak plasma concentration (60.52 vs. 55.74 micrograms x ml-1), the time to peak concentration (3.47 vs. 3.91 h), the absorption rate constant (0.12 vs. 0.12 h-1), and the area under the plasma concentration-time curve (1324.0 vs. 1268.5 micrograms x h x ml-1) did not differ significantly between treatments A and B (median, Wilcoxon test).",Lack of kinetic interaction between valproic acid and citrus pectin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357093/),[μg] / [ml],60.52,252017,DB00313,Valproic Acid
,9357093,peak plasma concentration,"The peak plasma concentration (60.52 vs. 55.74 micrograms x ml-1), the time to peak concentration (3.47 vs. 3.91 h), the absorption rate constant (0.12 vs. 0.12 h-1), and the area under the plasma concentration-time curve (1324.0 vs. 1268.5 micrograms x h x ml-1) did not differ significantly between treatments A and B (median, Wilcoxon test).",Lack of kinetic interaction between valproic acid and citrus pectin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357093/),[μg] / [ml],55.74,252018,DB00313,Valproic Acid
,9357093,time to peak concentration,"The peak plasma concentration (60.52 vs. 55.74 micrograms x ml-1), the time to peak concentration (3.47 vs. 3.91 h), the absorption rate constant (0.12 vs. 0.12 h-1), and the area under the plasma concentration-time curve (1324.0 vs. 1268.5 micrograms x h x ml-1) did not differ significantly between treatments A and B (median, Wilcoxon test).",Lack of kinetic interaction between valproic acid and citrus pectin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357093/),h,3.47,252019,DB00313,Valproic Acid
,9357093,time to peak concentration,"The peak plasma concentration (60.52 vs. 55.74 micrograms x ml-1), the time to peak concentration (3.47 vs. 3.91 h), the absorption rate constant (0.12 vs. 0.12 h-1), and the area under the plasma concentration-time curve (1324.0 vs. 1268.5 micrograms x h x ml-1) did not differ significantly between treatments A and B (median, Wilcoxon test).",Lack of kinetic interaction between valproic acid and citrus pectin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357093/),h,3.91,252020,DB00313,Valproic Acid
,9357093,absorption rate constant,"The peak plasma concentration (60.52 vs. 55.74 micrograms x ml-1), the time to peak concentration (3.47 vs. 3.91 h), the absorption rate constant (0.12 vs. 0.12 h-1), and the area under the plasma concentration-time curve (1324.0 vs. 1268.5 micrograms x h x ml-1) did not differ significantly between treatments A and B (median, Wilcoxon test).",Lack of kinetic interaction between valproic acid and citrus pectin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357093/),1/[h],0.12,252021,DB00313,Valproic Acid
,9357093,area under the plasma concentration-time curve,"The peak plasma concentration (60.52 vs. 55.74 micrograms x ml-1), the time to peak concentration (3.47 vs. 3.91 h), the absorption rate constant (0.12 vs. 0.12 h-1), and the area under the plasma concentration-time curve (1324.0 vs. 1268.5 micrograms x h x ml-1) did not differ significantly between treatments A and B (median, Wilcoxon test).",Lack of kinetic interaction between valproic acid and citrus pectin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357093/),[h·μg] / [ml],1324.0,252022,DB00313,Valproic Acid
,9357093,area under the plasma concentration-time curve,"The peak plasma concentration (60.52 vs. 55.74 micrograms x ml-1), the time to peak concentration (3.47 vs. 3.91 h), the absorption rate constant (0.12 vs. 0.12 h-1), and the area under the plasma concentration-time curve (1324.0 vs. 1268.5 micrograms x h x ml-1) did not differ significantly between treatments A and B (median, Wilcoxon test).",Lack of kinetic interaction between valproic acid and citrus pectin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9357093/),[h·μg] / [ml],1268.5,252023,DB00313,Valproic Acid
,23996245,clearance,"The typical clearance for CBZ was estimated to be 5.85 and 5.68 L/h from plasma and DBS concentrations, respectively.",Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996245/),[l] / [h],5.85,252948,DB00313,Valproic Acid
,23996245,clearance,"The typical clearance for CBZ was estimated to be 5.85 and 5.68 L/h from plasma and DBS concentrations, respectively.",Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996245/),[l] / [h],5.68,252949,DB00313,Valproic Acid
,15579303,total VPA concentration,The mean VPA daily dose was 16.2+/-11.2mg/kg and mean total VPA concentration was 48.5+/-24.8 mg/L.,"Valproic acid doses, concentrations, and clearances in elderly nursing home residents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579303/),[mg] / [l],48.5,253535,DB00313,Valproic Acid
,15579303,total VPA,"Mean daily dose (19.4+/-11.4, 16.3+/-12.1, and 11.3+/-7.6 mg/kg/day; p=0.003) and total VPA concentration (56.4+/-25.8, 47.7+/-22.6, and 38.7+/-23.1mg/kg/day; p=0.003) decreased by age groups (65-74, 75-84, and > or =85 years).","Valproic acid doses, concentrations, and clearances in elderly nursing home residents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579303/),[mg] / [d·kg],56.4,253536,DB00313,Valproic Acid
,15579303,total VPA,"Mean daily dose (19.4+/-11.4, 16.3+/-12.1, and 11.3+/-7.6 mg/kg/day; p=0.003) and total VPA concentration (56.4+/-25.8, 47.7+/-22.6, and 38.7+/-23.1mg/kg/day; p=0.003) decreased by age groups (65-74, 75-84, and > or =85 years).","Valproic acid doses, concentrations, and clearances in elderly nursing home residents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579303/),[mg] / [d·kg],47.7,253537,DB00313,Valproic Acid
,15579303,total VPA,"Mean daily dose (19.4+/-11.4, 16.3+/-12.1, and 11.3+/-7.6 mg/kg/day; p=0.003) and total VPA concentration (56.4+/-25.8, 47.7+/-22.6, and 38.7+/-23.1mg/kg/day; p=0.003) decreased by age groups (65-74, 75-84, and > or =85 years).","Valproic acid doses, concentrations, and clearances in elderly nursing home residents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579303/),[mg] / [d·kg],38.7,253538,DB00313,Valproic Acid
,15579303,concentration,"Mean daily dose (19.4+/-11.4, 16.3+/-12.1, and 11.3+/-7.6 mg/kg/day; p=0.003) and total VPA concentration (56.4+/-25.8, 47.7+/-22.6, and 38.7+/-23.1mg/kg/day; p=0.003) decreased by age groups (65-74, 75-84, and > or =85 years).","Valproic acid doses, concentrations, and clearances in elderly nursing home residents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579303/),[mg] / [d·kg],56.4,253539,DB00313,Valproic Acid
,15579303,concentration,"Mean daily dose (19.4+/-11.4, 16.3+/-12.1, and 11.3+/-7.6 mg/kg/day; p=0.003) and total VPA concentration (56.4+/-25.8, 47.7+/-22.6, and 38.7+/-23.1mg/kg/day; p=0.003) decreased by age groups (65-74, 75-84, and > or =85 years).","Valproic acid doses, concentrations, and clearances in elderly nursing home residents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579303/),[mg] / [d·kg],47.7,253540,DB00313,Valproic Acid
,15579303,concentration,"Mean daily dose (19.4+/-11.4, 16.3+/-12.1, and 11.3+/-7.6 mg/kg/day; p=0.003) and total VPA concentration (56.4+/-25.8, 47.7+/-22.6, and 38.7+/-23.1mg/kg/day; p=0.003) decreased by age groups (65-74, 75-84, and > or =85 years).","Valproic acid doses, concentrations, and clearances in elderly nursing home residents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15579303/),[mg] / [d·kg],38.7,253541,DB00313,Valproic Acid
,8557785,total,"Mean total and unbound VPA plasma concentrations were 97.9 +/- 34.9 and 13.2 +/- 10.6 micrograms/ml, respectively.","Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557785/),[μg] / [ml],97.9,253959,DB00313,Valproic Acid
,8557785,unbound,"Mean total and unbound VPA plasma concentrations were 97.9 +/- 34.9 and 13.2 +/- 10.6 micrograms/ml, respectively.","Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557785/),[μg] / [ml],97.9,253960,DB00313,Valproic Acid
,8557785,unbound,"Mean total and unbound VPA plasma concentrations were 97.9 +/- 34.9 and 13.2 +/- 10.6 micrograms/ml, respectively.","Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557785/),[μg] / [ml],13.2,253961,DB00313,Valproic Acid
,8557785,plasma concentrations,"Mean total and unbound VPA plasma concentrations were 97.9 +/- 34.9 and 13.2 +/- 10.6 micrograms/ml, respectively.","Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557785/),[μg] / [ml],13.2,253962,DB00313,Valproic Acid
,14520124,unbound fraction,"As doses and valproate serum concentrations increased, the unbound fraction (10.0%, 13.0%, 17.4%) and total clearance (4.8, 6.0, 6.7 mL/h/kg) increased, respectively.",Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520124/),,13,254961,DB00313,Valproic Acid
,14520124,unbound fraction,"As doses and valproate serum concentrations increased, the unbound fraction (10.0%, 13.0%, 17.4%) and total clearance (4.8, 6.0, 6.7 mL/h/kg) increased, respectively.",Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520124/),,17.4,254962,DB00313,Valproic Acid
,14520124,total clearance,"As doses and valproate serum concentrations increased, the unbound fraction (10.0%, 13.0%, 17.4%) and total clearance (4.8, 6.0, 6.7 mL/h/kg) increased, respectively.",Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520124/),[ml] / [h·kg],4.8,254963,DB00313,Valproic Acid
,14520124,total clearance,"As doses and valproate serum concentrations increased, the unbound fraction (10.0%, 13.0%, 17.4%) and total clearance (4.8, 6.0, 6.7 mL/h/kg) increased, respectively.",Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520124/),[ml] / [h·kg],6.0,254964,DB00313,Valproic Acid
,14520124,total clearance,"As doses and valproate serum concentrations increased, the unbound fraction (10.0%, 13.0%, 17.4%) and total clearance (4.8, 6.0, 6.7 mL/h/kg) increased, respectively.",Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520124/),[ml] / [h·kg],6.7,254965,DB00313,Valproic Acid
,14520124,Unbound clearance,"Unbound clearance decreased (49.4, 45.8, 39.4 mL/h/kg) with increasing valproate serum concentrations.",Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520124/),[ml] / [h·kg],49.4,254966,DB00313,Valproic Acid
,14520124,Unbound clearance,"Unbound clearance decreased (49.4, 45.8, 39.4 mL/h/kg) with increasing valproate serum concentrations.",Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520124/),[ml] / [h·kg],45.8,254967,DB00313,Valproic Acid
,14520124,Unbound clearance,"Unbound clearance decreased (49.4, 45.8, 39.4 mL/h/kg) with increasing valproate serum concentrations.",Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520124/),[ml] / [h·kg],39.4,254968,DB00313,Valproic Acid
,29564480,trough concentration (Ctrough),The objective of this work was to develop a population pharmacokinetic model for a prolonged-release granule formulation of valproic acid (VPA) in children with epilepsy and to determine the doses providing a VPA trough concentration (Ctrough) within the target range (50-100 mg/L).,A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29564480/),[mg] / [l],50-100,256110,DB00313,Valproic Acid
,29564480,Ctrough,"The probability to obtain Ctrough between 50 and 100 mg/L was determined by the Monte Carlo simulations for doses of 20, 30, 40, and 60 mg/kg/day and body weights between 10 and 70 kg.",A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29564480/),[mg] / [l],50 and 100,256111,DB00313,Valproic Acid
,29564480,unbound VPA clearance,Typical values for unbound VPA clearance and distribution volume were 6.24 L/h/70 kg and 130 L/h/70 kg respectively.,A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29564480/),[l] / [70·h·kg],6.24,256112,DB00313,Valproic Acid
,29564480,distribution volume,Typical values for unbound VPA clearance and distribution volume were 6.24 L/h/70 kg and 130 L/h/70 kg respectively.,A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29564480/),[l] / [70·h·kg],130,256113,DB00313,Valproic Acid
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.53,256724,DB00313,Valproic Acid
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.70,256725,DB00313,Valproic Acid
,6815599,clearance,"The antipyrine clearance at term (0.53 +/- 0.11 ml/min/kg, mean +/- SD) was lower than it was early during puerperium (0.70 +/- 0.14 ml/min/kg, P less than .05) and approximately 3 months after delivery (1.14 +/- 0.26 ml/min/kg, P less than .01).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],1.14,256726,DB00313,Valproic Acid
,6815599,clearance,"The antipyrine clearance in nonpregnant epileptics (1.17 +/- 0.44 ml/min/kg) was comparable to that found 3 months after delivery, whereas it was significantly (P less than .01) higher than that found in healthy women (0.47 +/- 0.02 ml/min/kg).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],1.17,256727,DB00313,Valproic Acid
,6815599,clearance,"The antipyrine clearance in nonpregnant epileptics (1.17 +/- 0.44 ml/min/kg) was comparable to that found 3 months after delivery, whereas it was significantly (P less than .01) higher than that found in healthy women (0.47 +/- 0.02 ml/min/kg).",Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6815599/),[ml] / [kg·min],0.47,256728,DB00313,Valproic Acid
,26071142,Sex ratio,Sex ratio male/female was 1.3.,[Therapeutic Drug Monitoring of Valproic Acid in Children: A Prospective Study of The Effect of The Compliance and The Economic Level on the Trough Plasmatic Concentrations and Epileptic Seizures]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071142/),,1,257418,DB00313,Valproic Acid
,26071142,TPC,The mean TPC was 62 µg/mL [0.12-131 µg/mL].,[Therapeutic Drug Monitoring of Valproic Acid in Children: A Prospective Study of The Effect of The Compliance and The Economic Level on the Trough Plasmatic Concentrations and Epileptic Seizures]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071142/),[μg] / [ml],62,257419,DB00313,Valproic Acid
,10792197,"Plasma AUC(0,12 h)","Plasma AUC(0,12 h) of VPA was significantly lower on day 21 than on day 7 (2.40 vs 2.84 micromol ml-1 h, 95% CI for the difference 0.13-0.81 micromol ml-1 h).",Apparent autoinduction of valproate beta-oxidation in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[h·μM] / [ml],2.40,260552,DB00313,Valproic Acid
,10792197,"Plasma AUC(0,12 h)","Plasma AUC(0,12 h) of VPA was significantly lower on day 21 than on day 7 (2.40 vs 2.84 micromol ml-1 h, 95% CI for the difference 0.13-0.81 micromol ml-1 h).",Apparent autoinduction of valproate beta-oxidation in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[h·μM] / [ml],2.84,260553,DB00313,Valproic Acid
,10792197,formation clearances,"However, formation clearances of plasma VPA to urinary E-2-en-VPA and 3-oxo-VPA were significantly increased from day 7 to day 21 (0. 010 vs 0.024 and 2.57 vs 3.60 ml kg-1 h-1, respectively, 95% CI for the differences -0.025 to -0.004 and -1.72 to -0.34 ml kg-1 h-1, respectively).",Apparent autoinduction of valproate beta-oxidation in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[ml] / [h·kg],0. 010,260554,DB00313,Valproic Acid
,10792197,formation clearances,"However, formation clearances of plasma VPA to urinary E-2-en-VPA and 3-oxo-VPA were significantly increased from day 7 to day 21 (0. 010 vs 0.024 and 2.57 vs 3.60 ml kg-1 h-1, respectively, 95% CI for the differences -0.025 to -0.004 and -1.72 to -0.34 ml kg-1 h-1, respectively).",Apparent autoinduction of valproate beta-oxidation in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[ml] / [h·kg],0.024,260555,DB00313,Valproic Acid
,10792197,formation clearances,"However, formation clearances of plasma VPA to urinary E-2-en-VPA and 3-oxo-VPA were significantly increased from day 7 to day 21 (0. 010 vs 0.024 and 2.57 vs 3.60 ml kg-1 h-1, respectively, 95% CI for the differences -0.025 to -0.004 and -1.72 to -0.34 ml kg-1 h-1, respectively).",Apparent autoinduction of valproate beta-oxidation in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[ml] / [h·kg],2.57,260556,DB00313,Valproic Acid
,10792197,formation clearances,"However, formation clearances of plasma VPA to urinary E-2-en-VPA and 3-oxo-VPA were significantly increased from day 7 to day 21 (0. 010 vs 0.024 and 2.57 vs 3.60 ml kg-1 h-1, respectively, 95% CI for the differences -0.025 to -0.004 and -1.72 to -0.34 ml kg-1 h-1, respectively).",Apparent autoinduction of valproate beta-oxidation in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[ml] / [h·kg],3.60,260557,DB00313,Valproic Acid
,10792197,Formation clearances,Formation clearances to VPA-glucuronide (0.534 vs 0. 505 ml kg-1 h-1) and 4-OH-VPA (0.112 vs 0.110 ml kg-1 h-1) were not significantly different.,Apparent autoinduction of valproate beta-oxidation in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[ml] / [h·kg],0.534,260558,DB00313,Valproic Acid
,10792197,Formation clearances,Formation clearances to VPA-glucuronide (0.534 vs 0. 505 ml kg-1 h-1) and 4-OH-VPA (0.112 vs 0.110 ml kg-1 h-1) were not significantly different.,Apparent autoinduction of valproate beta-oxidation in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[ml] / [h·kg],0. 505,260559,DB00313,Valproic Acid
,10792197,Formation clearances,Formation clearances to VPA-glucuronide (0.534 vs 0. 505 ml kg-1 h-1) and 4-OH-VPA (0.112 vs 0.110 ml kg-1 h-1) were not significantly different.,Apparent autoinduction of valproate beta-oxidation in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[ml] / [h·kg],0.112,260560,DB00313,Valproic Acid
,10792197,Formation clearances,Formation clearances to VPA-glucuronide (0.534 vs 0. 505 ml kg-1 h-1) and 4-OH-VPA (0.112 vs 0.110 ml kg-1 h-1) were not significantly different.,Apparent autoinduction of valproate beta-oxidation in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10792197/),[ml] / [h·kg],0.110,260561,DB00313,Valproic Acid
,20348051,plasmatic concentration,"An acidosis (pH = 7.24), a hyperlactatemia (2.72 mmol/L), a hyperammonemia (328.9 micromol/L), and were diagnosed valproic acid plasmatic concentration was 1190 microg/mL at 22 hours.",[Pharmacokinetics of biological tags in a case of acute valpromide self poisoning]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20348051/),,1190,260965,DB00313,Valproic Acid
,29460901,Cssmin,"In patients who used LTG in monotherapy, LTG Cssmin was 5.6±4.65 mg/l, Cssmax 7.59±5.54 mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],5.6,261732,DB00313,Valproic Acid
,29460901,Cssmax,"In patients who used LTG in monotherapy, LTG Cssmin was 5.6±4.65 mg/l, Cssmax 7.59±5.54 mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],7.59,261733,DB00313,Valproic Acid
,29460901,Сssmin,"In the group that received LTG in combination with valproate, LTG Сssmin was 7.8 [5.4; 11.8] mg / l and Cssmax 11.4 [7.3; 15.3] mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],7.8,261734,DB00313,Valproic Acid
,29460901,Cssmax,"In the group that received LTG in combination with valproate, LTG Сssmin was 7.8 [5.4; 11.8] mg / l and Cssmax 11.4 [7.3; 15.3] mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],11.4,261735,DB00313,Valproic Acid
,29460901,Cssmin,"In the group that received LTG in combination with drug-inducers of glucuronidation, Cssmin was 2.5 [1.99; 4.32] mg/l, Cssmax 4.73 [2.91; 6.70] mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],2.5,261736,DB00313,Valproic Acid
,29460901,Cssmax,"In the group that received LTG in combination with drug-inducers of glucuronidation, Cssmin was 2.5 [1.99; 4.32] mg/l, Cssmax 4.73 [2.91; 6.70] mg/l.",[The clinical significance of the lamotrigine pharmacokinetic variability]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29460901/),[mg] / [l],4.73,261737,DB00313,Valproic Acid
,6407847,terminal half-life,Serum level decline was biphasic in both instances with a terminal half-life of 27.2 after the single dose and 10.2 h at steady-state.,The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407847/),,27.2,262045,DB00313,Valproic Acid
,6407847,terminal half-life,Serum level decline was biphasic in both instances with a terminal half-life of 27.2 after the single dose and 10.2 h at steady-state.,The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407847/),h,10.2,262046,DB00313,Valproic Acid
,6407847,Total serum clearance,Total serum clearance was 0.0236 l/h/kg after the single dose and increased to 0.0408 l/h/kg after 5 months.,The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407847/),[l] / [h·kg],0.0236,262047,DB00313,Valproic Acid
,6407847,Total serum clearance,Total serum clearance was 0.0236 l/h/kg after the single dose and increased to 0.0408 l/h/kg after 5 months.,The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407847/),[l] / [h·kg],0.0408,262048,DB00313,Valproic Acid
,6407847,Free (intrinsic) serum clearances,Free (intrinsic) serum clearances were 0.1489 and 0.1518 l/h/kg and serum free fractions were 0.224 and 0.272 respectively for the single dose and steady-state studies.,The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407847/),[l] / [h·kg],0.1489,262049,DB00313,Valproic Acid
,6407847,Free (intrinsic) serum clearances,Free (intrinsic) serum clearances were 0.1489 and 0.1518 l/h/kg and serum free fractions were 0.224 and 0.272 respectively for the single dose and steady-state studies.,The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407847/),[l] / [h·kg],0.1518,262050,DB00313,Valproic Acid
,6407847,serum free fractions,Free (intrinsic) serum clearances were 0.1489 and 0.1518 l/h/kg and serum free fractions were 0.224 and 0.272 respectively for the single dose and steady-state studies.,The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407847/),,0.224,262051,DB00313,Valproic Acid
,6407847,serum free fractions,Free (intrinsic) serum clearances were 0.1489 and 0.1518 l/h/kg and serum free fractions were 0.224 and 0.272 respectively for the single dose and steady-state studies.,The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407847/),,0.272,262052,DB00313,Valproic Acid
,1981728,Ka2,Ka2 increased in groups IIa and IIb compared with the control group (35.79 hr-1 and 36.61 hr-1 vs. 28.18 hr-1).,Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],35.79,262175,DB00313,Valproic Acid
,1981728,Ka2,Ka2 increased in groups IIa and IIb compared with the control group (35.79 hr-1 and 36.61 hr-1 vs. 28.18 hr-1).,Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],36.61,262176,DB00313,Valproic Acid
,1981728,Ka2,Ka2 increased in groups IIa and IIb compared with the control group (35.79 hr-1 and 36.61 hr-1 vs. 28.18 hr-1).,Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],28.18,262177,DB00313,Valproic Acid
,1981728,Ka1,"However, Ka1 decreased in group IIb as compared with the control rats (2.34 hr-1 vs. 4.18 hr-1), whereas no modifications were seen in group IIa (4.35 hr-1).",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],2.34,262178,DB00313,Valproic Acid
,1981728,Ka1,"However, Ka1 decreased in group IIb as compared with the control rats (2.34 hr-1 vs. 4.18 hr-1), whereas no modifications were seen in group IIa (4.35 hr-1).",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],4.18,262179,DB00313,Valproic Acid
,1981728,Ka1,"However, Ka1 decreased in group IIb as compared with the control rats (2.34 hr-1 vs. 4.18 hr-1), whereas no modifications were seen in group IIa (4.35 hr-1).",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],4.35,262180,DB00313,Valproic Acid
,1981728,t1/2 beta,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),h,8.77,262181,DB00313,Valproic Acid
,1981728,t1/2 beta,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),h,7.78,262182,DB00313,Valproic Acid
,1981728,t1/2 beta,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),h,4.55,262183,DB00313,Valproic Acid
,1981728,Ke,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],0.86,262184,DB00313,Valproic Acid
,1981728,Ke,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],0.48,262185,DB00313,Valproic Acid
,1981728,Ke,"The t1/2 beta was greater in groups IIa and IIb than in the controls (8.77 hr and 7.78 hr vs. 4.55 hr), and Ke was lower in those groups than in the controls (0.86 hr-1 and 0.48 hr-1 vs. 0.98 hr-1), suggesting a decrease in the elimination of VPA following administration of a single dose of ethanol.",Influence of a single dose of ethanol on the kinetics of valproic acid in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981728/),1/[h],0.98,262186,DB00313,Valproic Acid
,15165635,oral clearance,"The mean (standard deviation) oral clearance values for unbound valproic acid were 94.3 (51.8) and 82.3 (28.2) mL/h/kg and for total valproic acid were 11.2 (3.77) and 9.06 (2.03) mL/h/kg in older children and adolescents, respectively.",Divalproex-ER pharmacokinetics in older children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15165635/),[ml] / [h·kg],94.3,262788,DB00313,Valproic Acid
,15165635,oral clearance,"The mean (standard deviation) oral clearance values for unbound valproic acid were 94.3 (51.8) and 82.3 (28.2) mL/h/kg and for total valproic acid were 11.2 (3.77) and 9.06 (2.03) mL/h/kg in older children and adolescents, respectively.",Divalproex-ER pharmacokinetics in older children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15165635/),[ml] / [h·kg],82.3,262789,DB00313,Valproic Acid
,15165635,oral clearance,"The mean (standard deviation) oral clearance values for unbound valproic acid were 94.3 (51.8) and 82.3 (28.2) mL/h/kg and for total valproic acid were 11.2 (3.77) and 9.06 (2.03) mL/h/kg in older children and adolescents, respectively.",Divalproex-ER pharmacokinetics in older children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15165635/),[ml] / [h·kg],11.2,262790,DB00313,Valproic Acid
,15165635,oral clearance,"The mean (standard deviation) oral clearance values for unbound valproic acid were 94.3 (51.8) and 82.3 (28.2) mL/h/kg and for total valproic acid were 11.2 (3.77) and 9.06 (2.03) mL/h/kg in older children and adolescents, respectively.",Divalproex-ER pharmacokinetics in older children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15165635/),[ml] / [h·kg],9.06,262791,DB00313,Valproic Acid
,3932898,elimination half-life,Valproic acid elimination half-life increased from 7.1 to 11.8 hours.,Valproic acid pharmacokinetics in children. Discontinuation of concomitant antiepileptic drug therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932898/),h,7.1,262802,DB00313,Valproic Acid
,3932898,elimination half-life,Valproic acid elimination half-life increased from 7.1 to 11.8 hours.,Valproic acid pharmacokinetics in children. Discontinuation of concomitant antiepileptic drug therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932898/),h,11.8,262803,DB00313,Valproic Acid
,3932898,serum protein binding,"Valproic acid serum protein binding varied among patients from 7 to 23.8%, but was not altered by AEDs.",Valproic acid pharmacokinetics in children. Discontinuation of concomitant antiepileptic drug therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932898/),%,7 to 23.8,262804,DB00313,Valproic Acid
,7633603,elimination half-life,"The elimination half-life of VPA and [13C4]VPA in the ewe were estimated to be approximately 3.5 +/- 0.4 and 3.2 +/- 0.4 h, respectively.",Determination of valproic acid and its metabolites using gas chromatography with mass-selective detection: application to serum and urine samples from sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7633603/),h,3.5,263454,DB00313,Valproic Acid
,7633603,elimination half-life,"The elimination half-life of VPA and [13C4]VPA in the ewe were estimated to be approximately 3.5 +/- 0.4 and 3.2 +/- 0.4 h, respectively.",Determination of valproic acid and its metabolites using gas chromatography with mass-selective detection: application to serum and urine samples from sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7633603/),h,3.2,263455,DB00313,Valproic Acid
,6799412,total plasma clearance,Pharmacokinetic evaluation of the data indicated a total plasma clearance of 17.3 +/- 3.6 ml/min (mean +/- SD).,Bioavailability of a slow-release preparation of valproic acid under steady-state conditions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6799412/),[ml] / [min],17.3,264645,DB00313,Valproic Acid
,3115782,bioavailability,The average bioavailability for suppositories compared with the oral form was 112.4% in Group A and 99.5% in Group B.,Bioavailability of sodium valproate suppositories during repeated administration at steady state in epileptic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3115782/),%,112.4,265596,DB00313,Valproic Acid
,3115782,bioavailability,The average bioavailability for suppositories compared with the oral form was 112.4% in Group A and 99.5% in Group B.,Bioavailability of sodium valproate suppositories during repeated administration at steady state in epileptic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3115782/),%,99.5,265597,DB00313,Valproic Acid
,16871388,clearance (CL),"The obtained estimates for clearance (CL) (L/h/kg) [0.075+/-0.029 (Group 1), 0.014+/-0.005 (Group 2), 0.025+/-0.008 (Group 3) and 0.044+/-0.011 (Group 4)] appear to be the most appropriate set to be implemented in clinical practice as prior information, as demonstrated by the accuracy and precision of the measurements.",Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16871388/),[l] / [h·kg],0.075,268279,DB00313,Valproic Acid
,16871388,clearance (CL),"The obtained estimates for clearance (CL) (L/h/kg) [0.075+/-0.029 (Group 1), 0.014+/-0.005 (Group 2), 0.025+/-0.008 (Group 3) and 0.044+/-0.011 (Group 4)] appear to be the most appropriate set to be implemented in clinical practice as prior information, as demonstrated by the accuracy and precision of the measurements.",Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16871388/),[l] / [h·kg],0.014,268280,DB00313,Valproic Acid
,16871388,clearance (CL),"The obtained estimates for clearance (CL) (L/h/kg) [0.075+/-0.029 (Group 1), 0.014+/-0.005 (Group 2), 0.025+/-0.008 (Group 3) and 0.044+/-0.011 (Group 4)] appear to be the most appropriate set to be implemented in clinical practice as prior information, as demonstrated by the accuracy and precision of the measurements.",Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16871388/),[l] / [h·kg],0.025,268281,DB00313,Valproic Acid
,16871388,clearance (CL),"The obtained estimates for clearance (CL) (L/h/kg) [0.075+/-0.029 (Group 1), 0.014+/-0.005 (Group 2), 0.025+/-0.008 (Group 3) and 0.044+/-0.011 (Group 4)] appear to be the most appropriate set to be implemented in clinical practice as prior information, as demonstrated by the accuracy and precision of the measurements.",Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16871388/),[l] / [h·kg],0.044,268282,DB00313,Valproic Acid
,21950147,maximum serum concentrations,"Mean maximum serum concentrations of 124.5 +/- 34.8 microg/ml and 134.2 +/- 31.1 microg/ml were obtained for the test and reference products, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[μg] / [ml],124.5,268996,DB00313,Valproic Acid
,21950147,maximum serum concentrations,"Mean maximum serum concentrations of 124.5 +/- 34.8 microg/ml and 134.2 +/- 31.1 microg/ml were obtained for the test and reference products, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[μg] / [ml],134.2,268997,DB00313,Valproic Acid
,21950147,AULo(t),"The AULo(t) and AUCo(infinity) were 2023.8 +/- 578.8 1 microg h/ml and 2705.3 +/- 792.1 microg h/ml for the test and 2068.2 +/- 526.4 microg h/ml and 2729.6 +/- 698.2 microg h/ml for the reference formulation, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[1·h·μg] / [ml],2023.8,268998,DB00313,Valproic Acid
,21950147,AULo(t),"The AULo(t) and AUCo(infinity) were 2023.8 +/- 578.8 1 microg h/ml and 2705.3 +/- 792.1 microg h/ml for the test and 2068.2 +/- 526.4 microg h/ml and 2729.6 +/- 698.2 microg h/ml for the reference formulation, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[h·μg] / [ml],2068.2,268999,DB00313,Valproic Acid
,21950147,AUCo(infinity),"The AULo(t) and AUCo(infinity) were 2023.8 +/- 578.8 1 microg h/ml and 2705.3 +/- 792.1 microg h/ml for the test and 2068.2 +/- 526.4 microg h/ml and 2729.6 +/- 698.2 microg h/ml for the reference formulation, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[h·μg] / [ml],2705.3,269000,DB00313,Valproic Acid
,21950147,AUCo(infinity),"The AULo(t) and AUCo(infinity) were 2023.8 +/- 578.8 1 microg h/ml and 2705.3 +/- 792.1 microg h/ml for the test and 2068.2 +/- 526.4 microg h/ml and 2729.6 +/- 698.2 microg h/ml for the reference formulation, respectively.",Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21950147/),[h·μg] / [ml],2729.6,269001,DB00313,Valproic Acid
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],880,269574,DB00313,Valproic Acid
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.1,269575,DB00313,Valproic Acid
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],977,269576,DB00313,Valproic Acid
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.2,269577,DB00313,Valproic Acid
,20006565,absolute recovery,The mean absolute recovery for all tested molecules was always found to be close to 100%.,HPLC determination of novel dithiolethione containing drugs and its application for in vivo studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006565/),%,100,270692,DB00313,Valproic Acid
,23784346,Reabsorbed fraction of bioavailable dose,"Reabsorbed fraction of bioavailable dose was 46.2 % in women and 21.8 % in men, revealing important sex differences in drug hepatobiliar output.",Sex related differences on valproic acid pharmacokinetics after oral single dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23784346/),%,46.2,271141,DB00313,Valproic Acid
,23784346,Reabsorbed fraction of bioavailable dose,"Reabsorbed fraction of bioavailable dose was 46.2 % in women and 21.8 % in men, revealing important sex differences in drug hepatobiliar output.",Sex related differences on valproic acid pharmacokinetics after oral single dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23784346/),%,21.8,271142,DB00313,Valproic Acid
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00313,Valproic Acid
,10217336,concentration/dose (C/D) ratio,"In 20 patients in monotherapy, the concentration/dose (C/D) ratio was 65 (range: 50-84) nmol/L/mg (mean and 95% confidence interval, antilog from lognormal distribution).",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],65,272553,DB00313,Valproic Acid
less,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],31,272554,DB00313,Valproic Acid
,10217336,C/D ratio,"In 37 patients with concomitant carbamazepine treatment, the C/D ratio was less than half that of the patients in monotherapy; 31 (2146) nmol/L/mg, and in 14 patients with phenytoin, it was even lower; 17 (13-23) nmol/L/mg.",Lamotrigine drug interactions in a TDM material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],17,272555,DB00313,Valproic Acid
,10217336,C/D,Valproic acid significantly increased the C/D to 251 (200-320) nmol/L/mg in 13 patients.,Lamotrigine drug interactions in a TDM material. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217336/),[nM] / [l·mg],251,272556,DB00313,Valproic Acid
